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A highly convergent strategy for the synthesis of the antitubulin polyketide 
disorazole C1 is proposed based around the alkyne precursor I, featuring a novel 
Evans-Tishchenko/ring closing alkyne metathesis approach. Due to the inherent 
symmetry of the molecule this retrosynthesis leads to two fragments: a β-
hydroxyketone II and the oxazole C(1)-(9) fragment III. 
 
A review of previous syntheses of disorazole C1 and established structure activity 
relationships (SARs) highlights a gap in current knowledge relating to the role of the 
oxazole in tubulin binding. Therefore, the focus of this research has been towards 
developing new routes for the synthesis of the C(1)-C(9) fragment that can be 



































Chapter 2 focuses on a disconnection at the C(5)-C(6) bond and a novel synthesis of 
the racemic C(1)-C(9) fragment has been achieved via a lithiation of methyl 2-
methyl-1,3-oxazole-4-carboxylate and coupling to aldehyde V. First generation 
asymmetric routes to the C(1)-C(9) fragment centred on i. a biomimetic amino acid 
condensation route via an oxazoline intermediate based on the precedent of Meyers 
et al. and ii. a C(4)-C(5) disconnection approach based around the epoxide VII; are 
discussed in chapter 3. A second generation C(4)-C(5) disconnection centred on the 
novel tosylate VIII is discussed in chapter 4. Attempts to synthesise the parent C(1)-
C(9) oxazole fragment using the tosylate VIII via i. a palladium catalysed C-H 
activation of ethyl 4-oxazole carboxylate and ii. lithiation of oxazole are reported. 
Coupling of fragment VIII (X = OTs) with ethyl 1H-pyrazole-4-carboxylate and a 
CuAAC coupling of the azide derived from tosylate VIII with methyl propiolate has 
allowed the successful completion of the synthesis of pyrazole and triazole analogues 
of this fragment. 
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1 Chapter 1: Introduction 
 
Natural products are an important source of anticancer agents and provide an excellent 
starting point to provide inspiration for developing new chemotherapy drugs. A review by 
Butler1 highlights 79 natural products and natural product derived drugs that entered 
clinical trials to treat cancer between 2005 and 2007. An important mechanism of action of 
these natural products is an interaction with tubulin and 25% of the compounds discussed 
by Butler exhibit this mode of action. Disorazole C1 is a natural product originating from a 
bacterial fermentation which has been proven to interact with tubulin and act as an 
anticancer agent. Further research into its biological activity, binding mode, mechanism of 
action and synthesis are ongoing in a number of research groups.     
 
1.1 Isolation and Biosynthesis 
 
Disorazole C1 (1) was first isolated in 1994 by Höfle et al.2 from the fermentation broth of 
the myxobacterium Sorangium cellulosum So ce12. The Höfle group were screening the 
bacteria for novel antibiotics and discovered sorangicin A and its structural variants. A 
series of antifungal co-metabolites, including the chivosazoles, sorangiolides and the 
disorazoles were also isolated. These metabolites were isolated by a series of solvent 
partitions and chromatographic techniques including reversed-phase medium pressure 
liquid chromatography (RP-MPLC), HPLC and column chromatography. Disorazole C1 is 
a member of a family of 29 closely related macrocyclic polyketides, the most abundant of 
which are shown in figure 1. Accounting for 71% of the mass of the isolated disorazoles, 
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Figure 1: Most abundant members of the disorazole family 
 
The structure elucidation of the disorazoles was based on disorazole A1 due to its high 
abundance. The molecular formula was deduced using negative and positive FAB mass 
spectrometry, high resolution mass spectrometry and elemental analysis. The structural 
subunits were determined using 1D and 2D NMR spectroscopy techniques. The NMR 
spectra of disorazole C1 were compared to those of disorazole A1 and a symmetric 
macrodiolide structure was suggested based on the southern half of disorazole A1. No 
stereochemical information was elucidated during this investigation. 
Introduction 
The disorazoles possess potent biological activity and are therefore medicinally attractive 
targets; for that reason, synthetic or fermentation routes to these compounds are required. 
As shown in figure 1 disorazole A1 is the most abundant of the family and the most 
efficient route to production of this compound would be through fermentation. 
Understanding the biosynthesis of the disorazoles would enable optimisation of the 
fermentation process; hence the gene cluster responsible for the biosynthesis of the 
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nonribosomal peptide synthetase (NRPS)
Figure 2: Disorazole biosynthetic pathway  3 
The first gene in the disorazole cluster is disA, which codes for a polyketide synthase 
(PKS). Unusually, the PKS domain begins with a ketosynthase (KS) and not the common 
acyltransferase (AT) loading module. It is most likely that initiation of biosynthesis occurs 
via a direct transfer of an acetyl group from coenzyme A (CoA) onto the KS module. This 
acetate starter undergoes condensation with malonyl-S-ACP1; the subsequent reduction of 
the β-keto intermediate is catalysed by a ketoreductase (KR) and dehydratase (DH) to 
form the enone. Chain extension proceeds in module two by a KS and KR; a methyl 
transferase (MT) follows to insert both of the methyl groups directly at C15. 13C-labelled 
methionine feeding studies showed that the methyl groups are derived from S-adenosyl 
methionine; rather than through a classical macrolide biosynthetic pathway of 
condensation with isobutyrate.2,5 The β-hydroxyl group is installed by the KS, KR and 




Modules four to six are located mainly on the DisB gene, where carbon chain extension 
continues through a series of KR, ACP, KS and DH domains resulting in the triene section 
of disorazole C1. Interestingly, a mixture of cis and trans double bonds are formed in this 
section, this has been attributed to the presence or absence of a key aspartic acid residue in 
the KR amino acid sequence. It can be seen in figure 3 that modules 4 and 5 do not possess 
the key aspartic acid residue and this is where the cis-double bonds are formed; whereas, 
KR6 does feature this aspartic acid reside and a trans-double bond results.3 This can be 
explained by the mechanism shown in scheme 1 where the β-ketoacyl chains enter the KR 
active site from opposite directions. The positions of the NADPH and lysine residue are 
fixed, resulting in the formation of opposite alcohol enantiomers 6a and 6b.3,6,7 
Dehydration of the β-hydroxyketones then results in the formation of the cis- and trans-
alkenes 7a and 7b respectively. 
              
        
KR1  R F G A I H G V V Q M A G V V E D K L I A G K T W E S V R R E M A P K V 
KR2 R F G A I H G V I H S A V I L G S H P I A T T D E A T F A A G V R A K I 
KR3 R F G A L H G V L H S A G V T A D A S L R N K S R D Q M V A V L A P K V 
KR4_cis  E F G E L H G I F H C A G V A D R T P L A R A T I A D F E R V L R P K V 
KR5_cis  R F G A L H G I L H A A G T D E A P P L A R A D A A S F A K V L D P K V 
KR6_trans R F G R I D G V V H A A G A L R D G L L S K K D P A D V D A V I S A K V 
KR7_cis         R F G A L H G V I H A A G V L D E R P V V E K T W G E F H E N L R P K V 
        
 
 
Scheme 1: Alkene biosynthesis 
Figure 3: Ketoreductase domain core region 
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Module seven installs the hydroxyl group at C6 via a KS, DH, KR and ACP sequence. 
Oxazole formation follows on the NRPS module, encoded by the disC gene. Unusually, 
the disorazole gene contains two heterocyclisation domains; it is unknown whether both of 
these are involved in the oxazole formation. The first domain incorporates serine, and 
either this first domain, or the second one initiates cyclisation to the oxazoline; which is 
oxidised to the oxazole by the oxidation domain (Ox). The carbon backbone is now 
complete, and it is thought that modules nine and ten could be involved in the release and 
cyclisation of the macrocycle.3 
 
 
Scheme 2: Disorazole biosynthetic cyclisation 
Thioesterases (TE) are the final modules of PKSs and they terminate the chain with a 
hydrolysis reaction. The release and cyclisation of the disorazoles is not fully understood, 
but one proposed mechanism is shown in scheme 2. The first monomer synthesised is 
transferred to the TE and the hydroxyl at C(6) of this monomer can attack the thioester 
bond of the carrier protein which is carrying the second monomer. The hydroxyl group 
from the second monomer can form the cyclised dimer and release the molecule from the 
protein.  As there is no MT present in module seven to methylate the hydroxyl at C6, this 
modification must take place once the molecule has been released from the PKS, by an 
enzyme not located within the Dis gene cluster. Also, epoxidation will take place post PKS 




1.2 Biological Activity 
 
After the initial isolation of the disorazoles, preliminary biological tests were carried out 
on disorazole A1, as it was the most abundant from the fermentation broth and therefore 
most readily accessible.8 Disorazole A1 showed activity against various filamentous fungi, 
with minimum inhibition concentration (MIC) values ranging from 0.1 to 1 µg/ml; but 
showed no activity against yeast or bacteria. Disorazole A1 was proved to be extremely 
toxic against mammalian cells with a MIC of 0.003 ng/ml against mouse fibroblast L 929 
cells and a MIC of 0.03 ng/ml against HeLa ATCC CCL 2 cells. 
 
 
Figure 4: The cell cycle9 
It was not until ten years after the discovery of the disorazoles that further biological 
evaluation and insight into the mode of action was published by Elnakady et al.10  
Disorazole A1 was found to be a highly effective inhibitor of cell proliferation in an MTT 
assay with mouse fibroblast L929 cells, demonstrating an IC50 of 3 pM. Disorazole A1 
exhibited greater potency than vinblastine and epothilone in a series of cell proliferation 
assays against a range of cell lines. For example, against cell line A-549 originating from a 
human lung carcinoma, disorazole A1 exhibited an IC50 of 0.0023 nM, epothilone B 0.26 
nM and vinblastine 5.9 nM. This trend was evident through all cell lines tested from 
different cancer cells, including a multi-drug resistant cell line.  The next investigation 
carried out by the group was to establish at which point in the cell cycle disorazole A1 
Introduction 
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takes effect. Treatment of histiocytic lymphoma U-937 cells with disorazole A1 and 
analysis by flow cytometry resulted in an accumulation of cells in the G2/M phase. Figure 
4 shows a schematic diagram of the eukaryotic cell cycle; the G2/M phase is at the end of 
interphase, where the cell is preparing to divide and the beginning of mitosis, where the 
cell starts to divide into two cells.  
 
A number of natural product chemotherapeutic agents interact with tubulin, for example 
the vinca alkaloids inhibit microtubule polymerisation, whereas taxanes promote it; both 
disrupt the cell cycle and result in cell death.11,12 Microtubules are important structural 
elements essential for a number of cell processes, including mitosis, cytokinesis and 
vesicular transport.11 Microtubules are polymers made up of the protein tubulin, which 
exists as a dimeric structure consisting of α and β subunits. The dimers assemble with an 
α unit adjacent to a β unit, resulting in a polarised microtubule structure (figure 5).13 The 
microtubules undergo a dynamic process of polymerisation from the (+)-end and 
depolymerisation from the (−)-end, as shown in figure 5;13 either of these mechanisms can 
be disrupted. The microtubules make up the mitotic spindle, which is essential for cell 
division and facilitates correct segregation of the chromosomes before the cell splits. 
Therefore, any disruption to the components of this process is detrimental to cell division.  
 
 




Microscopic investigations using immunofluorescence techniques confirmed that 
disorazole A1 interferes with the microtubular structures in the cell and the effect is 
concentration dependent.10 It was also established that disorazole A1 interacts with tubulin 
to inhibit its polymerisation. In addition, the effect of binding to tubulin was found to be 
irreversible, which suggests a high binding affinity between disorazole A1 and tubulin. 
 
Due to the low natural abundance of disorazole C1, biological studies were not carried out 
until the first total synthesis was completed by Wipf et al. in 2004.14,15,16 Nanomolar 
concentrations of disorazole C1 caused microtubule disorganisation and an increase in 
mitotic cells. Disorazole C1 showed a comparable degree of mitotic arrest as the vinca 
alkaloid vincristine.14 At high concentrations of disorazole C1 the mass of tubulin in the 
cells was found to decrease, which is in contrast to paclitaxel, which causes microtubule 
stabilisation.14,16 The IC50 of disorazole C1 was found to be less than 4 nM in 5 different 
cell lines; in comparison to the vinca alkaloids, vincristine showed an IC50 of 5-22 nM and 
vinblastine 1-2 nM.16 This therefore suggests that the disorazoles have a mode of action 
similar to the vinca alkaloids, which is different to paclitaxel. These results are 
encouraging, as it demonstrates that the chemically reactive vinyl oxirane and the tetraene 
moieties of disorazole A1 are not essential to the mode of action.  Competitive binding 
studies with tubulin showed that disorazole C1 inhibited vinblastine binding in a non-
competitive manner.16 It was also discovered that disorazole C1 exhibits non-competitive 
binding with dolastatin 10, which binds at the desipeptide binding site on tubulin, which 
overlaps the vinca alkaloid binding site. This therefore suggests that the disorazoles may 












1.3 Structure Activity Relationship of the Disorazoles 
1.3.1 Disorazole A1 
Disorazole A1 is extremely toxic to cells and realistically is too potent to be useful as a 
chemotherapeutic drug, as it is highly likely to cause side effects. Vinblastine, which has 
been used in clinical oncology for nearly 50 years,12 has an IC50 against the lung cancer 
cell line A549 of 5.9 nM;10 hence this is the target region of activity for an anticancer 
agent. Nevertheless, Disorazole A1 is an important starting point in order to gain an 
understanding of the biological activity and SAR, due its ease of availability from the 
fermentation broth. There have been a limited number of disorazole analogues synthesised 
due to the long synthetic routes involved. The essential functional groups of the 
disorazoles need to be identified in order to develop better synthetic strategies and simpler 
analogues. 
 
As disorazole A1 is the most accessible of the family from the fermentation broth, a 
starting point to develop some SAR would be to directly modify the extracted compound. 
Methanolysis of disorazole A1 was performed by Hearn et al17 (table 1), using 
dichloroacetic acid; during the reaction two methanol adduct products were observed in 
equal quantities (8 and 9). When stronger acids such as trifluroacetic acid, or 
methanesulfonic acid were used, only product 8 and dehydration products were observed. 
The structures of these products were elucidated using HRMS and 1H NMR spectroscopy 
as well as 2D NMR experiments such as COSY, HSQC, HMBC and TOCSY.17  
 
The methanolysis products were tested against a range of cancer cell lines (table 1) and 
showed equipotent inhibition of cell proliferation as disorazole A1 against breast and lung 
cancer cell lines (table 1, entries 1 and 3).17 However 8 and 9 were less active in multi-
drug resistant cell lines which overexpress the transporter protein P-glycoprotein 1 (pgp) 
(table 1, entries 2 and 5).17 Due to the high potency of these new analogues, it can be 
deduced that the epoxide in disorazole A1 (2) is not necessary for activity. Therefore, more 







Table 1: Disorazole A1 methanolysis 
   IC50 (nM)   
Entry Cell line Tumour origin Disorazole A1 8 9 
1 MCF-7 breast 0.25 0.24 0.62 
2 NCI/ADR breast, MDR 0.52 2.80 28 
3 A549 lung 0.31 0.25 0.73 
4 CCRF-CEM T-cell leukaemia 0.070 0.11 0.33 
5 CCRF-CEM/PTX T-cell leukaemia, MDR 0.066 0.24 1.30 
 
1.3.2 Disorazole C1 
 
The majority of the biological analysis of analogues of disorazole C1 has been carried out 
by the Wipf group and collaborators. 13,14,16,18,19 This work includes rationally designed 
analogues, as well as synthetic intermediates from the total synthesis of disorazole C1. The 
most noteworthy structures, synthetically, are the alkyne 1015 and the cyclopropyl 
analogue 11;20 these analogues display cytotoxic activity against cancer cell lines. A 
comparison of assays which have been carried out in equivalent cell lines for the 
Introduction 
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analogues, disorazole C1, A1 and vincristine is shown in table 2. It can be seen that against 
the PC3 prostate cancer derived cell line, the alkyne analogue 10 is 3 orders of magnitude 





Table 2: Biological activity of disorazole C1 analogues 
 
Interestingly, this large difference in activity between disorazole C1 and the alkyne 
analogue 10 was not expected, as the alkyne analogue contains only a minor structural 
change. Molecular modelling studies were therefore carried out to determine the lowest 
energy conformation of disorazole C1 and the alkyne analogue 10.14 A 10,000 step Monte 
Carlo conformational analysis was performed on the two molecules, with Macromodel 
5.5,21 using the chloroform solvation model and the MM2* force field.14 The 3D structures 
obtained from these studies are shown in figure 6.14 It can be seen that disorazole C1 forms 
a figure-of-eight-type shape (figure 6, A), which is bought about by the conformation of 
the (Z)-alkenes. This figure-of-eight motif is not common in macrodiolides, however, this 
C2-symmetric shape is apparent in this case and the folding brings the vinyl alcohol side 
chains into close proximity. In comparison, masking the C(9)-C(10) alkene of the triene as 
an alkyne greatly affects the 3D shape of the macrocycle and now a narrow bowl shape is 
 IC50 (nm)     






PC3 1.57 0.0071 4.68 2640   
HCT 116 1.09   35.2   28.3 
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evident (figure 6, B). The C2-symmetry is now lost and the methoxy groups and vinyl 
alcohol side chains are further apart; consequently the solvent accessible surface is 
reduced. The results of the biological assays and the molecular modelling can be 
combined, to suggest that the 3D structure of the disorazoles is highly important for the 




Figure 6: Energy minimised structures of A-Disorazole C1 and B-alkyne analogue
14 
 
The other analogue featured in table 2 to show noticeable activity was the cyclopropyl 
analogue 11, which can be compared to disorazole C1 in colon cancer cell line HTC 116.20 
With an IC50 of 28.3 nM the cyclopropyl analogue 11 is approximately 4-fold less active 
than disorazole C1; nevertheless this analogue has comparable activity to vincristine. 
However, only preliminary results for this analogue have been published and there was not 
a sample of disorazole C1 available for direct comparison in this recent assay; further 
investigations are on going. This cyclopropyl analogue shows potential for further 
development of SAR, to build on the fact that the highly labile triene moiety is not 







































































Figure 7: Disorazole C1 analogues 
                                                            
Other significant analogues synthesised by the Wipf group are shown in figure 7.19 These 
molecules were rationally designed to establish further SAR around specific areas of the 
macrodiolide. Structures 12-14 were designed to investigate the importance of the allylic 
alcohol side chain. The t-butyl analogue 12 was the easiest way to simplify the side chain, 
thereby replacing the allylic alcohol with a methyl group. This analogue was found to be 
inactive, therefore demonstrating that the allylic alcohol is essential for the biological 







 The next logical modification was to replace the C(17)-C(18) alkene with the isosteric 
cyclopropyl, thus probing the impact of the double bond on the binding, while 
theoretically maintaining the 3D shape of the molecule.19 Analogue 13 was inactive at 
concentrations of less than 5 µM, again supporting the necessity of the allylic alcohol for 
biological activity and for preserving the 3D shape of the molecule. 
 
 A theory for the importance of the allylic alcohol is based on in vivo oxidation of the 
C(16) alcohol to an enone, which could undergo irreversible conjugate addition to an 
amino acid, resulting in a breakdown of protein activity and therefore cellular disruption. 
Based on this theory, the alcohol of disorazole C1 was oxidised to the ketone 14. However, 
the analogue was found to be inactive at concentrations of less than 5 µM, suggesting the 
importance of the allylic alcohol may be based on a different interaction.19 The alkyne 
precursor to this enone analogue was also biologically tested, but it too proved to be 
inactive.19 It can be deduced that the allylic alcohol is highly important to the activity of 
the disorazoles and it cannot be altered in order to attempt to enhance the cytotoxicity of 
the molecule. 
 
Disorazole C1 was hydrogenated to yield the saturated analogue 15, which was also 
inactive in the range of cell lines tested.14,19 It is understandable that this saturated 
analogue would hold a different energy minimised shape to disorazole C1, which in turn 
would affect the binding to tubulin. 
 
Another molecule inspired by the desire to simplify the structure of disorazole C1 was the 
desmethoxy analogue 16. The synthesis of this compound could not be completed due to 
poor recovery of intermediates, difficult purification and possible instability of the 
compounds, perhaps by destabilising the sensitive triene moiety.19  
 
Late stage intermediates isolated during the total synthesis of disorazole C1 and the 
aforementioned analogues were also screened for efficacy, along with monomeric cyclic 





1.3.3 Disorazole Z 
Recently, a new member of the disorazole family was isolated and identified from the 
fermentation broth of Sorangium cellulosum and it was assigned the name disorazole Z 
17.22 This latest disorazole was found to be highly toxic against the mouse fibrolast cell 
line L929, exhibiting an IC50 of 30 pg/ml. This compound comprises of a smaller ring than 
disorazole C1 and it lacks the C(6) methoxy group; it also contains a methyl ester 
substitution on the side chain, rather than a gem-dimethyl moiety. Kalesse et al were also 
interested in investigating the SAR of the disorazoles and they synthesised the ‘simplified 
disorazole’ 18.23 This molecule contains the same ring structure as disorazole Z, but the 













 IC50 (nm)    
Cell line Disorazole C1 Disorazole A1 (Z,E,E) 18 (E,E,E) 19 
PC3 1.57 0.0071 1.44 50 
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The simplified disorazole 18 was tested against a range of cancer cell lines, and table 3 
highlights the prostate cancer cell line PC3, to enable the results to be compared to 
previous disorazoles tested in the same cell line. This simplified disorazole 18 showed 
comparable activity to disorazole C1, with an IC50 of 1.44 nM. This suggests that the 
methoxy group is not necessary for activity and a smaller ring is tolerated. However, the 
(E,E,E)-analogue 19, which was readily available from the synthetic procedure, 
demonstrated approximately 50 times less activity than the (Z,E,E)-analogue 18 against all 
cancer cell lines. This minor structural alteration would affect the 3D shape of the 
molecule, therefore influencing the binding interaction with tubulin and in turn, decreasing 
the activity. 
 
An in vitro tubulin polymerisation assay was conducted using purified microtubule protein 
from porcine brain. The results shown in figure 823 illustrate the same trend as the cell 
assays, where disorazole A1 is the most active by several orders of magnitude. The 
(Z,E,E)-analogue 18 showed intermediate activity, whereas, the (E,E,E)-analogue 19 is 
only slightly more active than the control. This suggests that it is the binding of the 
compounds to the protein tubulin that affects the IC50 in cell assays, rather than any 




Figure 8: Influence of compounds 18 and 19 on polymerization of purified porcine tubulin at 
37 °C in comparison with disorazole A1 (■ control; 
 
 18; 19; ○ disorazole A1; microtubule 




From all of the analogues published some SARs have been established and these findings 
are summarised in figure 9. It can be concluded that the allylic alcohol side chain is 
essential for activity and cannot be modified. The desmethoxy analogue 16 could not be 
synthesised, yet the simplified disorazole 18 does not contain the methoxy group and it 
maintained activity against cancer cells. Modifications of the sensitive triene system are 
tolerated, such as the cyclopropyl 11 and alkyne 10 analogues, but activity is 
compromised. The overall conclusion to be drawn from the available data, is that small 
alterations to the structure of the disorazoles can greatly affect the activity. From 
computational studies it appears that small structural changes can have a great impact on 
the 3D conformation of the molecules, thereby influencing the binding to tubulin. 
Disorazole C1 contains a number of functional groups and they are yet all to be explored to 
establish SAR. Furthermore, the binding and interaction with tubulin is still not fully 
















desmethoxy disorazole C1 unstable
analogue lacking CH2CHOMe
as active as disorazole C1
alkyne 103 times less active
cyclopropyl 4 fold less active
 









1.4 Synthesis of Disorazole C1 and Analogues 
1.4.1 Meyers Partial Synthesis of Disorazole C1 
The first efforts towards the synthesis of disorazole C1 were published by the Meyers 
group in 2000,24 which was prior to the relative or absolute stereochemistry of the 
disorazoles being determined. The initial efforts concentrated on forming what they 
assumed to be disorazole C1 (1b) from its monomeric triene subunit 20 by a dilactonisation 
reaction (scheme 3).24 The triene subunit 20 could be formed by a Stille coupling between 
the vinylstannane moiety 23 and the oxazole-containing vinyl iodide 24. However, it was 
found that the triene subunit was unstable and the synthesis of 1b could not be completed 
using this route. Therefore, attention was then focused towards the dienyne monomer 22, 
where the C(11)-C(12) alkene had been replaced by an alkyne.25 This target can be 
















































Scheme 3: Meyers retrosynthesis of Disorazole C1 
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 The synthesis of vinyl iodide 24 began from acid 26 (synthesised from L-malic 
acid), which was coupled with L-serine methyl ester hydrochloride to give amide 27 
(scheme 4). Cyclodehydration of 27 with DAST led to the oxazoline, which was 
oxidised with DBU and BrCCl3 to the oxazole 28; the acetonide of which was 
subsequently hydrolysed to the diol using Dowex-H+. The primary alcohol was then 
selectively protected as the TIPS ether, the free secondary alcohol was methylated 
and TIPS deprotection led to alcohol 29 in 48% yield over the 4 steps. Alcohol 29 
was subjected to Parikh-Doering oxidation26 and the resulting aldehyde was used 
directly in a Wittig reaction with triphenylphosphoranylidine acetaldehyde, to 
produce the enal 30. Aldehyde 30 was subjected to a Stork-Zhao27 modified Wittig 




Scheme 4:  Meyers synthesis of dienyl iodide fragment 
(a) L-SerOMe•HCl, 1,1’-CDI, THF, 67%; (b) DAST, DCM, −78 °C; (c) DBU, BrCCl3, DCM, 0 °C to 
rt, 79% over 2 steps; (d) Dowex-H+, MeOH; (e) TIPSOTf, 2,6-lutidine, DCM, −78 °C; (f) MeI, Ag2O, 
CH3CN, ∆; (g) TBAF, THF, 48% over 4 steps; (h) SO3·Pyr, DMSO, Et3N, DCM; (i) Ph3P=CH2CHO, 
THF, 45% over 2 steps; (j) I−Ph3P
+CH2I, NaHMDS, HMPA, −78 °C, 76%. 
 
The first step towards the alkyne fragment 25 (scheme 5) utilised a modified 
Mukaiyama aldol reaction between (E)-crotonaldehyde (31) and the tert-
butyldimethylsilyl ketene acetal 32 to give alcohol 33 in 85% yield and 92% ee. It 
was found that α,β-unsaturated ester 34 could be formed in a one-pot reaction, where 
NaH would cause a 1,5-O→O silyl migration of 33 followed by ethoxy elimination 
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to form the intermediate aldehyde. Then, a Horner-Wadsworth-Emmons reaction 
occurred with triethylphosphonoacetate to give alkene 34. The ester of 34 was 
reduced to the alcohol using DIBAL; Sharpless epoxidation of the alkene resulted in 
the epoxide 35 as the major product of a diastereomeric mixture (14:1). The mixture 
was selectively reduced to the 1,3-diol using Red-Al, and then protected as the PMB 
acetal 36, which was formed as a single diastereomer. The acetal ring was 
regioselectively opened under reductive conditions using DIBAL and the primary 
alcohol was oxidised to the aldehyde 37 using Dess-Martin periodinane. The 
resulting aldehyde was subjected to a Stork-Zhao modified Wittig reaction and the 
PMB protecting group was removed with DDQ to give the vinyl iodide 38. The vinyl 




Scheme 5: Meyers synthesis of alkyne fragment 
 (a) BH3•THF, N-Ts-L-valine, DCM, −78 °C, 85%; (b) (EtO)2P(O)CO2CH2Et, NaH (2 equiv), THF, 
−78 °C to rt, 72%; (c) DIBAL, DCM, −78 °C; (d) D-(−)-DIPT, t-BuOOH, Ti(O-i-Pr)4, DCM, −30 °C, 
80% over 2 steps; (e) Red-Al, THF, −20 to 0 °C; (f) p-methoxybenzylidene dimethyl acetal, PPTS, 
DCM, 77% over 2 steps; (g) DIBAL, DCM, −78 °C; (h) DMP, pyridine, t-BuOH, DCM, 90% over 2 
steps; (i) I−Ph3P
+CH2I, NaHMDS, HMPA, −78 °C; (j) DDQ, DCM, H2O, 67% over 2 steps; (k) 






Once the two key fragments had been synthesised, they could be coupled together 
using Sonogashira coupling to give the dienyne monomer 22 (scheme 6). The 
cyclodimerisation was attempted firstly by hydrolysing the methyl ester of 22 to the 
acid, which was treated with DPTC and DMAP to effect lactonisation. 





















Scheme 6:Meyers attempted cyclodimerisation 
 (a) PdCl2(PPh3)2, CuI, Et3N, CH3CN, −20 °C to rt, 87%; (b) 1 N LiOH, THF; (c) DPTC, DMAP, 
toluene, ∆, 46% over 2 steps. 
 
 
A stepwise approach (scheme 7) was then adopted to avoid monomer cyclisation. 
This involved protection of the alcohol of 22, saponification of the ester and coupling 
to another equivalent of 22 with a free hydroxyl group to give 40. Deprotection of 
the hydroxyl group and Yamaguchi lactonisation resulted in the desired cyclic dimer 
21. Attempts to remove the TBS protecting group resulted in a mixture of 
inseparable isomers and partial hydrogenation of the alkyne to provide the (Z)-alkene 






Scheme 7: Meyers stepwise dimerisation 
(a) TESOTf, 2,6-lutidine, DCM, −78 °C, 69%; (b) 1 N LiOH, THF; (c) 22, DPTC, DMAP, toluene, ∆, 
65% over 2 steps; (d) TFA, H2O, THF, 65%; (e) 1 N LiOH, THF; (f) 2,4,6-trichlorobenzoyl chloride, 



















1.4.2 Hoffmann Synthesis of Tetradehydro-Disorazole C1 
 
The absolute stereochemical configuration of disorazole C1 was published in 200028 
and with this information the Hoffmann group set about constructing the southern 
segment of disorazole A1 and C1. The Hoffmann group carried out initial 
computational studies to ascertain the best retrosynthetic strategy. The strategy was 
to avoid the problems encountered by the Meyers group, namely, the use of the 
sensitive triene fragment and the formation of the cyclic monomer. A Monte Carlo 
global minimum search was carried out using geometries minimised using the 
MMFF ForceField within MacroModel 7.2.21 The results of these calculations are 
shown in figure 10; it was concluded that placing the alkyne at the C(9)-C(10) 
position would lead to the most strained 15 membered macrocycle 42, but the desired 









The retrosynthesis shown in scheme 8 is the second generation approach used for the 
Hoffmann group’s total synthesis of disorazole C1. The key fragments for this 
synthesis were the alkyne 44 and vinyl iodide 45.30 
 
 



















The first generation approach to the synthesis of the oxazole fragment 52 (scheme 9) 
started with a Keck allylation of 2-benzyloxy acetaldehyde 46, using (R)-BINOL and 
allyltributylstannane, generating the homoallylic alcohol 47 in 84% yield and >94% 
ee. O-Methylation followed by ozonolysis, then oxidation of the resulting aldehyde 
gave the carboxylic acid 48. The oxazole was formed in three steps: an initial amide 
coupling between the acid 48 and serine methyl ester hydrochloride generated 
hydroxyamide 49. Cyclodehydration using DAST and subsequent oxidation of the 
resulting oxazoline furnished oxazole 50. The benzyl group was removed with 
hydrogen and carbon on palladium and the resulting alcohol was oxidised to the 
aldehyde 51. This underwent a Wittig reaction with TMS-protected propargyl 
triphenylphosphonium bromide (2.5:1, E:Z selectivity) and the TMS group was 
removed to give the terminal alkyne 52.29  
 
 
Scheme 9: Hoffmann’s  oxazole synthesis  
(a) (R)-BINOL, Ti(OiPr)4, 4 Å MS, allyltributylstannane, DCM, −20 °C, 84%; (b) NaH, MeI, THF, rt, 
94%; (c) O3, DCM, −78 °C; PPh3, rt, 86%; (d) NaClO2, KH2PO4, H2O2, CH3CN/MeOH/H2O (1:1:2), 
10 °C, 98%; (e) L-SerOMe•HCl, IBCF, NMM, THF, −25 °C to rt, 71%; (f) DAST, K2CO3, DCM, −78 
°C; (g) DBU, BrCCl3, DCM, 0 °C to rt, 79% from 49; (h) H2, Pd/C, EtOH, rt, 97%; (i) SO3•pyr, Et3N, 
DCM:DMSO (4:1), 0 °C, 75%; (j) Br−Ph3P
+CH2C≡CTMS, n-BuLi, THF, −78 to 0 °C, 49% (2.5:1, 








The first generation synthesis used Sonogashira coupling to join the oxazole alkyne 
52 with the vinyl iodide 62.29 Due to the selectivity problems encountered when 
constructing the C(7)-C(8) double bond (52) via a Wittig reaction, the Sonogashira 
coupling partners were reversed in the second generation synthesis.30 Therefore the 
oxazole fragment required the vinyl iodide functional group which was synthesised 
as shown in scheme 10. The alcohol 53 was oxidised to the aldehyde and then 
converted to the terminal alkyne 54 using the Ohira-Bestmann reagent (A). This 
alkyne was transformed selectively into the (E)-vinyl iodide 45 by 




Scheme 10: Hoffmann second generation oxazole fragment synthesis 
(a) i. (ClCO)2, Et3N, DMSO, DCM, –78 °C to –40 °C; ii. A, K2CO3, MeOH, 0 °C to rt, 75% from 53; 
(b) nBu3SnH, Pd(PPh3)4, THF, then I2, 88% (E-selective). 
 
 
The first step towards the synthesis of the alkyne fragment 44 involved an 
asymmetric Mukaiyama-aldol addition of silyl ketene acetal 55 to the readily 
available aldehyde 56, generating alcohol 57 in 96% yield and 88% ee. The 
secondary alcohol was protected as the TBS ether and the aldehyde was formed by 
reduction of the ester with DIBAL followed by Dess-Martin oxidation to give the 
aldehyde 58. Addition of lithiated (E)-1-bromoprop-1-ene resulted in a mixture of 
syn and anti alcohols 59a and 59b (59a:59b = 1.1:1), but these could be separated by 
column chromatography and the desired diastereomer 59a was carried through. The 
free alcohol was protected as the SEM ether 60 and then the primary alcohol was 
deprotected with DDQ, enabling Parikh-Doering oxidation to the aldehyde 61.  The 
aldehyde was converted to the vinyl iodide 62 using the Stork-Zhao procedure and 
this was coupled with (trimethylsilyl)acetylene in a Sonogashira coupling, resulting 
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in the terminal alkyne. Removal of the TBS group with TBAF concluded the 


















: R = TBS













Scheme 11: Hoffmann alkyne synthesis 
 (a) i. N-Tos-D-valine, BH3•THF, DCM, −78 °C; ii. K2CO3, MeOH, 96%; (b) TBSOTf, 2,6-lutidine, 
DMAP, DCM, rt, 99%; (c) DIBAL, toluene, −78 °C, 94%; (d) DMP, DCM, 0 °C to rt, 83%; (e) trans-
1-bromopropene, t-BuLi, Et2O/THF (1:1), −95 °C, 99% (59a:59b, 1.1:1); (f) separation of 
diastereomers; (g) SEMCl, iPr2NEt, Bu4N
+I−, DCM; (h) DDQ, DCM/H2O (10:1), 0 °C, 98% from 59a; 
(i) SO3•pyr, Et3N, DCM/DMSO (6:1), 0 °C, 80%; (j) I
−Ph3P
+CH2I, NaHMDS, THF/HMPA (10:1), 
−78 °C, 82%; (k) i. (trimethylsilyl)acetylene, PdCl2(PPh3)2, CuI, Et3N, CH3CN, rt, 99%; ii. TBAF (1.1 
equiv.), THF, 0 °C to rt, 81%; (l) TBAF (10.0 equiv.), THF, rt, 95%. 
 
The route towards the total synthesis of disorazole C1 is shown in scheme 12; this 
involved a Sonogashira coupling between the alkyne 44 and the vinyl iodide 45. 
Problems were encountered when removing the TBS group, so this was replaced by 
the more labile TES group and the ester of one half of the dimer was hydrolysed to 
the carboxylic acid 63. An esterification between alcohol 43 and acid 63 provided 64 
in a 35% yield; it was found this reaction was more efficient if the acid was activated 
portionwise resulting in an improved 60% yield. The final step involved selective 
saponification of the methyl ester, followed by Yamaguchi lactonisation to give 65. 
The tetradehydro-analogue could be deprotected and the alkyne reduced to the (Z)-














































Scheme 12: Hoffmann cyclisation 
 (a) PdCl2(PPh3)2, CuI, Et3N, DMF, rt, 89%; (b) Cl3C6H2COCl, Et3N, DMAP, toluene, rt, 8 h, 34%; (c) 
i. TBAF, AcOH/ H2O (1:1), THF, rt, 86%; ii. Ba(OH)2, H2O, MeOH, THF, rt, quant; iii. 















1.4.3 Wipf Total Synthesis of Disorazole C1 
 
To date, there has only been one total synthesis of disorazole C1, which was reported 
by Wipf and Graham in 2004.15 The retrosynthetic analysis shown in scheme 13 
proposed that disorazole C1 could be synthesised from the masked alkene analogue 
66 as based on the Hoffmann group studies. It was suggested that this cyclic diyne 












Scheme 13: Wipf retrosynthesis  29 
 
The synthesis of the enyne 67 is shown in scheme 14. The homoallylic alcohol 68 
was synthesised using known methods31 in 91% yield and 92% ee from naphthalene-
2-carboxylic acid 2,2-dimethyl-3-oxo-propyl ester via a TiF4/(S)-BINOL-catalysed 
allylation with allyltrimethylsilane. The terminal alkene of the homoallylic alcohol 
68 was converted to the alcohol by ozonolysis, followed by reduction with NaBH4; 
subsequent 1,3-diol protection and saponification led to alcohol 69. Swern oxidation 
was utilised to give the corresponding aldehyde, which was reacted with 1-
lithiopropyne to afford a ~1:1 mixture of alcohol diastereomers 70a and 70b, which 
were easily separable by column chromatography. The alkyne of the desired anti-
diastereomer 70a was reduced to the (E)-alkene using Red-Al. The resulting allylic 
alcohol was protected and the acetonide was removed to give the diol 71. Protecting 
group manipulation of the alcohol groups and oxidation of the terminal alcohol under 
Swern conditions provided the aldehyde, which was in turn reacted with lithiated 
1,3-bis(triisopropylsilyl)propyne. The protecting groups were removed to give the 
enyne 72 as a 1:8 mixture of double bond isomers (E/Z). Following separation of 
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these isomers by flash chromatography, desilylation of the alkyne 72a gave the 
required enyne 67.15  
 
 
Scheme 14: Wipf enyne synthesis 
(a) i. O3/O2, Sudan III, MeOH, DCM, −78 °C; ii. NaBH4, −78 °C to rt, 88%; (b) 2,2-
dimethoxypropane, PPTS, THF, 0 °C to rt, 36 h, 97%; (c) 1 M LiOH, THF, MeOH, 0 °C to rt, 20 h, 
82%; (d) (COCl)2, DMSO, Et3N, −78 °C; (e) CH3C≡CLi, −78 °C to 0 °C, 1.5 h (f) Red-Al, THF 
(degassed), reflux, 25 h, 83%; (g) PMB-Br, Et3N, KHMDS, THF, −78 °C, 1 h then rt, 2 h; (h) 
AcOH/THF/H2O (4:1:1), 60 °C, 12 h, 84% (2 steps); (i) TESOTf, 2,6-lutidine, DCM, 0 °C, 30 min; (j) 
(COCl)2, DMSO, Et3N, DCM, 75% (2 steps); (k) TIPSC≡CCH2Li, THF −78 °C, 30 min (l) 
chloroacetic acid, MeOH/DCM (3:1), rt, 14 h; (m) TBAF, THF, 0 °C to rt, 14 h, 94%. 
 
 
The synthesis of the oxazole fragment (scheme 15) started from silyl ether protection 
of hydroxynitrile 73, followed by DIBAL reduction, resulting in the aldehyde 74. 
The TMS-acetylene was added with control of absolute stereochemistry, using 
diethyl zinc, Ti(i-OPr)4 and (S)-Binol, producing alcohol 75. The enantiomeric 
excess was determined as 92% by converting the alcohol to the benzoate 76 and 
analysis by chiral HPLC. O-Methylation of 75 with dimethyl sulfate under phase 
transfer conditions resulted in concomitant loss of the TMS group. TIPS deprotection 
with HF, followed by oxidation of the resulting alcohol provided the carboxylic acid 
77. Coupling of serine methyl ester hydrochloride and acid 77, followed by 
cyclodehydration of the resulting hydroxyamide and oxidation of the oxazoline 
resulted in the desired oxazole 78, plus the bromide 79. Formation of the bromide 79 
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was unexpected, but it could rapidly be converted to the desired iodide 45 and then 





































Scheme 15: Wipf oxazole synthesis 31 
a) TIPS-Cl, imid, DMF, rt, 16 h; (b) DIBAL, DCM, −10 °C, 50 min, 78% (2 steps); (c) i. TMS-
cetylene, Et2Zn, toluene, reflux, 1 h; ii. (S)-Binol, Ti(O
iPr)4; iii. 74, rt, 20 h, 66%; (d) PhCOCl, 
MAP, pyridine, rt, 4 h, 100%; (e) HF (48% aq), CH3CN, rt, 12 h, 93%; (f) Dimethyl sulfate, n-
u4NHSO4, NaOH (50% aq, 
w/w), toluene, 0 °C to rt, 3.5 h, 95%; (g) i. HF, CH3CN, rt, 24 h; ii. 
aOCl, NaClO2, TEMPO, CH3CN, phosphate buffer (pH 6.7), 45 °C, 18 h, 99%; (h) SerOMe•HCl, 
DC, HOBt, NMM, DCM, 0 °C to rt, 16 h, 55%; (i) i. DAST, DCM, −78 °C, 1 h; ii. K2CO3, −78 °C 
o rt, 40 min; (j) DBU, BrCCl3, DCM, 0 °C to 4 °C, 20 h; (k) NBS, AgNO3, acetone, rt, 1 h, 54%; (l) i. 
-Bu3SnH, PdCl2(PPh3)2, THF, −78 °C to rt, 3 h; ii. I2, 0 °C, 45 min, 92%; (m) LiOH, H2O, THF, rt, 
2 h, 97%. 
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Wipf et al. constructed Disorazole C1 from the four segments as shown in scheme 
16; firstly coupling fragments 45 and 67 in a Sonogashira coupling to give alkyne 81. 
Coupling the alcohol of 81 with the carboxylic acid 80 led to 82, which was 
subjected to a further Sonogashira coupling with 67, resulting in 83. Selective mono-
saponification of the methyl ester, followed by Yamaguchi lactonisation provided the 
macrocycle 66 in 79% yield. Finally, reduction of the alkyne with Lindlar’s catalyst 




















   Scheme 16: Wipf synthesis of disorazole C1  32 
 
(a) 67, PdCl2(PPh3)2, CuI, Et3N, CH3CN, −20 °C to rt, 75 min, 94%; (b) 80, DCC, DMAP, DCM, 0 °C 
to rt, 14 h, 80%; (c) 67, PdCl2(PPh3)2, CuI, Et3N, CH3CN, −20 °C to rt, 75 min, 94%; (d) LiOH, H2O, 
THF, rt, 13.5 h, 98%; (e) 2,4,6-trichlorobenzoyl chloride, Et3N, THF, rt, 2 h then DMAP, toluene, rt, 
16 h, 79%; (f) DDQ, phosphate buffer, DCM, rt, 15 min, 61%; (g) H2, Lindlar catalyst, quinoline, 




1.5 Synthesis of Analogues 
1.5.1 t-Butyl Analogue 
The t-butyl analogue 12 synthesised by Graham19 consisted of a simpler side chain 
than disorazole C1, which was constructed in a similar way to the alkyne 67 required 
for the total synthesis (scheme 17). An enantioselective allylation between 
pivaldehyde (84) and allyl trimethyl silane, followed by protection of the alcohol, 
resulted in the silyl ether 85 in a good yield (78%) over the two steps and 91% ee. 
Ozonolysis of the olefin, followed by a reductive workup, provided the aldehyde, 
which underwent condensation with 1,3-bis(triisopropylsilyl)propynyl lithium to 
yield the alkyne. Cleavage of the TBS group resulted in a mixture of enynes 86a and 
86b (~1:4, E:Z) which were easily separable by column chromatography. The TIPS 
group was removed to reveal the terminal alkyne 87, which was coupled to the vinyl 
iodide 45 via a Sonogashira reaction to provide the t-butyl monomer methyl ester 88 
in 94% yield. The synthesis of the macrocycle was completed in an analogous 






















Scheme 17: t-Butyl analogue synthesis 
(a) i. allyltrimethylsilane, (S)-BINOL, TiF4, CH3CN, DCM; ii. HF (48% aq), CH3CN, 56%; (b) TBS-
Cl, imid, DMF, 99%, 91% ee; (c) O3, Sudan III, DCM, then PPh3; (d) TIPSC≡CCH2Li, THF −78 °C, 
30 min; (e) aq HF, (Z)-86a 43% (3 steps), (E)-86b 10% (3 steps); (f) TBAF, AcOH, THF, 76%; (g) 





1.5.2 C(17)-C(18) Cyclopropyl Analogue 
 
For the synthesis of the C(17)-C(18) cyclopropyl analogue 13, again only the side 
chain required modification and the synthesis of this fragment is shown in scheme 
18.19 The alkene of the allylic alcohol 89 was converted to the cyclopropane 90 via a 
Furukawa-modified Simmons-Smith cyclopropanation,32 which displayed excellent 
diastereoselectivity (>9:1). The secondary alcohol was protected as the 3,4-
dimethoxybenzyl ether and the acetonide group was removed using acidic 
conditions, providing the diol 91 in good yield (84%) over the two steps.  The diol 
was protected as the bis-triethylsilylether and selective Swern oxidation followed, 
yielding the aldehyde 92. Analogous to the previous side chain syntheses, the 
aldehyde underwent condensation with 1,3-bis(triisopropylsilyl)propynyl lithium to 
provide the alkyne. The triethylsilylether was removed and the desired (Z)-isomer 
93a was isolated in 32% yield over 4 steps. The sequence was completed with 
removal of the TIPS group to provide alkyne 94, which could undergo Sonogashira 
coupling to the vinyl iodide 45. This provided the required monomer to complete the 
analogue synthesis in an equivalent manner to the total synthesis of disorazole C1.19 
 
 
Scheme 18: C(17)-C(18) Cyclopropyl analogue synthesis 
(a) CH2I2, Et2Zn, DCM, 98%, dr>9:1; (b) 3,4-DMBBr, Et3N, KHMDS, THF; (c) AcOH/THF/H2O 
(4:1:1), 84% over 2 steps; (d) TESOTf, 2,6-lutidine, DCM; (e) (COCl)2, DMSO, then Et3N, DCM; (f) 
TIPSC≡CCH2Li, THF −78 ° C, 30 min; (g) chloroacetic acid, MeOH/DCM (3:1) (Z)-93a 32% (4 




1.5.3 Attempted Synthesis of the C(6)-Desmethoxy Analogue 
 
A modified oxazole fragment was required in order to synthesise the C(6)-
desmethoxy analogue 16.19 This was constructed using a comparable route to that 
used for the total synthesis of disorazole C1; but with the benefit of a shorter 
sequence, due to the lack of substitution at C(6), as shown in scheme 19. The 
commercially available 4-pentynoic acid (95) was coupled to serine methyl ester 
hydrochloride to provide the hydroxyamide 96. Cyclodehydration of the 
hydroxyamide 96 with DAST to the oxazoline and subsequent oxidation resulted in 
the oxazole. The terminal alkyne was subjected to bromination using NBS and silver 
nitrate, affording the bromoalkyne 97 in 51% yield over 3 steps. The bromoalkyne 
underwent a hydrostannylation-iodination to yield the vinyl iodide 98, which in turn 
was coupled to the alkyne 67 in a Sonogashira reaction to give the alkyne 99. 
Saponification of the ester followed by dimerisation under Yamaguchi conditions 
was attempted, but this resulted in low yields and this route was not completed. As a 
result, a stepwise approach was attempted (cf. scheme 16: Wipf synthesis of 
disorazole C1), but, unfortunately low yields were encountered through the route and 
the target compound 16 could not be isolated in acceptable yield or in a pure form. 
The problems faced could have been due to possible instability of the molecule. 
 
 
Scheme 19: Attempted synthesis of the C(6)-desmethoxy analogue 
(a) SerOMe•HCl, EDC, HOBt, NMM, DCM, 34%; (b) DAST, DCM; (c) DBU, BrCCl3, DCM; (d) 
NBS, AgNO3, DMF 51% over 3 steps; (e) n-Bu3SnH, PdCl2(PPh3)2, THF, then I2, 90%; (f) 67, 




1.5.4 Hydrogenated Disorazole C1 
 
During the hydrogenation of the alkyne 10 to disorazole C1 1 (scheme 16), a mixture 
of by-products were collected that had similar structures, perhaps originating from 
alkene isomerisation or saturation. This mixture was treated with hydrogen and 
palladium on carbon to provide a single saturated analogue (15) in 61% yield.19 
 
 
Scheme 20: Hydrogenated disorazole C1 synthesis 
(a) H2, Pd/C, MeOH, rt, 2 h, 61% 
 
 
1.5.5 C(16)-Ketone Analogue 
 
The ketone analogue 14 was simply prepared via a Dess-Martin oxidation of 
disorazole C1, affording the analogue in an excellent yield (91%). 
 
Scheme 21: Ketone analogue synthesis 




1.5.6 (−)-CP2-Disorazole C1 
 
The most recent analogue to be published by the Wipf group is (−)-CP2-disorazole C1 
(11), the retrosynthesis of which is shown in scheme 22.20 The key fragments 
required for this analogue synthesis were the phosphonium salt 100 and the protected 
alcohol 101. In a forward sense the alcohol would be deprotected and oxidised to the 
aldehyde, in order to carry out a Wittig olefination. 
 
 
Scheme 22: (−)-CP2-Disorazole C1 retrosynthesis 
 
The synthesis of the oxazole fragment 101 is shown in scheme 23. The known 
alkyne33 102 was subjected to basic conditions to remove the TMS group and 
hydrogenation of the alkyne resulted in the alkene 103 in excellent yields. Cross 
metathesis of  alkene 103 with alkene 105 (which had been prepared by means of a 
Wittig olefination of the known aldehyde 104) resulted in an inseparable mixture of 
the E/Z isomers of alkene 106 (E/Z = 10:1), which was nonetheless carried forward.34 
O-Methylation, enzymatic ester hydrolysis and coupling of the resulting acid with 
serine methyl ester hydrochloride gave amide 107 in a good yield (65%). Cyclisation 
to the oxazoline and oxidation to the oxazole furnished 101 in good yields. The PMB 






Scheme 23: (−)-CP2-Disorazole C1 oxazole fragment synthesis 
(a) K2CO3, MeOH, 85%; (b) H2, Lindlar cat., quinoline, EtOAc, 96%; (c) I
−Ph3P
+CH3, KHMDS,  
THF, −78 to 0 °C, 74%; (d) 103, Grubbs II (5 mol%), DCM, 40 °C, 70% (E/Z = 10:1); (e) Ag2O, MeI, 
Et2O, 98%; (f) PLE, pH 7.0 phosphate buffer, EtOH, quant; (g) L-SerOMe•HCl, PyBOP, 
iPr2NEt, 
DMF, 65%; (h) DAST, DCM, −78 °C, then K2CO3, 69%; (i) BrCCl3, DBU, 71%; (j) DDQ, 
DCM/H2O, pH 7.0, 0 °C, 97%; (k) DMP, NaHCO3, DCM, 0 °C, 98%. 
 
The synthesis of the corresponding phosphonium salt fragment 100 commenced with 
an asymmetric Mukaiyama aldol reaction under Kiyooka’s conditions35 between the 
silyl ketene acetal 55 and crotonaldehyde (32), yielding the aldol product 109 in very 
good yield and 93% ee (scheme 24). The alcohol was protected as a DMB ether, the 
ester was reduced and the resulting alcohol was oxidised to the aldehyde 110 under 
Swern conditions. Duthaler-Hafner allylation36 conditions using the titanium catalyst 
111 proved to be the most successful method of subsequent asymmetric allylation, 
forming the alcohol 112 in 87% yield and a 4.8:1.0 diastereomeric ratio, favouring 
the anti-configuration. The free secondary alcohol was protected as a TES ether and 
the DMB group was removed and exchanged for a TBS ether. This was to prevent 
formation of an unwanted tetrahydropyran by-product which was observed in the 
later stage formation of the alkyl iodide (step l) when the free allylic alcohol 112 was 
carried through the sequence. Oxidative cleavage of the alkene 113, followed by 
NaBH4 reduction of the resulting aldehyde afforded the alcohol 114 in a good yield 
Introduction 
 39 
of 73% over the 3 steps. Iodination and generation of the phosphonium salt afforded 
100, which in turn was subjected to Wittig olefination conditions with the oxazole 
aldehyde fragment 108, furnishing the (Z)-alkene selectively in 86% yield. Finally, 




Scheme 24: Synthesis of the phosphine and subsequent Wittig reaction 
(a) N-Ts-D-Val, BH3•THF, DCM, −78 ºC, 79%, 93% ee; (b) 3,4-DMBBr, NaH, DMF, 75%; (c) 
LiAlH4, Et2O, −78 ºC, 91%; (d) (COCl)2, DMSO, Et3N, −78 °C, 94%; (e) allylmagnesium chloride, 
Et2O, −78 ºC, 87% (dr = 4.8:1.0); (f) TESOTf, 2,6-lutidine, DCM, 0 ºC, 93%; (g) DDQ, pH 7.0, 
DCM/t-BuOH/H2O (2:1:1), 0 ºC, 85%; (h) TBSCl, Imid., DMF, 50 ºC, 84%; (i) OsO4, NMO, t-
BuOH/H2O (2:1), 0 ºC; (j) NaIO4, dioxane/H2O (2:1), 0 ºC to rt; (k) NaBH4, MeOH, 0 ºC, 73% over 3 
steps; (l) I2, PPh3, imid., DCM, 0 ºC, 85%; (m) PPh3, 
iPr2NEt, toluene, 130 ºC, 92%; (n) 108, 
KHMDS, THF, −78 ºC to 0 ºC, 86%; (o) PPTs, MeOH, 0 ºC, 65%. 
 
Dimerisation of the acid of 115 was desired, however all attempts resulted in the 15-
membered cyclic monomer. Therefore, a more stepwise approach was taken (scheme 
25), proceeding with the ester hydrolysis of 101 and coupling to the alcohol 115, to 
afford ester 116. The PMB group was removed revealing the primary alcohol, which 
was oxidised to the aldehyde under Dess-Martin conditions. The resulting aldehyde 
and phosphonium salt 100 underwent a Wittig reaction to afford the (Z)-alkene 117 
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exclusively. The final steps towards the synthesis of the analogue involved selective 
deprotection of the more labile TES ether over the TBS ether, followed by 
saponification of the methyl ester with barium hydroxide. Shiina lactonisation37 with 
2-methyl-6-nitrobenzoic anhydride and DMAP was utilised to form the macrocycle. 
Removal of the TBS ether resulted in completion of the synthesis of (−)-CP2-










































Scheme 25: (−)-CP2-Disorazole C1 synthesis 
(a) LiOH, THF/H2O; (b) 115, DCC, DMAP, DCM, 0 ºC to rt, 89% (2 steps); (c) DDQ, DCM, H2O, 
pH 7.0, 0 ºC, 81%; (d) DMP, NaHCO3, DCM, 0 ºC, 99%; (e) 114, KHMDS, THF, −78 ºC to 0 ºC, 
74%; (f) PPTs, MeOH, 0 ºC, 63%; (g) Ba(OH)2, THF/H2O; (h) MNBA, DMAP, Et3N, toluene, 55% 









1.5.7 Synthesis of Simplified Disorazole 18 
 
The retrosynthesis of the simplified disorazole 18, designed by Kalesse and co-
workers,23 shown in scheme 26 also centred on a key Wittig reaction, requiring the 
phosphonium salt 118 and the aldehyde 119. 
 
Scheme 26: Simplified disorazole retrosynthesis 
 
The synthesis of the aldehyde fragment 119 (scheme 27) commenced with a Kiyooka 
aldol reaction,35 generating the allylic alcohol 121 in 86% yield, 92% ee and 4:1 
diastereoselectivity. Exposing the acetal 121 to NaHMDS resulted in migration of 
the TBS group to the secondary alcohol and concurrent generation of the aldehyde 
122 in excellent yield. The desired (Z)-configured lactone 125 was obtained in 30% 
yield and a diastereoselectivity of 5:1, via an asymmetric vinylogous aldol reaction 
under Campagne’s conditions38 making use of Carreira’s catalyst.39 The undesired 
open chain (E)-isomer 124 was isolated in 25% yield, however this was not a great 
hindrance as this by-product could be incorporated into the synthesis at a later stage 
to create the (E,E,E)-analogue 19. The lactone 125 was reduced to the lactol, which 
in turn was subjected to a Wittig-Horner reaction with triethyl phosphonoacetate, 
generating the E-alkene. Finally, protection of the secondary alcohol as the TMS 
ether, followed by reduction of the ethyl ester and oxidation to the aldehyde resulted 





Scheme 27: Simplified disorazole: aldehyde fragment 
(a) N-Ts-D-Val, BH3•THF, DCM, −78 ºC, 86%, 92% ee, dr = 4:1; (b) NaHMDS, THF, −78 ºC to 0 ºC, 
92%; (c) 123, CuF•(R)-Tol-BINAP (10 mol%), THF, rt, 125 30%, dr = 5:1, 124 25%, dr = 3:1; (d) 
DIBAL, DCM, −78 ºC, 88%; (e) Triethyl phosphonoacetate, LiHMDS, THF, 0 ºC to rt, 87%; (f) 
TMSOTf, 2,6-lutidine, DCM, 0 ºC, 93%; (g) DIBAL, DCM, −78 ºC, 91%; (h) MnO2, DCM, rt, 96%. 
 
The synthesis of oxazole fragment 118 (scheme 28) started with the condensation of 
serine methyl ester hydrochloride and methyl acetimidate hydrochloride (127), 
providing the oxazoline, which in turn was oxidised to the oxazole 128. Radical 




Scheme 28: Simplified disorazole: oxazole fragment 
(a) DL-SerOMe•HCl Et3N, DCM, 0 ºC to rt, 54%; (b)  DBU, BrCCl3, DCM, −10 ºC to rt, 50%; (c) 







With the two key fragments 118 and 119 in hand, the synthesis was completed as 
shown in scheme 29. A Wittig reaction between aldehyde 119 and phosphonium salt 
118, followed by selective cleavage of the TMS group and hydrolysis of the methyl 
ester resulted in the triene 129. The conjugated triene proved to be difficult to handle, 
therefore all reactions including the ester hydrolysis and subsequent steps had to be 
performed in brown glassware and in the absence of light. Dimerisation was 
successfully executed using Shiina’s lactonisation conditions,40 providing the 
macrocycle in 26% yield. Finally, the TBS groups were cleaved to afford the novel 



























Scheme 29: Completion of simplified disorazole 
(a) KOtBu, THF, −78 ºC to 0 ºC, 85%; (b) HF•Py, pyridine, THF, 0 ºC to rt, 75%; (c) exclusion of 
light, 1 M LiOH, THF, 0 ºC to rt, quant; (d) exclusion of light, MNBA, DMAP, toluene, rt, 26%; (e) 









1.6 Novel Disorazole C1 Synthesis Utilising the Evans-
Tishchenko Reaction and Ring Closing Alkyne Metathesis  
 
All of the previous strategies towards disorazole C1 and its analogues have featured 
macrolactonisation, which requires protecting group strategies and can be poor 
yielding; therefore a novel methodology towards the total synthesis as shown in 
scheme 30 was proposed. This strategy will exploit the C(9)-C(10) alkyne 10, which 
has proven to be a successful precursor to disorazole C1 by masking the unstable 
triene moiety. However, in this approach, the macrocycle will be constructed using 
alkyne metathesis, thus developing a highly convergent route. Ring closing alkyne 
metathesis (RCAM) was chosen over ring-closing metathesis (RCM) due to the fact 
that the (Z)-alkene geometry can be controlled via hydrogenation with Lindlar’s 
catalyst, whereas the geometrical outcome of RCM cannot always be predicted. The 
proposed diyne can be disconnected to the β-hydroxyketone 130 and the aldehyde 
131, which in a forward sense would be joined via an Evans-Tishchenko (ET) 
reaction.41 The ET reaction is regioselective and proceeds with excellent 
diastereoselectivity, as demonstrated by the Hulme synthesis of octalactin,42 which 
successfully applied an Evans-Tishchenko/RCM approach to this medium ring 
lactone. This approach also holds the benefits of avoiding the need for protecting 
groups on the allylic alcohol side chain, which have to be chosen carefully to avoid 
problems late on in the synthesis as exemplified by the Meyers’ synthesis of 
disorazole C1 (section 1.4.1). As highlighted by the SAR summary in figure 10, 
generating heterocyclic analogues of disorazole C1 is a novel area of research, and it 
is an area in which this highly convergent original strategy can be applied. Herein, 
novel approaches to the synthesis of the C(1)-C(9) fragment and heterocyclic 

































Scheme 30: Novel retrosynthesis of disorazole C1  
Results and Discussion 1 
 46 
2 Chapter 2: Racemic Fragment Synthesis 
2.1 Oxazole Natural Products 
  
Oxazoles are a common functionality in natural products, where they are derived 
from enzymatic post-translational modifications of peptidic precursors. This is 
exemplified in the biosynthesis of disorazole C1 (section 1.1), where the oxazole is 
incorporated at a late stage in the process by a non-ribosomal peptide synthetase 
(NRPS). The exact role and involvement in oxazole formation of each domain 
sequenced on the disC gene is unknown; however, a general mechanism for oxazole 
biosynthesis has been established as shown in scheme 31.43 The hydroxyl of amide 
132, derived from serine, undergoes a heterocyclisation onto the preceding carbonyl 
to form 133. This is followed by a dehydration to form the oxazoline 134; finally a 
two-electron oxidation generates the oxazole 135. 
 
 
Scheme 31: Oxazole biosynthesis 
 
Oxazole-containing natural products, such as those shown in figure 11, possess a 
range of valuable biological activities. For example, hennoxazole A 136 exhibits 
potent activity against the herpes virus (IC50 = 0.6 µg mL-1).44 Virginiamycin M2 137 
and related compounds form a family of streptogramin antibiotics.45 The 
phorboxazoles A and B (138a and 138b) display potent antifungal activity, as well as 
anticancer activity.46 




Figure 11: Examples of oxazole containing natural products 
 
2.2 Disorazole C1 C(1)-C(9) Fragment Retrosynthesis 
 
As discussed in Chapter 1, the previous syntheses of the oxazole fragment of 
disorazole C1 have been long and linear; in contrast to this, a novel convergent route 
that can be adapted towards heterocyclic analogues was desired. Taking this into 
consideration, the initial retrosynthesis developed is shown in scheme 32, where the 
disconnection is made at the C(5)-C(6) bond. In a forward sense both routes require 
the aldehyde 140: route A will involve a metal-halogen exchange of the 
halomethyloxazole 139, whereas route B will require a lateral lithiation of methyl 
oxazole 141. 
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Scheme 32: C(1)-C(9) fragment retrosynthesis: disconnection at C(5)-C(6) 
 
2.3 C(1)-C(5) Oxazole Syntheses 
2.3.1 Halomethyloxazole Syntheses 
 
In order to examine the metal-halogen exchange reaction (route A scheme 32), the 
chloro-, bromo- and iodomethyloxazoles were synthesised, as at this stage the 
reactivity of these oxazoles towards the C(6)-C(9) aldehyde was not known. The 
chloromethyloxazole 139a was synthesised following a literature procedure,47 in a 2-
step process. This sequence commenced with condensation of dichloroacetonitrile 
142 and serine methyl ester hydrochloride via an imidate intermediate to give the 
oxazoline 143. Subsequent DIPEA mediated elimination of HCl afforded the 
















Scheme 33: Chloromethyloxazole synthesis 
(a) NaOMe, MeOH, DCM, 0 ºC then DL-SerOMe•HCl, DCM, rt, 24 h, 84%; (b) iPr2NEt, DCM, 50 ºC, 
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Analysis of the literature suggested that the most successful syntheses of the desired 
bromomethyloxazole 139b have been via the route shown in scheme 34.48,49 This 
involves the nucleophilic attack of ethyl diazoacetate (144) onto Vilsmeier’s 
reagent50 to form ethyl 2-diazo-3-oxopropanoate (145) and ethyl chloroacetate (146). 
Treatment of ethyl 2-diazo-3-oxopropanoate (145) with catalytic rhodium acetate 
forms the corresponding carbene, which reacts with bromoacetonitrile to form the 
oxazole 147. This reaction was attempted and appeared to be moderately successful 
by NMR spectroscopy analysis; however, product (147) of acceptable purity was not 
obtained following the purification steps. Other drawbacks to this route include the 
use of an expensive rhodium catalyst and the requirement of having to handle a 
sensitive aldehyde intermediate. As a result, this route was not investigated further 
and an alternative method was sought.  
 
 
Scheme 34: Attempted bromomethyloxazole synthesis  
(a) N,N-Dimethylformiminium chloride, CHCl3, 10 ºC to rt, 1 h; (b) bromoacetonitrile, Rh2(OAc)4, 70 
ºC, 6 h. 
 
Following the success of using dichloroacetonitrile and serine methyl ester 
hydrochloride to synthesise the chloromethyloxazole 139a, it was envisaged that this 
method could be adapted towards the synthesis of the desired bromomethyloxazole 
139b. This was a novel route towards the bromomethyloxazole; pleasingly, the 
synthesis of the required dibromoacetonitrile (149) from cyanoacetic acid (148)  and 
NBS was rapid (5 minutes) and high yielding (96%).51 Subsequently, the analogous 
sequence of reactions that were used for the synthesis of chloromethyloxazole was 
followed. That is, condensation with serine methyl ester hydrochloride, followed by 
base promoted elimination to afford the bromomethyloxazole 139b in moderate to 
good yields. 
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Scheme 35: Bromomethyloxazole synthesis 
(a) NBS, H2O, rt, 5 min, 96%; (b)  NaOMe, MeOH, DCM, 0 ºC then DL-SerOMe•HCl, DCM, rt, 24 h, 
64%; (c) DBU, DCM, 0 ºC, 1 min, 79%. 
 
With the chloromethyloxazole 139a in hand, a simple transformation to the 
iodomethyloxazole 139c via a halogen-exchange reaction with sodium iodide in THF 
was effected,47 thus concluding the synthesis of the required halomethyloxazoles 
(139a-c). Attention was then focused towards the synthesis of the methyl oxazole 
128 for subsequent aldehyde coupling following the lateral lithiation approach. 
 
 
Scheme 36: Iodomethyloxazole synthesis 
(a) NaI, THF, rt, 20 min, 79%. 
 
2.3.2 Methyloxazole Synthesis 
 
The preferred route to the desired methyloxazole 128 was a synthesis which had been 
optimised by an industrial process group52 and consequently the route has been used 
to produce the oxazole in bulk quantities (scheme 37). The route was also analogous 
to the successful routes used towards the halomethyloxazoles 139. The first step of 
the reaction involved formation of an imidate, originating from the treatment of 
chloroacetonitrile (150) with sodium methoxide. This was followed by condensation 
of the imidate with serine methyl ester hydrochloride to form the oxazoline 151. 
Treatment of the crude oxazoline with DBU resulted in elimination of HCl to 
produce the desired methyl oxazole 128, which precipitated out as a colourless solid. 
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Preliminary investigations into this route provided the oxazole 128 in low yields of 
approximately 25%, however, recrystallisation of serine methyl ester from anhydrous 
ethanol and the use of dry solvents increased the yield to a more acceptable 65% 
overall from chloroacetonitrile. 
 
Scheme 37: Methyloxazole synthesis 
(a) NaOMe, MeOH, DCM, 0 ºC then DL-SerOMe•HCl, DCM, rt, 24 h; (b) DBU, DCM, 30 ºC, 30 
min, 65% over 2 steps. 
 
After initial difficulties in generating the methyloxazole 128 in a good yield, other 
routes to the oxazole were probed. One alternative route involved the reaction of 
ethyl acetimidate hydrochloride 152 and serine methyl ester hydrochloride, to 
provide the oxazoline 153, which was oxidised to the oxazole 128 with copper (II) 
bromide (scheme 38).53 Overall, the yield was lower than the original route and 












Scheme 38: Alternative methyloxazole synthesis 
(a) DL-SerOMe•HCl, Et3N, DCM, rt, 18 h; (b) i. CuBr2, DBU, HMTA, 20 min, 0 ºC; ii. 153, THF, 3 h, 
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Another alternative option was a modified literature procedure,54 involving the 
reaction between acetamide 154 and ethyl bromopyruvate, generating the oxazoline 
155; and elimination of water provides the oxazole 156 (scheme 39). Unfortunately, 
the desired product could not be isolated, however, the conditions for the first route 
(scheme 37) had been now been optimised and no further investigations were 












Scheme 39: Ethyl bromopyruvate based methyloxazole synthesis 
(a) Ethyl bromopyruvate, NaHCO3, THF, reflux, 24 h; (b) TFAA, 2,6-lutidine, THF, 0 ºC, 1 h. 
 
Once the synthesis of the methyloxazole 128 was satisfactorily optimised, the methyl 
ester was reduced to the alcohol 141 in good yield (70%), using lithium aluminium 
hydride following the procedure of Carey et al.52 With syntheses towards the 
halomethyloxazoles and the methyloxazole established, attention was now focused 
towards the aldehyde required for both coupling strategies. 
 
 
Scheme 40: Methyl ester reduction 
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2.4 C(6)-C(9) Aldehyde Synthesis 
 
The synthesis of the required enyne side chain was based on the synthesis of the 
related TMS protected alkyne 160 published by Trost and et al.55 (scheme 41). Ethyl 
propiolate (157) was regio- and stereoselectively hydroiodinated to the (Z)-alkene 
158 with sodium iodide in acetic acid. Literature procedures for this reaction reported 
reaction times of over 12 hours; however, by TLC monitoring the reaction was found 
to be complete in 3 hours and the (Z)-alkene 158 was obtained in excellent yield 
(91%). Formation of the (Z)-alkene was confirmed by a J-coupling value of 9.0 Hz in 
the proton NMR spectrum. Isomerisation with hydroiodic acid afforded the (E)-
alkene 159 in 92% yield, confirmed by a J-coupling value of 14.8 Hz. 
 
In order to develop a highly convergent synthesis towards the C(1)-C(9) fragment, a 
Negishi coupling56 with propynylmagnesium bromide was anticipated to be the most 
suitable coupling strategy; rather than attempting a Sonogashira reaction with 
gaseous propyne. The Negishi coupling between the vinyl iodide 159 and propynyl 
magnesium bromide proceeded smoothly, and generated the enyne 161 in an 
excellent 90% yield. The best yields for the Negishi coupling were obtained when 
solid zinc chloride was dried under vacuum with a heat gun (~400 ºC) and a fresh 
slurry in THF was prepared, rather than using a commercial solution. Further 
optimisation of the reaction indicated Pd(PPh3)2Cl2 to be the optimum catalyst over 
Pd(PPh3)4.57  
 Scheme 41: (E)-Vinyl iodide synthesis 
 (a) NaI, AcOH, 70 °C, 13 h, 95%; (b) HI (aq), benzene, 80 °C, 8 h, 95% (E:Z 16:1); (c) 
trimethylsilylacetylene, CuI, Pd(PPh3)2Cl2, Et3N, 50 °C, 13 h, 89%; (d) DIBAL, toluene, −95 °C, 1 h, 
70%;55(e) NaI, AcOH, 70 ºC, 3 h, 91%; (f) HI (57% aq), toluene, 80 ºC, 8 h, 92 % (20:1, E:Z); (g) i. 
ZnCl2, propynylmagnesium bromide, THF, 0 ºC, 15 min; ii. 159, Pd(PPh3)2Cl2, rt, 18 h, 90 %. 
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Attempts were made to reduce the ethyl ester 161 directly to the aldehyde 140 with 
DIBAL, but unfortunately, either incomplete conversion, or over reduction to the 
alcohol were observed. As a result, a two-step approach involving total reduction to 
the alcohol 162 with DIBAL, followed by partial oxidation to the aldehyde was 
adopted. Since the aldehyde 140 is volatile and unstable (boiling point = 56 ºC58), a 
suitable oxidation procedure had to be established which was mild and required little, 
or no purification. Oxidations with IBX in either DMSO,59 or hot ethyl acetate 
resulted in poor yields and the product was contaminated with IBX by-products. 
Manganese dioxide has been shown to be effective at oxidising similar allylic 
alcohols,58,60 and taking this into consideration, the aldehyde 140 was successfully 
generated from alcohol 162 using manganese dioxide, in sufficient purity to be used 
directly in the next step without further purification. It is worthwhile to note that a 
cleaner oxidation was observed when the activated manganese dioxide was sonicated 
in diethyl ether prior to the addition of the alcohol. Now with all of the required 
coupling partners in hand, the coupling strategies could be examined, starting with 
the halomethyloxazoles and aldehyde via route A. 
 
 
Scheme 42: Enyne aldehyde synthesis 
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2.5 Halomethyloxazole and Aldehyde Coupling-Route A 
 
Within the last 20 years, the use of Barbier-type reactions for the synthesis of 
oxazole-containing natural products has increased and it was envisaged that this 
approach could be applied to the synthesis of the C(1)-C(9) fragment of disorazole 
C1. The Barbier reaction is a one-pot, metal-mediated addition between an alkyl 
halide and a carbonyl group thereby generating an alcohol product. A number of 
different metals have been used in this type of reaction, including zinc,61 samarium,62 
indium,63 chromium,64 tin65 and cadmium.66 The proposed Barbier coupling between 
the halomethyloxazoles 139a-c and C(6)-C(9) aldehyde 140 is shown in scheme 43. 
Literature examples of Barbier reaction involving halomethyloxazoles will now  be 
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2.5.1 Oxazole Zinc Barbier-Type Coupling 
 
Helquist et al. realised that the bromomethyloxazole could be used to generate an 
organometallic reagent. Hence, a simple zinc-promoted Barbier reaction with 
bromomethyloxazole 147 was developed and the scope of the reaction was 
investigated.67 The reaction proved to be versatile, affording moderate to excellent 
yields of the alcohol products 164 with aliphatic, aromatic and conjugated aldehydes 
(table 4, entries 1-6). The reaction also proceeded successfully with ketones (table 4, 
entries 7-10) and no Michael addition products were observed with α,β-unsaturated 
ketones (table 4, entries 11 and 12). The group proceeded to use this methodology to 
develop a synthesis of the C(9)-C(23) fragment of virginiamycin M2 and madumycin 




(a) i. Zn, THF, 0 ºC; ii. Carbonyl compound. 














Entry Substrate Yield % 
1 hexanal 92 
2 benzaldehyde 96 
3 PhCH=CHCHO 97 
4 (Me)2C=CHCHO 62 
5 2,4-hexadienal 40 
6 TBDMSO(CH2)3CHO 62 
7 Me2CH(CH2)2C(O)Me 39 
8 cyclohexanone 49 
9 PhC(O)Me 47 
10 cyclopentenone 90 
11 PhCH=CHC(O)Me 93 
12 H2C=CHC(O)Me 52 
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A zinc Barbier reaction was found to be the optimum coupling strategy for a key step 
in the synthesis of siphonazole (scheme 44). The coupling between 
iodomethyloxazole 166 and aldehyde 165 provided the required alcohol product 167 
in 73% yield.70 In this case, the zinc was activated with 1,2-dibromoethane, 
trimethylsilyl chloride and the Lewis acid boron trifluoride diethyletherate. In 
addition, it was established that the iodomethyloxazole was essential for reactivity; a 
result notably in contrast to the successful bromomethyloxazole method developed 





(a) Zn, 1,2-dibromoethane, Me3SiCl, BF3•OEt2, 73%.  
 
 
2.5.2 Oxazole Samarium Barbier-type coupling 
 
The importance of samarium diiodide in organic synthesis was highlighted by Kagan 
and it is now a widely used reagent for a number of transformations.71 Kagan 
demonstrated its use in deoxygenation reactions, reductions of double bonds, 
reduction of halides and tosylates, as well as alkylations of ketones by organic 
halides or organic sulfonates.71 SmI2 has proven to be superior to other metals 
commonly used in the Barbier reaction, by promoting otherwise sluggish reactions. 
For example, in Williams and co workers’ synthesis of phorboxazole A (scheme 45), 
the organozinc oxazole derivative of iodomethyloxazole 169 was found to have long 
reaction times when coupling to aldehyde 168 and only low yields of the alcohol 
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product 170 were obtained. However, when SmI2 was utilised, extremely rapid 





















Scheme 45: Sm Barbier reaction towards the synthesis of phorboxazole A 
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Following on from the total synthesis of phorboxazole A, the Williams group further 
investigated the scope of the samarium Barbier reaction with iodomethyloxazoles, 
benzoxazoles and thiazoles with aliphatic aldehydes.47 The studies with 2,4-
substituted oxazoles 171 are highlighted in table 5. It was found that aromatic 
aldehydes could not be used in this reaction, as they gave rise to competing pinacol 
coupled products. However, 3-phenylpropanal and 3-(benzyloxy)propanal generated 
the desired alcohol products 172 in moderate yields (table 5, entries 1 and 2). 
Isobutyraldehyde provided the most successful results in the samarium-mediated 
Barbier coupling, generating the alcohol product in 98% yield (table 5, entry 3). 
Conversely, α-benzyloxyacetaldehyde showed diminished yields of only 40% (table 




(a) SmI2, aldehyde, THF, rt. 
Table 5: Scope of SmI2 Barbier reaction 
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In contrast to Schlessinger’s synthesis of virginiamycin M2 which utilised a zinc 
Barbier reaction,69 Panek et al. opted for a samarium based approach and the Barbier 
reaction was used to close the macrocyclic ring (scheme 46).73 Interestingly, when 
THF was used as the solvent, low yields of the macrocycle 173 were obtained 
(~10%); however, the yield was increased to 42% when the reaction was carried out 
in benzene. Benzene was required as the solvent to limit a competitive 
dehalogenation, which occurred when the oxazole benzylic radical abstracted a 
hydrogen from THF, which in turn prevented the formation of the organosamarium 
intermediate. It is also noteworthy, that in this case, the chloromethyloxazole and 
iodomethyloxazole demonstrated similar reactivities, providing the macrocycle 174 
in comparable yields of 40 and 42% respectively.  
 
 
Scheme 46: Intramolecular Sm Barbier reaction 
(a) SmI2, benzene, 42%. 
 
2.5.3 Use of Other Metals in Oxazole Centred Barbier Reactions 
 
Other metals have also been used in studies towards the synthesis of oxazole-
containing natural products. For example, Uguen’s synthesis of virginiamycin M2 
featured a building block similar to the one utilised by Panek (scheme 46); however, 
in this case the macrocycle was constructed using a Takai coupling, which generated 
an organochromium species in situ using LiAlH4 and CrCl3.74 This reaction was not 
as successful as Panek’s samarium-mediated coupling and afforded the macrocycle 
in 23% yield. It was postulated that the low yield could be due to restricted rotation 
around the peptide bond, resulting in an unfavourable conformation for the 
organochromium and aldehyde to react. 
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After considerable experimentation, the Smith group found a Grignard exchange 
reaction most successful towards their synthesis of (+)-phorboxazole A (scheme 
47).75 This reaction presumably occurred through a Grignard exchange of the 
bromomethyloxazole, to generate the metallooxazole, which in turn attacked the 
lactone 175, to generate the alcohol 176 as a single stereoisomer. This 




(a) 2-(bromomethyl)oxazol-4-yl trifluoromethanesulfonate, iPrMgCl, −78 to −15 ºC, 76%. 
 
 
2.5.4 Route A: Attempted Synthesis of C(1)-C(9) fragment 
 
Based on the review of the literature regarding halomethyloxazole Barbier reactions, 
zinc and samarium Barbier conditions were attempted, in order to develop a route 
towards the C(1)-C(9) fragment of disorazole C1. Model studies were performed 
using commercially available crotonaldehyde (31), which was deemed a suitable 
substitute for the unstable and volatile C(6)-C(9) aldehyde 140. 
 
The simple zinc Barbier conditions developed by Helquist et al.67 were applied to the 
model system, but unfortunately their successes could not be repeated. The 
chloromethyloxazole 139a appeared to be less reactive than the bromomethyloxazole 
139b, yet both reactions with HCl-activated zinc (table 6, entries 1 and 2) generated 
the methyl oxazole 128. In 3 hours 12% of the chloromethyloxazole 139a had been 
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converted to the methyloxazole 128, compared to the majority of the 
bromomethyloxazole 139b being converted to the methyloxazole 128 in the same 
amount of time. In addition, traces of the desired product 177 could be seen in the 
NMR spectrum of the bromomethyloxazole crude reaction mixture. The use of 
diethylaluminium chloride69 as an activating agent (table 6, entry 3), again resulted in 
the majority of the bromomethyloxazole 139b being converted to the methyloxazole 
128, with traces of starting material and product visible in the NMR spectrum. No 
reaction was observed when the zinc Barbier reaction was carried out in the presence 
of ammonium chloride76 (table 6, entry 4). Submitting the HCl-activated zinc and 
bromomethyloxazole 139b to ultrasonic vibration prior to the addition of aldehyde 
31 and leaving the reaction for an extended time of 40 hours, also resulted in 
conversion to the methyloxazole 128 (table 6, entry 5). The conversion to the 
methyloxazole suggests that the bromozinc species was formed, but was 




Table 6: Attempted Barbier reactions 








HCl activated Zn (1.5 equiv), THF, 0 ˚C, 3 h 88 0 12 
2 Br 
139b 
HCl activated Zn (1.5 equiv), THF, 0 ˚C, 3 h trace trace 99 
3 Br 
139b 
Zn (2.4 equiv), Et2AlCl3 (1 equiv) THF, 30 ˚C, 1 h trace trace 99 
4 Br 
139b 
Zn, aq NH4Cl:THF (1:1), rt, 18 h 100 0 0 
5 Br 
139b 
HCl activated Zn (1.5 equiv), sonication, THF, rt, 40 h 48 0 52 
6 I 
139c 
SmI2 (2.5 equiv), THF, rt, 30 min 100 0 0 
a NMR analysis of reaction mixture.  
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Williams’ samarium Barbier conditions47 were also attempted, this time utilising the 
iodomethyloxazole 139c, but again, no desired alcohol product 177 could be isolated 
(table 6, entry 6). The samarium diiodide was successfully formed after sonication of 
samarium metal and iodine in THF, in the absence of light. The formation was 
confirmed by the colour change of the mixture from orange to the dark blue of the 
Sm(II). Following the literature precedent, it is unknown why the reaction between 
the halomethyloxazoles 139 and crotonaldehyde failed, especially when taking into 
consideration that in Helquist’s investigations, 3-methylcrotonaldehyde afforded the 
alcohol product in 62% yield (table 4, entry 4). The difficulties could have been due 
to the known air and moisture sensitivities of metal-halogen species; especially the 
SmI2. In addition, previous publications have reported difficulties in reproducing or 
adapting known Barbier reactions.47 
 
After unsuccessful attempts at applying the common methods of Barbier reactions 
for halomethyloxazoles, new reagents and methods were sought. The halomethyl 
group can be considered as a heteroaromatic benzylic moiety, therefore more general 
reagents to activate benzylic halides were investigated. The Knochel group are 
currently at the forefront of organometallic research and recent publications77,78,79 
appeared to be applicable to the oxazole coupling. It is reported that LiCl facilitates 
the insertion of zinc into the carbon-chlorine bond; a particularly interesting example 
featured the coupling of ethyl 3-(chloromethyl)benzoate 178 and 4-
bromobenzaldehyde to generate the secondary alcohol 179 in 91% yield (scheme 
48).78 Accordingly, these conditions were applied to the chloro- and 
bromomethyloxazoles (139a and b) and crotonaldehyde (31) model system (scheme 
48); but unfortunately, no reaction was observed. Again, the problems could have 
arisen in the metal activation step; 1,2-dibromoethane and TMSCl were used as 
activating reagents, and consequently it is possible that acidic impurities in the 
TMSCl could have quenched the organometallic species. However, after premixing 
the TMSCl with triethylamine to eliminate acidic impurities, none of the desired 
alcohol 177 could be identified by NMR spectroscopy and in fact, formation of 
methyloxazole 128 was now observed. 
 




















Scheme 48: Lithium/zinc halogen exchange 
(a) i. LiCl, Zn; ii. 4-bromobenzaldehyde, THF, 0 ºC to rt, 4 h, 91%;78(b) i. LiCl, Zn; ii. 
crotonaldehyde, THF, 0 ºC to rt, 2 h. 
  
 
A subsequent publication by the Knochel group reported an improved formation of 
benzylic zinc chlorides.79 This reaction is promoted by a rapid formation of a 
magnesium chloride species, followed by in situ transmetallation with zinc chloride, 
to generate the benzylic zinc chloride species. The zinc chloride species was 
successfully reacted with electrophiles, such as, acyl chlorides and aldehydes. For 
example, the reaction between chloride 180 and 4-bromobenzaldehyde as shown in 
scheme 49 generated the alcohol 181 in 82% yield. Once more, these conditions 
could not be transferred to our model system and no desired alcohol product 177 
could be identified by TLC, or from the crude NMR spectrum. With this metallation 
approach proving to yield no results towards the desired product, attention was 
turned toward alternative routes including, a Fukuyama coupling and the 
aforementioned lateral lithiation approach. 
 




Scheme 49: Mg/LiCl/ZnCl2 halogen exchange 
(a) i. Mg, LiCl, THF, 1.5 h, 0 ºC to rt; ii. ZnCl2; iii. 4-bromobenzaldehyde, THF, 2 h, 82 %;
79(b) i. 
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2.5.5 Fukuyama Coupling 
 
An alternative line of investigation towards the C(1)-C(9) fragment of disorazole C1 
involved forming the ketone 183, which could then be stereoselectively reduced to 
the required alcohol 163. From the bromomethyloxazole 139b and ester 161 it was 
envisaged that a Fukuyama coupling could be established. The Fukuyama coupling 
involves the formation of a bromo- or iodozinc species followed by a palladium 
catalysed reaction with a thioester.80 The thioester 182 was effectively generated in a 
quantitative yield from the ethyl ester 161, via a displacement with 
(ethylthio)trimethylsilane and aluminiumtrichloride.81 The Fukuyama coupling failed 
when applied to the bromomethyl ester 139b and enyne thioester 182 (scheme 50), 
probably due to zinc activation issues, as previously discussed (section 2.5.4). In 
addition, there is no record of this type of coupling with similar substrates in the 
literature; therefore, the failure of the reaction could have been due to poor reactivity 
of one, or both of the coupling partners. However, no further screening was 
performed to investigate the problematic substrates, as progress was being made 
through the lateral lithiation approach, which is to be discussed in the next section. 
 
 Scheme 50: Attempted Fukuyama coupling 
(a) Me3SiSEt, AlCl3, THF, 70 ºC, 3 h, quant; (b) i. 139b, Zn, THF, 70 ºC, 2 h; ii. Pd(PPh3)2Cl2, 182, 
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2.6 Methyloxazole and Aldehyde Coupling - Route B 
 
With established routes to the methyl oxazole 141 and aldehyde 140 it was believed 
that a lateral lithiation of the methyloxazole to generate the anion, followed by 
nucleophilic addition to the aldehyde would provide a highly convergent route 
towards the C(1)-C(9) fragment of disorazole C1. 
 
Scheme 51: Proposed lithiation approach towards C(1)-C(9) fragment 
 
2.6.1 Oxazole Lateral Lithiation Background 
 
One of the first examples of lateral lithiation on a 2-methyloxazole was published by 
Lipshutz.82 Following lithiation of the trimethyloxazole 185 with LDA, the resulting 
lithium species was reacted with a variety of electrophiles, including ketones, 
epoxides, alkyl halides and, of particular interest towards our investigations, 
aldehydes were successfully coupled  to provide secondary alcohols.  An example of 
this is the reaction between the trimethyloxazole 185 and benzaldehyde (186) to 
afford the alcohol 187 in 89% yield (scheme 52). Only lithiation at the C-2 methyl 
group was observed and, interestingly, when the first product (187) was subjected to 
a further lithiation, electrophilic addition once more occurred at the C-2 methyl 
position.  
 
Scheme 52: Lithiation of trimethyl oxazole 
(a) LDA, THF, −78 ºC, 89%. 
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The higher reactivity of C-2 methyl groups over the other positions of the oxazole 
can be attributed to the resonance stabilisation of the ionic intermediate, as shown in 
scheme 53, where the negative charge can be delocalised into the C=N π system 
(189).83 
 
Scheme 53: Methyl oxazole resonance 
 
Although 2,4-substituted oxazoles are a common structural feature of natural 
products, it was not until 15 years after Lipshutz first published the lithiation of 
methyl oxazoles that this methodology was applied to natural product synthesis. Two 
examples of the application of lithiation of oxazoles to natural product synthesis are 
shown in scheme 54. During the synthesis of phenoxan, Peña’s group observed a 
selective alkylation with allyl bromide 190 at the C-2 methyl of (2-methyl-1,3-
oxazol-4-yl)methanol (141) using LDA, thereby generating the oxazole 191 in 50% 
yield.84 Pattenden’s synthesis of virginiamycin also centres around the (2-methyl-1,3-
oxazol-4-yl)methanol (141) and featured a deprotonation with nBuLi, followed by 
nucleophilic attack of the resulting anion on to the aldehyde 192.85 The desired 
alcohol 193 was obtained in a 34% yield. 
 
 
Scheme 54: (2-Methyl-1,3-oxazol-4-yl)methanol lithiation examples in natural product synthesis 
(a) i. LDA (2 equiv), THF; ii. 190, 50%; (b) i. nBuLi (2 equiv), THF; ii. 192, 34%. 
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2.6.2 Results: Initial Investigation into (2-Methyl-1,3-oxazol-4-
yl)methanol Lithiation 
Encouraged by the regioselectivity demonstrated by Peña and Pattenden’s lithiations 
of (2-methyl-1,3-oxazol-4-yl)methanol, lithiations with nBuLi and LDA formed the 
starting point for our investigations towards the synthesis of the C(1)-C(9) fragment 
of disorazole C1 (table 7). Once again, the crotonaldehyde model system was applied 
to initial studies, with the intention of optimising and developing the reaction 
conditions in preparation for application to the enyne aldehyde 140. When oxazole 
141 was treated with nBuLi at −78 °C, followed by addition of crotonaldehyde (32), 
two products were observed (table 7, entry 1). An inseparable mixture (~1.5:1 
194:195) of the desired alcohol 194 and the alcohol 195 was obtained, where 
deprotonation had occurred at the C-5 position. The identity of the by-product 195 
was determined from the NMR spectrum by the disappearance of the C-5 oxazole 
proton and the continued presence of the C-2 methyl group. Contrary to Peña’s 
group’s reports that a selective lithiation occurs with LDA, a ~1:1.7 mixture of 
desired product 194 and by-product 195 was observed when deprotonation with LDA 
was applied to the crotonaldehyde model system (table 7, entry 2). 
 
The unexpected formation of the by-product (195) led to further investigations into 
the lithiation reaction and a range of bases were screened as highlighted in table 7. 
Hamana and Sugasawa demonstrated the use of 9-BBN triflate and 
diisopropylethylamine to selectively deprotonate 2-methyl-4-phenyl-1,3-oxazole at 
the C-2 methyl group, and upon reaction with benzaldehyde they successfully 
generated the alcohol product in 70% yield.86 Unfortunately, when the reported 
conditions were applied to our model system, no alcohol product could be identified 
by NMR spectroscopy (table 7, entry 3). It should be noted that Hamana and 
Sugasawa only observed reactions with benzaldehyde derivatives and attempts to 
apply these conditions to aliphatic aldehydes and ketones failed. Deprotonation with 
LHMDS also failed to provide any of the desired alcohol 194 (table 7, entry 4). 
Conditions developed by the Evans group involving nBuLi and diethylamine87 
provided the most promising results, whereby no by-product 195 was observed, but 
unfortunately only 44% of the oxazole starting material 141 was converted into the 
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desired product 194 (table 7, entry 5). Inspired by these promising results and with 
the knowledge that the base can affect the regioselectivity of the reaction, the use of 
sparteine as a chiral directing agent, as well as an additive base was investigated 
(table 7, entry 5). Unfortunately, this reaction did not proceed to completion and in 
addition, the reaction was not regioselective, with 26% desired product (194) and 
21% by-product (195) observed in the crude NMR spectrum. 
 
Table 7: Initial investigations into lithiation of (2-methyl-1,3-oxazol-4-yl)methanol 












1 nBuLi (2) 1  1.5 8 57 35 
2 LDA (2.1) 1  1 3 36 64 
3 9-BBN triflate (1) 1 iPrNEt(1.2) 18 100 0 0 
4 LHMDS (2) 1.1  2 100 0 0 
5 nBuLi (2) 1.2 NHEt2 (3) 0.75 56 44 0 
6 nBuLi (5) 2 sparteine (6) 0.75 53 26 21 
a NMR analysis of crude reaction mixture after work up 
2.6.3 Evans Group Investigation into Base Effect 
 
The influence of diethylamine on the regioselectivity of the lithiation of 
methyloxazoles was discovered by the Evans group, through the development of 
routes towards the total synthesis of the phorboxazoles.87 Table 8 highlights some of 
the results obtained by the Evans group that are relevant to our studies and 
understanding of the mechanism of this reaction. The initial studies featured a range 
of functional groups at the C-4 position of oxazole and of particular interest were the 
investigations with (2-methyl-1,3-oxazol-4-yl)methanol (table 8, entries 1-3). These 
results are comparable to the results obtained in our crotonaldehyde model system; 
that is, approximately 50:50 ratio of product and by-product when nBuLi or LDA are 
utilised, but regioselectivity is observed when lithium diethylamine is employed as 
the base. Two equivalents of nBuLi were required for this reaction, as the alcohol 
proton is first removed, followed by deprotonation of the C-2 methyl group. A 
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greater excess of diethylamine was also required for reactions with (2-methyl-1,3-
oxazol-4-yl)methanol compared to other C-4 substituents, where there was no free 
alcohol present. 
 
More detailed mechanistic investigations were carried out by the Evans group with a 
methyloxazole featuring an (E)-alkene side chain (196), as a model study towards the 
synthesis of the phorboxazoles.87 It was found that increasing the temperature of the 
reaction from −78 to −50 ºC favoured the formation of the desired C-2 methyl 
substituted product 197. This effect was more pronounced when the amine base used 
was diisopropylamine, rather than TMP (table 8, entry 8). Furthermore, 
regioselectivity could be achieved with diisopropylamine by increasing the reaction 
time to 60 minutes, as well as performing the reaction at −50 ºC (table 8, entry 9). 
Interestingly, when the temperature of the nBuLi mediated reaction was increased to 
−50 ºC, the ratio of product 197 to by-product 198 was not significantly affected, but 
a small amount of decomposition was observed (table 8, entry 10). It is also 
noteworthy to mention that the Evans group experienced incomplete consumption of 
starting materials; however most reactions proceeded with ≥93% conversion. 
 
(a) i. see table, THF (amine); ii. MeOTf. 
Table 8: Evans investigation into base effect on lithiation regioselectivity 




nBuLi  −78 20 55:45 
2 LDA  −78 20 50:50 






nBuLi  −78 20 61:39 
5 nBuLi Et2NH −78 10 >95:5 
6 nBuLi iPr2NH −78 10 66:34 
7 nBuLi TMP −78 10 64:36 
8 nBuLi iPr2NH −50 10 82:18 
9 nBuLi  iPr2NH −50 60 >95:5 
10 nBuLi  −50 60 55:45 
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2.6.4 Proposed Lithiation Mechanism 
 
Based on the experimental results obtained by the Evans group, a mechanism for the 
lithiation reaction has been proposed. As increasing the temperature of nBuLi 
reaction had no effect on the ratio of the products, it can be assumed that during this 
reaction a kinetic mixture of the products 197 and 198 is formed and there is no 
interconversion between the two lithiated species 205 and 206 (scheme 56). After a 
series of crossover experiments at −78 ºC (scheme 55), Knaus and Meyers also drew 
the conclusion that lithiated 2,4-dimethylthiazole does not interconvert between the 
two lithium intermediates 199 and 202.88 For example, when the lithiated 
methylthiazole 199 was exposed to 2-methyl-4-phenylthiazole 200, followed by 
quenching with iodomethane, only the ethylthiazole 201 was isolated. The 
corresponding experiment where the C-5 lithiated species 202 was exposed to 2,4-
dimethylthiazole 203, followed by quenching with iodomethane resulted in only the 
trisubstituted thiazole 204. This suggests that no lithium-proton exchange takes place 
at −78 ºC, as there was no evidence of the crossover products. Knaus and Meyers 
have suggested that at −78 ºC the kinetic acidities of the C-2 methyl proton and the 
C-5 proton are similar. However, a +I effect (for example CH2OH or methyl) can 
increase the electron density at C-5, making the proton less acidic and therefore, the 
C-2 methyl proton is more likely to be removed by a base. This idea is reflected in 
the observed results obtained by Evans, where the 55:45 ratio of product 197 to by-
product 198 slightly favours 2-methyl lithiation when nBuLi is used as a base. 
 
 
Scheme 55: Meyers methylthiazole crossover experiments 
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Evans et al. have proposed that once an amine is introduced into the lithiation 
reaction, interconversion between the lithiated regioisomers (205 and 206) can occur 
via a reversible pathway, which is now available (scheme 56). Via this pathway, the 
5-lithiated species 206 converts to the more thermodynamically stable 2-methyl 
lithiated species 205, which goes on to react with the electrophile, therefore 
providing the ethyl oxazole 197 as the major product. Evidence of the two lithiated 
intermediates (205 and 206) and their equilibration to C-2 methyl intermediate 205 
has been observed by NMR experiments.87 It can be observed from the results in 
table 8 that the steric bulk of the amine affects the kinetics of this equilibrium, with 
diethylamine proving to be the quickest and TMP the slowest. Moreover, increasing 
the reaction time gave a longer duration for interconversion to the more 
thermodynamically stable product 205. Based on these findings, it was suggested that 
the regioselectivity encountered when LiNEt2 was used as a base resulted from the 
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Encouraged by the results obtained while working with the Evans group, Smith went 
on to further investigate the factors controlling this equilibrium pathway in detail.89 It 
was established that other lithium dialkylamides facilitate the equilibrium between 
the two lithiated oxazole species. The effectiveness of the lithium base centres on the 
pKa of the conjugate acid lying between the pKas of the C-5 ring proton and the C-2 
methyl proton. When the base satisfies this pKa condition, the conjugate acid of the 
lithium amide base can act as a proton shuttle between the two lithiated oxazole 
species. The base investigation was performed on the phenylmethyloxazole 207 and 
table 9 highlights the lithium amide bases that were screened, in increasing order of 
size. As pKa and amine size parallel each other, an increase in pKa can also be 
assumed on descending the table. Excellent regioselectivity and good conversion was 
observed for LiNEtMe, LiNEt2, LiNiPr2 and LiNEtiPr (table 9, entries 2-5). 
Therefore, it can be assumed that these bases are an appropriate size and posses the 
correct pKa range to initiate the equilibrium pathway between the lithio-
intermediates. Conversely, regioselectivity and conversion declined when the 
stronger and larger bases LiNnBu2 and LiNiPr2 were employed (table 9, entries 6 and 
7); furthermore, dialkylation was also observed. LiN(SiMe3)2 demonstrated high 
regioselectivity (table 9, entry 1), but only moderate conversion was observed and 
significant amounts of double alkylated products were detected; a result that could 












(a) i. base, THF, −78 ºC, 30 min; ii. MeI, −78 ºC, 3 h. 
Table 9: Smith further investigation into the effect of base on the  lithiation reaction 
Entry Base  pKa of conjugate acid 208:209 Conversion (%) 
1 LiN(SiMe3)2 29.5 95:5 59 
2 LiNEtMe 30.9 >99:1 >99 
3 LiNEt2 31.7 >99:1 89 
4 LiNnPr2  >99:1 97 
5 LiNEtiPr  99:1 79 
6 LiNnBu2  53:47 67 
7 LiNiPr2 34.4 23:77 72 
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Another factor that could influence the regioselectivity of this reaction is the nature 
of the electrophile. Smith’s group found that as the reactivity of the electrophile 
decreased, there was in increase in regioselectivity towards the C-2 methyl product 
210 (table 10).89 However, this trend was only apparent when nBuLi or LDA was 
used as the base. Consistent with previous results, high regioselectivity for the C-2  




(a) i. base, THF, −78 ºC, 30 min; ii. Electrophile, −78 ºC, 3 h. 
Table 10: Smith investigation into the effect of electrophiles with methyloxazole 
  nBuLi LiNiPr2 LiNEt2 
Entry Electrophile (210:211)  Conversion 
(%) 
(210:211)  Conversion 
(%) 
(210:211)  Conversion 
(%) 
1 benzaldehyde <1:99 >99 <1:99 >99 98:2 86 
2 TMSCl 4:96 97 1:99 78 >99:1 92 
3 MeOTf 9:91 ≥90 9:91 ≥90 99:1 ≥90 
4 MeI 14:86 83 37:63 78 99:1 89 
5 acetone 20:80 78 58:42 61 96:4 88 
 
The differences in product ratio and conversion rate on descending table 10 has been 
attributed to a difference in nucleophilicity of the two lithium intermediates (205 and 
206) resulting in different rates of reaction with the electrophiles. A reactive 
electrophile such as benzaldehyde (table 10, entry 1) will result in a product ratio 
reflecting the kinetic ratio of the lithio-intermediates. However, if a less reactive 
electrophile such as acetone (table 10, entry 5) is used the more nucleophilic C-2 
methyl anion reacts preferentially and this is reflected in the observed product ratio. 
A decrease in starting material conversion is also observed as electrophilicity 
decreases. 
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2.6.5 Results: Base Optimisation 
 
With the nBuLi and diethylamine reaction being the only conditions to promote a C-
2 methyl regioselective lithiation onto oxazole 141, attempts were made to optimise 
the reaction and to facilitate consumption of the oxazole starting material 141. It was 
found that increasing the reaction time from 45 minutes to one hour had little effect 
on the outcome of the reaction. It could even be considered to be detrimental, with a 
37% conversion to the desired product 194 in one hour, compared to a 44% 
conversion observed in the 45 minute reaction (table 11, entry 1 and table 7, entry 5). 
In addition, increasing the quantity of nBuLi did not seem to affect the product (194) 
to starting material (141) ratio; 82-84% conversion was observed when the molar 
ratio of nBuLi was increased from 2.8 to 5 equivalents (table 11, entries, 2-4). 
Interestingly, it was the increase in quantity of diethylamine (from 3.3 equivalents to 
6 equivalents) that had the greatest influence on the conversion of starting material to 
product, with this modification to the reaction conditions providing an 85% yield of 
alcohol 194 (table 11, entry 3). However, this could not be improved upon, and 
increasing the excess of crotonaldehyde to 3 equivalents resulted in a slightly 











Time (h)  141 (%)a 194 (%)a 195  
(%)a 
1 nBuLi (2.2) 2 3.3 1 63 37 0 
2 nBuLi (2.8) 2 6 0.5 18 82 0 
3 nBuLi (4) 2 6 0.5 14 86 0 
4 nBuLi (5) 2 6 0.75 16 84 0 
5 nBuLi (4) 3 6 0.5 14 78 8 
a NMR analysis of crude reaction mixture after work up 
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2.6.6 Alcohol Protecting Group Effect 
 
The best results obtained from the model studies with (2-methyl-1,3-oxazol-4-
yl)methanol (141) and crotonaldehyde (32) are comparable with those published by 
Evans,87 whereby excellent C-2 methyl regioselectivity was achieved. However, the 
reaction did not proceed to completion; this is also consistent with literature reports.  
Unfortunately, a further problem became apparent in that, in this case, the product 
195 could not be separated from the unreacted starting material 141, despite 
numerous attempts at optimising solvent conditions for column chromatography. 
Based on the proposed mechanism by Evans and Smith,87 we wanted to investigate 
the effect of protecting groups on the alcohol, specifically to see if larger groups 
might block lithiation at the C-5 position. In addition, it was envisaged that a 
protecting group could aid the purification step of separating product from unreacted 
starting material. A range of different sized protecting groups and groups containing 
different functionalities were investigated. As shown in scheme 57, TBDMS, MOM 





P = TBDMS 212a (a) TBDMSOTf, 2,6-lutidine, DCM, 0 ºC, 1 h, 89 %; P = SEM 212b (b) i. NaH; ii. 
SEMCl, THF, 0 ºC to rt, 3 h, 68 %; P = MOM 212c (c) i. NaH; ii. MOMCl, THF, 0 ºC to rt, 3 h, 73 %.  
 
The protected alcohol oxazoles 212 were subjected to the optimised conditions for 
the oxazole lithiation with crotonaldehyde (32), however, fewer equivalents of nBuLi 
(two rather than four) were required as initial deprotonation of the alcohol did not 
have to be considered in these reactions. Highly interesting was the reaction with the 
TBDMS protected oxazole 212a, as no reaction was observed over several attempts 
(table 12, entry 2). This could have been because the TBDMS group is sterically 
bulky and may be hindering access of the nBuLi to the C-5 proton. Therefore, the C-
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5 lithio-species is not generated and the diethylamine cannot act as a proton shuttle to 
convert to the C-2 methyl lithiated intermediate.  
 
Pleasingly, the reactions with the SEM (212b) and MOM (212c) protected oxazoles 
were highly regioselective, with no addition at C-5 observed. Also, the reactions 
showed a greater conversion of starting material 212 to product 213 than the 
corresponding free alcohol (table 12, entries 3 and 4). These protecting groups are 
longer chained and more flexible than the TBDMS group; it is therefore postulated 
that the nBuLi is required to first deprotonate at C-5 and subsequently the 
interconversion to the C-2 methyl lithio-species is facilitated by diethylamine. 
Unfortunately, the SEM protected product 213b could not be separated from the 
unreacted oxazole starting material 212 by column chromatography. Nevertheless, 
the MOM protected oxazole 212c demonstrated the highest conversion rate and 
separation of the desired product and starting material was possible. However, the 
purification process required the mixture to be passed through two silica gel 
columns, run at a slow rate with 2% methanol in DCM; even then there was some co-
elution of the two components 212 and 213. In the interest of maximising purity, 
these were discarded to give a satisfactory isolated yield of the desired product 213 
(50%). To this end, a satisfactorily optimised lateral lithiation of methyloxazole had 
been established using a model system and this could now be applied to the synthesis 
of the C(1)-C(9) fragment of disorazole C1. 
 
 
(a) i. nBuLi, THF, −78 C; ii. NHEt2; iii. Crotonaldehyde. 
 
Table 12: Investigation into effect on alcohol protecting group 
Entry P 212 (% by NMR) 213 (% by NMR) 213 isolated yield (%) 
1 H 14 86  
2 TBDMS 100 0  
3 SEM 8 92  
4 MOM 4 96 50 
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2.7 Completion of the Racemic C(1)-C(9) Fragment of Disorazole 
C1 
 
With the required methyl oxazole 212c and aldehyde 140 in hand, the optimised 
conditions for the lateral lithiation could be applied to these key substrates (scheme 
58). As with the model system, the coupling reaction did not proceed to completion, 
and unexpectedly, there was approximately 80% conversion of starting material 
212c, as determined by NMR spectroscopy which was less than that observed for the 
model system. This could have been due to the change of aldehyde; the enyne 
aldehyde 140 is volatile and unstable and the exact quantity added to the reaction 
was unknown, as it was used in crude form directly from the previous oxidation step. 
Nevertheless, alcohol product 214 was obtained in a 40% yield based on the starting 
material 212c recovered from the silica column.  
 
The final steps to the desired fragment involved sodium hydride-mediated O-
methylation of 214 with iodomethane, which generated the methyl ether 215 in a low 
yield of 29%. This was followed by deprotection of the MOM group under acidic 
conditions and finally, Dess-Martin oxidation90 of the resulting primary alcohol to 
the aldehyde (±)-131 in 43% yield. Some of these reactions were low yielding; 
however, no attempt was made to optimise these steps as alternative routes towards 
the fragment synthesis were now being investigated. Overall, the desired C(1)-C(9) 
fragment of disorazole C1 (±)-131 was synthesised in a racemic manner, with the 
longest linear route being 9 steps and an overall yield of 1.6 %.  
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Scheme 58: Completion of the racemic C(1)-C(9) fragment of disorazole C1 
(a) i. nBuLi, THF, −78 ºC, 45 min; ii. NHEt2, 45 min; iii. 140, 45 min, 40%; (b) i. NaH, THF, 0 ºC; ii. 
MeI, 0 ºC to rt, 18 h, 29 %; (c) HCl, MeOH, rt, 18 h, 74%; (d) DMP, NaHCO3, DCM, 0 ºC, 2 h, 43%. 
 
2.8 Summary 
Two routes towards the C(1)-C(9) fragment of disorazole C1 have been attempted 
following a C(5)-C(6) disconnection. Zinc or samarium promoted metal-halogen 
exchange with halomethyloxazoles, followed by nucleophilic attack of 
crotonaldehyde proved to be unsuccessful. Investigations into lateral lithiation of (2-
methyl-1,3-oxazol-4-yl)methanol provided some interesting results and changing the 
protecting group of the “benzylic” alcohol had an effect on the regioselectivity of the 
reaction and ease of purification of the product. Following optimisation of this route 
the coupling between the methyl oxazole and the enyne aldehyde was successfully 
completed, albeit in low yield. Consequently, the racemic synthesis of the C(1)-C(9) 
fragment was completed. It was initially anticipated that the desired enantiomer 
could be separated from the racemic mixture, for example using a lipase catalysed 
kinetic resolution. However, ultimately this lithiation route resulted in some low 
yielding steps and in order to complete the total synthesis of disorazole C1 it was 
deemed not to be an optimum synthetic route. Alternative disconnections were 
therefore investigated which might allow greater flexibility for analogue synthesis 
and easier generation of the stereogenic centre. 
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3 Chapter 3: Enantiospecific Fragment Synthesis I 
3.1  Adaptation of Previous Disorazole C1 Syntheses 
 
After the successful synthesis of the racemic fragment, focus was now towards an 
asymmetric synthesis that could provide rapid access to the C(1)-C(9) fragment and 
possibly be adapted towards heterocyclic analogues. Inspiration was drawn from the 
previous syntheses of disorazole C1 and these routes will now be discussed.  
3.1.1 Meyers Based Approach 
After examining the other previous syntheses of disorazole C1 (section 1.4), it 
appeared that the Meyers synthesis,25 featuring a condensation between the acid 26b 
and serine methyl ester 216, would be the shortest route and it could be adapted to 
provide the desired C(1)-C(9) fragment. There was also the added advantage that the 
required alcohol starting material 220 containing the stereogenic centre is 
commercially available. Another attractive feature of the Meyers based approach is 
that it could be adapted towards heterocyclic analogues, such as the triazole 217, as 
highlighted by the retrosynthesis shown in scheme 59. The triazole could be 
constructed from methyl propiolate 218 and the azide 219 via a copper catalyzed 
azide-alkyne cycloaddition (CuAAC) reaction. This route towards the triazole was 
investigated by the Hulme group; however, some difficulties were encountered and 
an improved route was later discovered which will be discussed in Chapter 4. 
 
 
Scheme 59: Meyers based retrosynthesis of oxazole and triazole analogue 
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When the Meyers group commenced the total synthesis of disorazole C1 the 
stereochemistry of the molecule had not been assigned. It was later confirmed28 that 
that the Meyers group had synthesised the incorrect stereoisomer at the C(6) centre; 
this incorrect assignment therefore had to be taken into consideration when following 
this route.  
 
Direct routes for the oxidation of the commercially available alcohol 220 to the 
carboxylic acid 26b were investigated, as shown in table 13. Oxidation with 
NaIO4/RuCl3 (table 13, entry 1) resulted in loss of the acetonide group, which was 
unexpected, as oxidation under these conditions had successfully been performed on 
a molecule containing an acetonide group.91 Oxidation with PDC92 (table 13, entry 2) 
resulted in complete conversion of the alcohol to the acid by NMR spectroscopy, 
however purification and isolation was difficult, resulting in a low isolated yield of 
the acid 26b. A milder oxidation involving TEMPO/NaClO2/NaOCl (table 13, entry 
3) only resulted in 40% conversion of the alcohol 220 to the acid 26b.93 It was 
therefore decided to adopt a two-step oxidation of the alcohol 220 to the acid via the 
aldehyde 221.  
 
 
Table 13: Attempted oxidation of alcohol to acid 
Entry Reagents Result 
1 RuCl3, NaIO4 No desired product isolated, removal of acetonide observed 
2 PDC 100% conversion, but difficult isolation 
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A Swern oxidation,94 followed by oxidation with sodium chlorite and hydrogen 
peroxide95 proved to be most successful, providing the acid 26b in 76% yield over 
the two steps (scheme 60). However, both the acid 26b and aldehyde 221 were found 




Scheme 60: Carboxylic acid synthesis 
(a) (COCl)2, DMSO, Et3N, DCM, −78 °C, 2 h, assume quant; (b) NaClO2, H2O2, tBuOH/H2O, rt, 18 h, 
76 % over 2 steps. 
 
The succeeding steps shown in scheme 61 followed the Meyers synthesis (section 
1.4.1),25 commencing with an amide coupling between serine methyl ester 
hydrochloride and the acid 26b to provide the amide 27b in 47% yield. This low 
yield was unexpected, as the Meyers group reported a yield of 67%.25 All attempts to 
improve the yield were unsuccessful and isolation and purification of the amide 27b 
proved difficult, due to the high polarity of the molecule; hence, some of the product 
could have been lost during aqueous work-up and column chromatography. 
Diminished yields were also encountered when the oxidation (scheme 60) and amide 
coupling reactions (scheme 61) were performed on larger scales, therefore these 
reactions had to be performed in batches of approximately 5 g of the starting alcohol 
220. Cyclodehydration of the amide 27b to the oxazoline with DAST, followed by 
oxidation with DBU and BrCCl3 resulted in the oxazole 28b in 68% yield over the 
two steps. A by-product was also isolated after column chromatography of the 
oxazole; analysis of the by-product by NMR spectroscopy suggested the compound 
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Scheme 61: Oxazole formation 
(a) HCl•L-SerOMe, 1,1’-CDI, THF, 0 ºC to rt, 18 h, 47%; (b) DAST, K2CO3, DCM, −78 °C to rt, 2 h; 
(c) DBU, BrCCl3, DCM, 0 °C to rt, 18 h, 66% over 2 steps. 
 
The subsequent four steps (scheme 62) revolved around alcohol protecting group 
manipulations, starting with the deprotection of the acetonide 28b using acidic 
DOWEX resin. This allowed for simple isolation of the product following removal of 
the resin by filtration, providing the diol (quantitative yield) of suitable purity to 
advance to the next step. The primary alcohol was selectively protected with a TIPS 
group providing 223 in 78% yield, allowing for methylation of the secondary alcohol 
(63% yield). This was followed by TIPS deprotection with TBAF, furnishing the key 
primary alcohol 53 in 73% yield. 
 
 
Scheme 62: Formation of alcohol 
(a) Dowex-H+, MeOH, rt, 18 h, quant; (b) TIPSOTf, 2,6-lutidine, DCM, −78 °C to rt, 2 h, 78%; (c) 
MeI, Ag2O, CH3CN, 60 °C, 18 h, 63%; (d) TBAF, THF, 0 °C to rt, 18 h, 73%. 
 
Alcohol 53 and its enantiomer 24 were key intermediates in both the Meyers 
synthesis25 and the Hoffmann synthesis30 of disorazole C1 and both syntheses 
involved the oxidation to the unstable aldehyde 224. As described in Section 1.4.2, 
the Hoffmann synthesis went on to form the vinyl iodide 45 through a reaction with 
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the Ohira-Bestmann reagent, followed by hydrostannylation/metal–iodine exchange. 
However, in order to shorten the route it was realised that a Takai olefination96 could 
convert the aldehyde 224 directly to the vinyl iodide 45. Taking into consideration 
the unstable nature of the aldehyde, an oxidation method with a straightforward 
purification was required. Therefore, a Parikh-Doering oxidation,26 as used by 
Meyers, was utilised and the aldehyde was immediately subjected to Takai 
olefination conditions (scheme 63). Unfortunately, only small amounts of the vinyl 
iodide 45 could be isolated. A Dess-Martin oxidation90 was also attempted as an 
alternative oxidation method, but no improvement could be made to the yield of the 
vinyl iodide 45.  A trial Negishi reaction, to complete the fragment synthesis, was 
attempted on 2 mg of the vinyl iodide 45. Analysis of the crude reaction mixture by 
NMR spectrometry showed evidence of the alkyne CH3 coupled to one of the alkene 
protons with a doublet at 1.96 ppm, demonstrating the synthesis of desired product 
225. Sadly, the final fragment 225 could not be isolated due to the small scale of the 
reaction. The Meyers route was not as easily reproducible as expected and, in 
particular, difficulties were encountered in performing the initial steps towards the 
oxazole formation. Therefore, this route was abandoned in favour of the development 
























Scheme 63: Attempted synthesis of C(1)-C(9) fragment 
(a) SO3•Pyr, DMSO, Et3N, DCM or DMP, NaHCO3, DCM; (b) CrCl2, CHI3, THF/dioxane (1:6), rt, 
18 h; (c) i. propynylmagnesium bromide, ZnCl2, toluene, rt, 15 min; ii. Pd(PPh3)2Cl2, 45, rt, 18 h. 
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3.1.2 Wipf Based Approach 
 
Another previous synthesis of disorazole C1 which looked adaptable towards our 
fragment synthesis was the Wipf strategy (Section 1.4.3).15 The Wipf group’s 
synthesis featured alkyne 77, which was coupled to serine methyl ester hydrochloride 
and cyclised to form the oxazole 78. 
 
Scheme 64: Wipf oxazole synthesis 
(a) SerOMe•HCl, EDC, HOBt, NMM, DCM, 0 °C to rt, 16 h, 55%; (b) i. DAST, DCM, −78 °C, 1 h; 
ii. K2CO3, −78 °C to rt, 40 min; (c) DBU, BrCCl3, DCM, 0 °C to 4 °C, 20 h. 
 
The Wipf synthesis consisted of 8 steps to generate the oxazole 78, however a 
concise route to the TMS protected alkyne 102 was published in 2008 (scheme 65);33 
it was thought this new route would provide rapid access to our desired oxazole 
fragment. With a desire to shorten the route further, we commenced the synthesis 
using ethyl propiolate 157, rather than the TMS protected alkyne 226. Condensation 
of the lithium enolate of ethyl acetate with ethyl propiolate generated the β-ketoester 
228. The product could be identified by proton NMR spectroscopy, but the presence 
of keto-enol tautomers complicated the spectrum. Unfortunately, the β-ketoester 228 
appeared to be unstable, as low yields of product were isolated and decomposition 
was observed over a few days. Nevertheless, the crude mixture obtained from the 
reaction was advanced to the next step involving an enantioselective reduction of the 
ketone 228 in the presence of Saccharomyces cerevisiae. However, none of the 
desired alcohol 229 could be isolated.  




Scheme 65: Attempted synthesis of alkyne alcohol 
(a) i. iPrNH, nBuLi, −78 ºC, THF; ii. EtOAc, 1 h; iii. AcOH, 91%; (b) S. cerevisiae, glucose, H2O, 
EtOH, 30 °C, 18 h, 72%, 92% ee; (c) i. iPrNH, nBuLi, −78 ºC, THF; ii. EtOAc, 1 h; iii. AcOH; (d) S. 
cerevisiae, glucose, H2O, EtOH, 30 °C, 18 h. 
 
After our unsuccessful attempts at the synthesis of the alkyne 229, the Wipf group 
published the synthesis of (−)-CP2-disorazole which featured the Meyer and Cossy33 
route towards alkyne 102 (Section 1.5.6 and scheme 66).20 However, no yield or 
enantiomeric excess were reported by the Wipf group for their synthesis of the 
alkyne after reproducing the literature procedures. The TMS protecting group was 
cleaved under mild basic conditions and the alkyne was reduced to the alkene 103 
using Lindlar’s catalyst. Alkene cross metathesis between the alkenes 103 and 105 
resulted in alkene 106, which was later transformed into the oxazole segment. It 
would appear that the TMS group is necessary for the stability of the β-ketoester 227, 
however, our attention was now focused on alternative more convergent routes 
towards the C(1)-C(9) fragment and the synthesis of the TMS protected alkyne 102 
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 Scheme 66: Wipf use of alkyne 102 in (−)-CP2-disorazole C1 synthesis 
 (a) K2CO3, MeOH, 85%; (b) H2, Lindlar cat., quinoline, EtOAc, 96%; (c) Grubbs II (5 mol%), DCM, 
40 °C, 70% (E/Z = 10:1). 
 
3.1.3 Summary 
Investigations into adapting the previous syntheses of the oxazole section of 
disorazole C1 proved to be more difficult than expected and a number of problems 
were encountered. The initial steps of the Meyers based route from the alcohol to the 
oxazole, involved unstable intermediates and synthesis of these intermediates on a 
large scale resulted in poor yields. This in turn limited options for optimising later 
stage reactions. Overall, this was a long linear sequence involving unstable 
intermediates and low yielding steps and adequate amounts of late stage 
intermediates could not be isolated. The Wipf based route also involved handling 
unstable intermediates and this synthesis could not be progressed. A convergent, 
adaptable route towards the C(1)-C(9) fragment was always desired, therefore focus 
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3.2 C(4)-C(5) Disconnection Approach 
3.2.1 C(1)-C(9) Fragment Retrosynthesis 
 
After investigating a C(5)-C(6) disconnection (as outlined in Chapter 2) and 
encountering difficulties with designing an enantioselective route based around this, 
or the literature precedented routes to the disorazoles (section 3.1) it was decided that 
a different disconnection approach was required. Therefore, the next disconnection 
we chose to investigate was at the C(4)-C(5) bond (scheme 67). This would still 
generate a convergent synthesis towards the desired fragment and heterocyclic 
analogues, with the advantage now being that the stereogenic centre would be set 
into the epoxide fragment 231 prior to the key coupling to the oxazole. The 
retrosynthesis shown in scheme 67 is akin to the retrosynthesis discussed in Chapter 
2, where the epoxide 231 could either be coupled to a halooxazole 230 via a metal-




Scheme 67: C(4)-C(5) disconnection of the C1 C(1)-C(9) fragment 
 
There is no literature precedent for the formation of C-2 substituted oxazoles via a 
coupling with epoxides, there are however examples of opening epoxides to produce 
secondary alcohols with aromatics such as bromobenzene, 2-
(bromomethyl)thiophene and furan. As demonstrated by Carnell and Allan (scheme 
68, reaction A),97 a simple bromine-lithium exchange on arylbromides 233a-c 
facilitated the regioselective opening of propylene oxide to generate 1-phenyl 
propan-2-ol 234a, 1-thienyl propan-2-ol 234b and 1-furyl propan-2-ol 234c, all in 
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good yields. Newman et al.98 (scheme 68, reaction B) generated the Grignard reagent 
phenylmagnesium bromide from bromobenzene 235, which in turn was used in a 
regioselective nucleophilic opening of (S)-epichlorohydrin, catalysed by copper 
iodide, to generate the secondary alcohol 236 in a very good  yield (85%). An 
example of direct lithiation of a heterocycle, followed by epoxide opening was 
published by Lipshutz (scheme 68, reaction C).99 The C-2 lithiated furan was 
generated, which in turn was converted to a cuprate. The Lewis acid boron trifluoride 
diethyletherate was required to promote the nucleophilic, regioselective ring opening 
of the epoxide by this cuprate and the secondary alcohol 238 was generated in a high 
yield of 81%. Based on these high yielding, regioselective examples of generating 
secondary alcohols from epoxides and aryl rings, the retrosynthesis of the C(1)-C(9) 
fragment outlined in scheme 68 appeared to be a viable, convergent route and the 
synthesis of the required oxazoles and epoxide was commenced.  
 
 
Scheme 68: Examples of epoxide opening 
(a) i. nBuLi, THF, −30 ºC to rt, 30 min; ii. −30 ºC to rt, 1 h, propylene oxide, Ar = 1-phenyl propan-2-
ol 234a 68%, 1-thienyl propan-2-ol 234b 61%, 1-furyl propan-2-ol 234c 77%; (b) i. Mg, I2, THF, 
reflux, 30 min; ii. (S)-epichlorohydrin, CuI, THF, −60 ºC to rt, 1 h, 85%; (c) i. nBuLi, THF, −30 ºC to 
rt, 1 h; ii. CuCN, −30 ºC to 15 ºC; iii. 2-pentyloxirane, BF3•Et2O, −78 ºC, 2 h, 81%.  
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3.2.2 C(1)-C(4) Oxazole Synthesis 
3.2.2.1 Halooxazoles 
 
Hodgetts and Kershaw pioneered the synthesis of ethyl 2-chlorooxazole-4-
carboxylate 230a to create a simple building block which could be elaborated to aid 
the synthesis of the common 2,4-disubstituted oxazole motif.100 Their method was 
repeated, commencing with the condensation of ethyl bromopyruvate (239) and urea 
to provide the HCl salt of aminooxazole 240 in 73% yield (scheme 69). This was 
followed by conversion of the aminooxazole 240 into the chlorooxazole 230a by 
treatment with tert-butyl nitrite and copper (II) chloride. Despite other published 
reproductions of this transformation,101,102 in our hands only low yields of the desired 
chlorooxazole 230a product could be isolated, with the greatest yield being 27%. 
Monitoring the consumption of the aminooxazole 240 was difficult by TLC due to 
the highly polar nature of the compound. Formation of the product 230a could be 
observed by TLC; however analysis of the reaction mixture by mass spectrometry 
did show some starting material remaining. The isolated yield of the desired product 
230a could not be improved by increasing the reaction time.  
 
 
Scheme 69: Synthesis of chlorooxazole 
(a) Urea, EtOH, 85 ºC, 2 h, 73%; (b) tBuO-NO, CuCl2, CH3CN, 60-80 ºC, 2 h, 27%. 
 
The analogous bromooxazole 230b would also be a desirable intermediate; however 
when this synthesis was attempted by Hodgetts and Kershaw the desired 
monobromooxazole 230b was generated in only 21% yield; in addition, the 
dibromooxazole 241 was isolated in 16% yield (scheme 70).100 Attempts by Hodgetts 
and Kershaw to optimise this reaction were unsuccessful, the yield could not be 
improved and selectivity for one product over the other could not be established.100 
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Following our disappointing results towards the synthesis of the chlorooxazole 230a, 
and considering the limited published routes towards the bromooxazole 230b, it was 
decided not to pursue the synthesis of the bromooxazole 230b. Reported yields of the 
synthesis of the corresponding iodooxazole are also low (28%),103 therefore, 
attention was turned to the synthesis of ethyl 1,3-oxazole-4-carboxylate. 
 
 
Scheme 70: Literature synthesis of bromooxazole 
(a) tBuO-NO, CuCl2, CH3CN, 60-80 ºC, 2 h, 230b 21%, 241 16%. 
 
3.2.2.2 Synthesis of 1,3-Oxazol-4-ylmethanol 
Known compound ethyl 1,3-oxazole-4-carboxylate 244 was synthesised following a 
literature procedure via a condensation between formic acid (242) activated by 1,1’-
carbonyldiimdazole and ethyl isocyanoacetate (243), as shown in scheme 71.104 
Ethyl 1,3-oxazole-4-carboxylate 244 was readily generated on a large scale of up to 6 




Scheme 71: Synthesis of ethyl 1,3-oxazole-4-carboxylate 
(a) 1,1’-CDI, NEt3, THF, rt to 80 ºC, 24 h, 80%. 
 
The simple reduction of the ethyl ester 244 to the primary alcohol 245 proved to be 
more difficult than anticipated. Reductions with common agents, such as sodium 
borohydride,105 lithium aluminium hydride,106 lithium triethylborohydride107 and 
DIBAL showed complete consumption of the ethyl ester 244; formation of the 
product alcohol 245 was confirmed by proton NMR spectroscopy. However, isolated 
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yields of 245 were very poor and the alcohol proved to be volatile and therefore 
difficult to handle. The alcohol 245 was required for a multi-step synthesis and hence 
large quantities of this intermediate were desired; however, due to the volatile nature 
of the alcohol these requirements could not be met.  Following on from the 
discoveries of chapter 2, where the protecting group was shown to affect the 
regioselectivity of the lithiation of the 2-methyl oxazole, it was thought that a 
protecting group could also affect lithiation reactions with 1,3-oxazol-4-ylmethanol. 
Therefore attempts were made to immediately protect alcohol 245 with a TBDMS 
group (simultaneously increasing the weight of the molecule and decreasing the 
volatility). Unfortunately, the desired product 246 could not be isolated in reasonable 










 Scheme 72: Ester reduction to alcohol 
(a) H−; (b) TBDMSOTf, 2,6-lutidine, DCM, 0 ºC, 1 h. 
 
Despite promising literature precedent for the synthesis of the chlorooxazole 230a 
and oxazole 245 the procedures could not reliably be reproduced. The alcohol 245 
proved difficult to handle due to volatility and attempts to ease handling by adding a 
TBDMS group failed. Investigations into the synthesis of the epoxide were being 
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3.2.3 C(5)-C(9) Epoxide Retrosynthesis 
The desired epoxide 231 can be disconnected at the C(7)-C(8) double bond to the 
alkene 247 and enyne 248, which in a forward sense would be coupled by an alkene 
cross metathesis (Scheme 73, route A). An alternative would be route B (scheme 73), 
where the alkene can be constructed from the aldehyde 249 and phosphine salt 250 













249 250  
Scheme 73: C(7)-C(8) alkene disconnection 
 
3.2.4 C(7)-C(8) Alkene Bond Formation via Cross Metathesis -
Route A 
3.2.4.1 Alkene Cross Metathesis Background 
 
It was envisaged that the epoxide enyne 231 could be synthesised via a cross 
metathesis reaction between (S)-2-vinyloxirane 247 and pent-1-en-3-yne 248. 
Metathesis reactions are now commonly used in organic synthesis and the 
development of new catalysts and reaction conditions is on going. Cross metathesis 
(CM) reactions hold the caveat of limited selectivity of the CM product over the 
homometathesis products. The CM between 2-vinyloxirane 247 and pent-1-en-3-yne 
248 has not been reported and their respective reactivities were unknown, therefore 
investigations into this coupling were carried out. 
 
 
Scheme 74: Proposed cross metathesis reaction 
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Examples of the use of 2-vinyloxirane 247 in olefin cross metathesis (CM) have 
shown formation of the (E)-isomer as the major product. For example, when 
exploring the scope of a new catalyst 251, the Grubbs group showed CM between 2-
vinyloxirane and the alkene 249 to be sucessful.108 The CM product 250 was isolated 
in 55% yield and an E:Z ratio of 5:1.108 The yield of the CM product was greatest 
when the 2-vinyloxirane was added slowly over 12 hours, rather than all in one 
portion; homodimerisation of the starting materials was also observed. In their 
synthetic studies towards (+)-strictifolione, Kumar et al. investigated a CM route 
between (S)-2-vinyloxirane and the alkene 252 catalysed by Grubbs’ II catalyst.109 
The desired product 253 was isolated in a low 16% yield (6:1, E:Z) and 
homodimerisation products from both starting materials were observed. The yields 
from both of these CM reaction with 2-vinyloxirane were low; however, the (E)-
isomer was the major product, which was encouraging for our own investigations 
into CM with 2-vinyloxirane. 
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Scheme 75: Literature examples of CM with 2-vinyloxirane 
(a) 2-vinyloxirane, catalyst 251 (5 mol%), DCM, reflux, 12 h, 55% (5:1, E:Z);108(b) (S)-2-
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The first investigations into CM with conjugated enynes were published in 2003 by 
Chang et al.110 CM reactions with 4-phenyl-1-buten-3-yne (255), catalysed by 
Grubbs I or Grubbs II failed and the starting material (255) was recovered in 
quantitative yield. It is thought that the alkyne triple bond binds to the ruthenium 
centre of the catalyst, therefore rendering it inactive.110 The binding of the enyne to 
the catalyst was monitored by IR spectroscopy, where the peak of the alkyne shifted 
from 2217 to 2151 cm-1, representing a weakened triple bond due to binding to a 
metal. When a new catalyst 257, developed by the Grubbs group,111 was employed in 
CM reactions with enynes, the desired CM products were isolated in acceptable 
yields. For example, the CM reaction between 4-phenyl-1-buten-3-yne (255) and 
allyltrimethylsilane catalysed by 257 resulted in the alkene product 256 in 60% yield; 
surprisingly, an E:Z ratio of 1:3.1 was observed (scheme 76). Conversely, Hansen 
and Lee reported successful CM reactions with various conjugated enynes catalysed 
by Grubbs II catalyst.112 They found that yields were not greatly improved by the use 
of catalyst 257; but interestingly, the (Z)-isomer was once again the major product.112 
 
 
Scheme 76: Example of CM with enyne 
(a) Allyltrimethylsilane, catalyst 257 (10 mol%), toluene, reflux, 12 h, 60% (1:3.1, E:Z). 
 
Olefin CM reactions commonly generate the (E)-isomer as the major product, as it is 
the most thermodynamically stable isomer. Consequently, the results observed with 
the enynes reported by Chang and Hansen and Lee were unexpected. The generation 
of the (Z)-isomer as the major product was repeatedly observed across a range of 
enyne substrates and alkene coupling partners. Examining the metallacyclobutane 
intermediate of the CM mechanism (scheme 77), it can be seen that the N-
heterocyclic carbene ligand blocks one face of the metallacyclobutane 258. This 
would force the two alkene substrates to approach from the same side, because if the 
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substrates approached from different sides it would result in unfavourable steric 
hindrance as shown in intermediate 260. In addition, it has been suggested that the 
enynes do not participate in the reversible metathesis cycles,113 therefore it is the 

























Scheme 77: Enyne CM metallacyclobutane intermediates 
3.2.4.2 C(7)-C(9) Enyne Synthesis 
Inspired by the successful synthesis of the enyne ester 161 in Chapter 2 (scheme 41), 
Negishi conditions were applied to 1-propynylmagnesium bromide (262) and vinyl 
bromide in an attempt to synthesise the enyne 248 (scheme 78). The enyne 248 is 
reported to have a boiling point of 60 ºC;114 therefore care had to be taken during 
work-up and purification. After work-up and extraction with diethyl ether, the crude 
mixture was distilled to isolate the desired product. A proton NMR spectrum of the 
distillate showed small amounts of the desired enyne 248, however THF from the 
solutions of 1-propynylmagnesium bromide and vinyl bromide had co-distilled and 
was the major component of the distillate.  
 
Scheme 78: Negishi reaction to generate enyne 
(a) i. ZnCl2, toluene, rt, 15 min; ii. Pd(PPh3)2Cl2, vinyl bromide (1 M in THF), rt, 18 h. 
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Eglington and Whiting reported the conversion of β,γ-acetylenic tosylates to 
vinylacetylenes under alkaline conditions.115 To this end, the alcohol 263 was treated 
with tosylchloride in pyridine to provide the tosylate 264 in excellent yield (scheme 
79). The tosylate 264 was subsequently heated with potassium hydroxide in ethanol 
and water at 120 ºC; a few drops of detergent were also added as Eglington and 
Whiting reported cleaner reactions and higher yield when a trace of “Teepol” was 
added to the reaction mixture.115 The enyne 248 was evolved as a gas and to aid 
purification, the product was collected by passage through a fractionating column 
and condenser. The liquid collected was highly volatile and identification of the 
product 248 was confirmed through proton NMR spectroscopy. Some co-distillation 
of ethanol was observed, as evidenced by the NMR spectrum, however the liquid 
collected was mainly composed of the enyne 248, which was used immediately in 
the next step. 
 
 
Scheme 79: Enyne synthesis 
(a) TsCl, pyridine, 0 ºC to rt, 18 h, 92%; (b) KOH, EtOH, H2O, 120 ºC, assume quant. 
 
3.2.4.3 Attempted Cross Metathesis 
Based on the published results, it seemed likely that the (Z)-alkene would be the 
major isomer for our system. However, CM conditions have not been applied to 
these exact substrates, therefore investigations were carried out. The enyne 248 was 
used immediately after distillation from the previous step, it was treated with 2-
vinyloxirane 247 and Grubbs II catalyst in DCM (scheme 80). After heating at reflux 
for 5 hours more catalyst was added and the reaction mixture was stirred overnight. 
Following purification by silica column chromatography, the only isolable product 
was the homodimer of 2-vinyloxirane (254). The identification of 254 was based on 
the observations of Kumar et al.,109 and comparison of NMR data to the literature.116  
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Scheme 80: Attempted cross metathesis between 2-vinyloxirane and pent-1-en-3-yne 
 (a) Grubbs II (20 mol%), DCM, 40 ºC, 24 h. 
 
The enyne 248 is highly volatile and proved difficult to handle, and it is also likely 
that the (Z)-isomer would be the major product in the CM reaction. Therefore, further 
investigations into cross metathesis were terminated and attention was turned to the 
Wittig reaction. 
3.2.5 C(7)-C(8) Alkene Bond Formation via Wittig Reaction - Route 
B 
It was envisaged that the desired epoxide 231 could be constructed via a Wittig 
reaction between the epoxide aldehyde 249 and the phosphorus ylide 250. 
Considering stabilised ylides favour the formation of the (E)-alkene in the Wittig 
reaction, the butyne section was chosen to contain the ylide, as it is more stabilised 
than the epoxide half. In addition, there is literature precedent for using this ylide 250 








249 250 231  
Scheme 81: Proposed Wittig reaction 
Examples of the use of these the aldehyde 249 and ylide 250 are shown in scheme 
82. But-2-ynyltriphenylphosphonium bromide 250 was utilised in a Wittig reaction 
with aldehyde 265 in the synthesis of pheromone dodeca-8E,10E-dien-1-ol. Despite 
the low yield of the product 266, the (E)-isomer was generated as the major isomer 
with an E:Z ratio of 7:3.117 An example of the use of an in situ oxidation of glycidol 
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267, followed by a Wittig reaction is also shown in scheme 82; the (E)-isomer of 268 
was generated in 70% yield as the major isomer, though no E:Z ratio was reported.118 
 
Scheme 82: Examples of Wittig reaction with alkyne 250 and epoxide 267 
(a) i. nBuLi, THF, −78 ºC, 30 min; ii. 265, −78 to −40 ºC, 1 h; iii. H+, 37% (7:3, E:Z); (b) DMSO, 
(COCl)2, Et3N, DCM, −78 ºC, 1 h; (c) Ph3PCHCOPh, rt, 20 h, 70% over 2 steps. 
 
The phosphine salt required for the Wittig reaction, shown in scheme 83, was readily 
synthesised from 1-bromo-2-butyne 269 and triphenyl phosphine;119,120 the 
phosphorus ylide 250 was generated after exposure to potassium tert-butoxide. 
Glycidol (267) was oxidised to the aldehyde 249, using BAIB and TEMPO,121 and it 
was used immediately in the next step (as it was predicted to be unstable and 
volatile). After work-up and purification of the Wittig reaction, no alkene product 
231 could be isolated and the triphenyl phosphine oxide (270) by-product was 
difficult to separate. It is likely that the enyne epoxide 231 is volatile, therefore a 
simple purification procedure was required. Therefore, the use of polymer supported 
triphenylphosphine was investigated, as this has proven to be advantageous in other 
Wittig reactions involving volatile and unstable products.122 
 
 
Scheme 83: Attempted Wittig reaction 
(a) PPh3, rt, 16 h, 72%; (b) BAIB, TEMPO, DCM, rt, 4 h, assume quant; (c) i. tBuOK, DCM, rt, 1 h; 
ii. 249, rt, 18 h. 
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A polymer supported phosphorus ylide would enable the triphenyl phosphine oxide 
to be removed by filtration, thereby simplifying the purification and isolation of the 
desired product. The polymer supported phosphine salt was synthesised by heating 1-
bromo-2-butyne 269 and polymer supported triphenylphosphine in DMF for 48 
hours (scheme 84). This time, the aldehyde 249 was synthesised by a Dess-Martin90 
oxidation of glycidol (267); the phosphorus ylide generated after treatment of salt 
271 with potassium tert-butoxide was added directly into the oxidation reaction. 
After filtration of the polymer support, aqueous work-up of the crude mixture and 
column chromatography, none of the desired enyne epoxide 231 could be isolated. 
This reaction was attempted a number of times, and the base to form the phosphorus 
ylide was altered to nBuLi, but to no avail.  
 
 
Scheme 84: Polymer supported Wittig reaction 
(a) polymer supported PPh3, DMF, 70 ºC, 48 h, quant; (b) DMP, NaHCO3, DCM, 0 ºC to rt, 2 h, 
assume quant; (c) i. tBuOK, DCM, rt, 1 h; ii. 249, rt, 18 h. 
 
Intriguingly, each time the reaction was performed the only compound isolated was 
an unidentified by-product. This by-product was only isolated in small amounts, for 
example 50 mg was isolated when the reaction was performed on 1.74 mmol of 
phosphorus ylide. With a desire to identify this by-product full characterisation was 
carried out. The main distinguishing peaks in the NMR spectrum included an ethyl 
group and a doublet at 6.74 ppm, representing a proton on a trisubstituted alkene next 
to a CH. After further analysis of the proton and carbon NMR spectra, the remaining 
peaks appeared to correspond to an epoxide. It can be seen from the HSQC-TOCSY 
spectrum (figure 12), that the ethyl group is contained in a separate spin-system from 
the rest of the molecule. 
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Figure 12: HSQC-TOCSY NMR spectrum of the unknown by-product  
 
A distinctive carbonyl peak was visible in the IR spectrum at 1693 cm-1, which 
represents a conjugated carbonyl group. The total number of carbon and hydrogen 
atoms could be deduced from the NMR spectra, which corresponded to 7 and 9 
respectively. Interestingly, an unexpected characteristic bromine isotope pattern was 
observed in the mass spectrum of the isolated product and after piecing together the 
data already collected, the main peaks in the mass spectrum did not correspond to the 
expected mass. Taking into consideration the data collected the mass expected to be 
seen in the EI spectrum was 203/205 (C7H9BrO2), however the highest mass peak 
was observed at 174/176. This difference of 29 mass units could be attributed to the 
loss of an ethyl group; however it is more likely to be due to the fragmentation of an 
epoxide and loss of formaldehyde. Epoxides are relatively unstable and 
fragmentation is highly likely, especially by the harsh conditions of EI mass 
spectrometry, thereby explaining the absence of the predicted mass peaks at 203/205. 
A mechanism for epoxide fragmentation is shown in scheme 85; initially a 
rearrangement tales place to provide aldehyde 273, which undergoes loss of 
formaldehyde, generating the cation 274, which is observed in the mass spectrum.123 




Scheme 85: Epoxide fragmentation under EI mass spectrometry conditions123 
 
Upon mass spectrometry analysis of the commercial 1-bromo-2-butyne (269) a small 
amount of 1,1-dibromobut-2-yne was evident. Based on this observation, and after 
combining the available data, the structure 277 was proposed. A plausible 
mechanism is shown in scheme 86: ylide 275 could have been formed from 1,1-
dibromobut-2-yne and a subsequent Wittig reaction with aldehyde 249 could have 
resulted in enyne 276. Hydrolysis of the alkyne 276 would generate the enone 277. 
Alternatively, the alkyne on the ylide could have been hydrolysed to generate 278 
and this could have undergone a Wittig reaction to generate the enone 276.  It is 
thought that this was the only compound isolated from the reaction mixture as it was 
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249 278 277  
Scheme 86: Possible routes to Wittig reaction by-product  
As the desired epoxide enyne 231 could not be obtained through the cross-metathesis 
or Wittig reaction, alternative routes including the HWE reaction and epoxidation of 
an aldehyde were briefly investigated 
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3.2.6 Horner-Wadsworth-Emmons Reaction 
HWE reactions have the advantage over Wittig reactions of the dialkylphosphate salt 
by-product being water soluble and therefore it can be more easily removed from the 
reaction mixture. An example of the synthesis of an enyne by the HWE reaction is 
shown in scheme 87. The phosphonate ester 279 was exposed to KHMDS and the 
reaction with acetaldehyde resulted in the enyne 280 in 66% yield, however no E:Z 
ratio was reported.124 
 
Scheme 87: HWE enyne synthesis 
(a) KHMDS, acetaldehyde, THF, −78 ºC, 66% 
 
The required phosphonate ester 281 was readily synthesised from 1-bromo-2-butyne 
(269) in quantitative yield. The phosphonate ester was subsequently subjected to 
similar conditions used in the Wittig reaction described above. Unfortunately, no 
desired product 231 could be identified in a proton NMR spectrum of the crude 
reaction mixture. Despite the literature precedent for the synthesis of enynes with the 
HWE reaction, the phosphonate ester 281 is not as stabilised as common HWE 
reagents. Also, the alkyne is not a strong electron withdrawing group, which would 
decrease the reactivity of the phosphonate salt and decrease the likelihood of the 
reaction proceeding to give the desired alkene product 231.  
 
 
Scheme 88: Attempted HWE reaction 
(a) P(OEt)3, 160 ºC, 3 h, quant; (b) DMP, NaHCO3, DCM, 0 ºC to rt, 2 h, assume quant; (c) i. nBuLi, 
DCM, 1 h, rt; ii. 249, rt, 18 h. 
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3.2.7 Epoxidation of C(6)-C(9) Aldehyde 
The cross metathesis and Wittig reaction routes both hold the disadvantage that the 
formation of the alkene bond tends not to be stereoselective, resulting in E/Z isomer 
mixtures. It would therefore be advantageous to develop a route with greater alkene 
stereoselectivity, hence a brief investigation was carried out into a Corey-
Chaykovsky epoxidation125 of the C(6)-C(9) aldehyde 140, which had been 
previously synthesised (Section 2.4). The viability of this reaction was initially tested 
on a racemic system. Purpura and Krause, reported the epoxidation of enyne 
aldehyde 282 following treatment with trimethylsulfonium bromide and base to 
provide the enyne epoxide 283 in 80% yield (scheme 89).126 These conditions were 
applied to the aldehyde 140, however no desired product 231 could be identified in 
the crude reaction mixture. The conditions of the epoxidation were tested on a more 
stable aldehyde, namely 4-bromobenzaldehyde (284) and the epoxide 285 was 
successfully synthesised in 78% yield.127 This result would suggest the aldehyde 140 
is not a good substrate for this epoxidation, or the epoxide product was too unstable, 
or volatile to be isolated. Chiral sulfur ylides can be used to establish asymmetric 
syntheses of epoxides,128,129 however this methodology has only been used to create 
non-terminal epoxides. Taking this into consideration, this route was not investigated 
any further; as the development of an enantioenriched fragment would most likely 
require a kinetic resolution of a racemic mixture of product which would be difficult 
on this volatile, unstable intermediate.  
   
Scheme 89: Aldehyde epoxidation 
(a) Me3S
+Br−, KOH, H2O, MeCN, 60 ºC, 2 h, 80%;
126(b) Me3S
+I−, KOH, H2O, MeCN, 60 ºC, 2 h; (c) 
Me3S
+I−, KOH, H2O, MeCN, 60 ºC, 2 h, 78%. 
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3.2.8 Summary 
Despite promising literature precedent for this novel epoxide based route, the C(4)-
C(5) disconnection approach involved many small, unstable, volatile intermediates 
that were difficult to handle. The problem of generating the chiral centre at C(6) was 
solved by using commercially available chiral starting materials, however with this 
route there was now the issue of stereoselectively generating the (E)-alkene. 
Progression of this epoxide based approach was difficult and it would not be a 
suitable route to generate the C(1)-C(9) fragment of disorazole C1. The C(4)-C(5) 
disconnection led to a highly convergent route and we were encouraged by the 
potential of the chemistry introduced in section 3.1.1 (Meyers based approach), 
therefore, a new route was developed and this will be discussed in Chapter 4. 
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4 Chapter 4: Enantiospecific Synthesis II and 
Heterocyclic Analogues 
4.1 Retrosynthesis of C(1)-C(9) Fragment and Heterocyclic 
Analogues 
 
A new approach towards the synthesis of the C(1)-C(9) fragment was desired and a 
convergent synthesis which could be adapted to analogue syntheses was the main 
priority. The C(4)-C(5) disconnection, as discussed in Chapter 3, was still attractive 
as a convergent route, however alternative synthons were required. To overcome the 
earlier difficulties encountered with generating the epoxide, it was anticipated that a 
large leaving group (e.g. OTs or I) would reduce the volatility of the intermediate 
and increase ease of handling. The C(4)-C(5) retrosynthesis of 286, shown in scheme 




Scheme 90: C(4)-C(5) disconnection of fragment and heterocyclic analogues 
 
4.2 Synthesis of C(5)-C(9) Tosylate  
 
A strategy inspired by chemistry developed in the Meyers based approach (section 
3.1.1) was adopted towards the synthesis of the desired tosylate fragment, due to the 
commercial availability of the chiral alcohol 289. The initial steps involved a 
straightforward tosylation of the alcohol 289 with tosyl chloride in pyridine, 
providing the tosylate 290 in quantitative yield. This was followed by deprotection of 
the acetonide group with acidic DOWEX resin, resulting in the diol 293 in an 
excellent yield (87%). 




Scheme 91: Synthesis of diol 
(a) TsCl, pyridine, 0 ºC to rt, 18 h, quant; (b) DOWEX, MeOH, rt, 18 h, 87%. 
 
In order to shorten the synthesis and avoid the use of alcohol protecting groups, 
attempts were made to selectively oxidise the primary alcohol of 291 over the 
secondary alcohol. It was predicted that the aldehyde 292 would be unstable, 
therefore, it was used immediately in the Takai olefination step without isolation. 
Mild oxidation with sodium hypochlorite, potassium bromide, and TEMPO looked 
promising with the aldehyde visible by TLC;130 however, only on one occasion was 
the resulting vinyl iodide 293 isolated and in a very poor yield (scheme 92). It was 
therefore decided that alcohol protecting group strategies would enable progression 
though this route. 
 
 
Scheme 92: Attempted selective oxidation of primary alcohol followed by Takai olefination 
(a) NaOCl, KBr, TEMPO, NaHCO3, DCM/H2O (9:1), 0 ºC, 10 min, assume quant; (b) CrCl2, CHI3, 
THF:dioxane (1:6), rt, 18 h, 10 % over 2 steps. 
 
As the TIPS protection had proved to be successful in the Meyers based approach 
(section 3.1.1), the primary alcohol was protected as a TIPS ether and O-methylation 
of the secondary alcohol provided the methyl ether 294 in 55% yield (scheme 93). 
However, deprotection of the TIPS group with TBAF resulted in a mixture of 
products (including compounds where the tosylate group had been removed) and the 
desired product 295 could not be isolated in an acceptable yield. 
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Scheme 93: TIPS protection 
(a) TIPSOTf, 2,6-lutidine, DCM, −78 °C to rt, 2 h, quant; (b) MeI, Ag2O, CH3CN, 60 °C, 18 h, 55%; 
(c) TBAF, THF, 0 °C to rt, 18 h. 
 
Reducing agents, such as DIBAL, can promote reductive cleavage of the PMB 
acetals of 1,2-diols to generate primary alcohols.131 It was therefore anticipated that a 
PMB acetal could be reductively cleaved to give the protected secondary alcohol, 
enabling further manipulations of the primary alcohol. Treatment of the diol 291 with 
p-methoxy benzaldehyde dimethyl acetal and p-toluenesulfonic acid in DMF 
afforded the PMB acetal 296 in 80% yield (scheme 94). The acetal precipitated out 
as a colourless solid, thus some product may have been lost during filtration, or lost 
in solution. When DIBAL cleavage of the acetal was performed at 0 ºC a mixture of 
the desired alcohol 297 and a by-product was obtained, in approximately 3:2 ratio. 
From analysis of the NMR spectrum the by-product was found to be alcohol 298. 
Loss of the tosyl group could have occurred through a substitution of hydride for the 
tosylate generating 298; this is feasible as there were 3 equivalents of DIBAL in the 
reaction mixture.  
 Scheme 94: PMB acetal formation and ring opening 
(a) TsOH•H2O, p-methoxy benzaldehyde dimethyl acetal, DMF, rt, 18 h, 80%; (b) DIBAL, DCM, 0 
ºC, 1 h. 
 
 
Pleasingly, when the reaction temperature was reduced to −78 ºC the by-product 298 
could not be detected. Also, the amount of DIBAL could be reduced to 2.3 
equivalents without detrimental effect to the yield and the alcohol was isolated in 
quantitative yield. The presumed product was the primary alcohol 297, however 
upon oxidation under Swern94 or Dess-Martin90 conditions the expected aldehyde 
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was not observed (scheme 95). In the proton NMR spectrum two singlets of 
integration 2H were visible at 4.79 and 4.17 ppm, thereby indicating that the ketone 
300 had been generated and the product from the DIBAL cleavage was in fact the 
secondary alcohol 399. 
 
Scheme 95: PMB acetal opening 
(a) DIBAL, DCM, −78 ºC, 1 h, quant; (b) Swern or Dess-Martin oxidation. 
 
The generation of the secondary alcohol can be explained by the mechanism shown 
in scheme 96. DIBAL can co-ordinate to the oxygen of the tosylate (301) and 
cleavage of the acetal results in the PMB protection of the primary alcohol (302).131 
Even though the protected primary alcohol 297 would have been preferred, the 
synthesis of the secondary alcohol 299 was straightforward. All steps to the 
secondary alcohol 299 were relatively high yielding; therefore this route was used as 
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Scheme 96: DIBAL opening of PMB acetal to generate secondary alcohol 
 
Methylation of the secondary alcohol furnished the methyl ether 303 in a high yield 
of 85% (scheme 97), however a by-product (~10% yield) was routinely isolated after 
column chromatography. Comparison to literature data132 indicated the epoxide 304 
had been formed, where the alcohol had undergone an intra-molecular cyclisation 
and elimination of the tosyl group followed. Further optimisation of this reaction 
could be carried out in the future to eliminate this by-product. Oxidative cleavage of 
the PMB group with DDQ provided the key alcohol 295 in 79% yield. 




Scheme 97: O-Methylation and PMB deprotection 
(a) MeI, Ag2O, CH3CN, 60 ºC, 18 h, 85%; (b) DDQ, DCM:H2O (10:1), 30 min, rt, 79%. 
 
With a route to the key alcohol 295 developed (6 steps, 47% overall yield), 
investigations towards the synthesis of the vinyl iodide 305 were commenced. Based 
on the results obtained towards the Meyers synthesis of the oxazole fragment 
(Section 3.1.1), it was predicted that the intermediate aldehyde would be unstable, 
therefore the aldehyde was carried straight through to the Takai olefination step.96 
Swern and Dess-Martin oxidations followed by Takai olefination were carried out in 
parallel and the Dess-Martin oxidation resulted in the greatest yield of the desired 
vinyl iodide 305 (scheme 98). Evans et al. discovered that there is a solvent effect on 
the stereoselectivity of the Takai olefination, with a mixture of THF/dioxane 
providing the highest E/Z ratio.133 In our investigations the highest yield of the vinyl 
iodide 305 obtained was 45%; with E/Z ratio of 5:1, as determined by NMR 
spectroscopy. These results were not always reproducible, the reaction is unreliable 
and the desired product could not be isolated every time the reaction was performed. 
It is likely that the intermediate aldehyde is unstable, and in addition, chromium (II) 
chloride is extremely hygroscopic and water sensitive. Steps taken to keep the 
chromium (II) chloride dry included, drying it under vacuum with a heat gun (~400 
ºC) before use and oven dried glassware was used; in addition the reaction was 
carried out under an inert atmosphere of nitrogen or argon. Carrying out the reaction 
in a glove bag under nitrogen made no improvement to the yield. Nevertheless, 
adequate amounts of the vinyl iodide 305 were isolated in order to carry out 
subsequent reactions. Further optimisation of the oxidation and conversion to the 
vinyl iodide should be able to improve the yield. The Negishi reaction conditions 
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developed in Section 2.4 were successfully applied to the vinyl iodide 305 to provide 
the desired enyne fragment 306 in 86% yield. 
 
 
Scheme 98: Completion of enyne 
(a) DMP, NaHCO3, DCM, rt, 2 h, assume quant; (b) CrCl2, CHI3, THF:dioxane (1:6), rt, 18 h, 45% 




4.3 Investigations into Oxazole C(1)-C(4) and Tosylate Coupling 
4.3.1 Oxazole C-H Activation 
 
Direct palladium catalysed C-H activation of (hetero)aromatic rings is a highly active 
area of current research in organic synthesis and its applications to the synthesis of 
C-2 substituted oxazoles is a recent development.134 Based on recent advances in the 
palladium C-H activation of oxazole, a route towards the C(1)-C(9) fragment of 
disorazole C1 was proposed as shown in scheme 99. This involved the coupling 
between ethyl 4-oxazole carboxylate 244 and the tosylate 306. 
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4.3.1.1 Oxazole C-H Activation Background 
Hoarau et al. realised the importance of the development of a methodology to 
regioselectively synthesise 2,4-substituted oxazoles, due to their occurrence in 
natural products. A model system investigating the coupling between ethyl 4-oxazole 
carboxylate 244 and phenyliodide was used as a basis to investigate reaction 
conditions to develop a C-2 regiospecific arylation of oxazoles (scheme 100).135 
After screening a range of palladium catalysts, ligands and solvents, the optimum 
conditions to direct a C-2 arylation of oxazole 244 were found to be Pd(OAc) (5%), 
Cs2CO3 (2 equiv) and P(o-Tol)3 in toluene. With these conditions, the oxazole 308 




Scheme 100: Hoarau optimised Pd catalysed arylation conditions 
(a) PhI (1 equiv), Pd(OAc) (5%), Cs2CO3 (2 equiv), toluene, P(o-Tol)3, 110 ºC, 86%. 
 
During the optimisation studies Hoarau et al. discovered that the solvent and ligand 
can have an effect on the regioselectivity of the reaction. However, it was found that 
ligand/catalyst concentration did not have an effect on the reaction outcome.135 
Copper iodide has been shown to promote arylation at acidic sites of heterocycles,136 
however, applying a copper iodide co-catalyst to the reaction conditions with ethyl 4-
oxazole carboxylate 244 failed. This therefore suggests that the reaction does not go 
by the cross-coupling mechanism shown by other heterocycles (scheme 101, route 
A). An aromatic electrophilic substitution mechanism (scheme 101, route B) has 
therefore been proposed. At this stage, the regioselectivity of the reaction was 
attributed to the steric bulk of the phosphine ligand, with the largest ligands 
selectively generating the C-2 phenyl product. 
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Scheme 101: C-H activation mechanism 
 
Further developments have been made towards C-2 arylations of oxazoles, however 
of particular interest to our investigations were the C-2 alkylations of oxazoles. The 
first examples of alkylations of oxazoles by palladium catalysed C-H activation were 
published by the Hoarau group in 2009.134 Ligand screening was carried out based on 
the reaction between oxazole 244 and 1-bromo-2-methylpropene. The optimum 
conditions were found to be palladium acetate, 2-(dicyclohexylphosphino)-biphenyl 
ligand (313), caesium carbonate and dioxane; which provided exclusively the C-2 
alkenylated product 312a in 92% yield (table 14, entry 1). With these optimised 
conditions, the substrate scope of the reaction was investigated with alkenyl-, benzyl- 
and alkyl halides, the most interesting examples are highlighted in table 14. The 
initial reaction between the oxazole 244 and butylbromide (1 equiv, table 14, entry 2) 
resulted in an isolated yield of the product 312b of 32%; but this was increased to 
60% through the use of 2 equivalents of the bromide (table 14, entry 3). 
Butylchloride (table 14, entry 4) was inactive under these reaction conditions and 
screening of ligands could not generate the desired product 312b. Reactions with the 
sterically hindered t-butylbromide also failed (table 14, entry 5). Methylation with 
iodomethane successfully generated the methyloxazole 312d (table 14, entry 6) in 
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(a) X–R, Pd(OAc)2 (5 mol%), 313 (10 mol%), Cs2CO3 (2 equiv), 1,4-dioxane, 110 ºC, 18 h. 
 
Table 14: Hoarau Pd catalysed oxazole alkenylations and alkylations 






      
2  Br 1 
 
32 
3  Br 2 60 
4  Cl 2 n.r. 






      





Miura et al have recently carried out a more detailed investigation into the palladium 
catalysed alkylation of benzoxazoles and oxazoles.137 Catalysts and ligands were 
screened in order to optimise the reaction between benzoxazole and bromohexane. 
The optimal conditions were found to be [{PdCl(η3-C3H5)}2] (3.75 mol%), P(nBu)3 
(30 mol%) and LiO-tBu (3 equivalents) in diglyme, heated at 120 °C for 4 hours. 
Application of the optimised conditions to oxazoles was also successful, as shown by 
the examples in figure 13. An acetal protecting group was tolerated providing the 
product 314 in 67% yield from the alkyl chloride. In these examples with 
unfunctionalised alkyl halides the alkyl chloride provided higher yield (315, 60%) 
than the alkyl bromide (316, 44%). The majority of the published examples were 
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performed on 5-substituted oxazoles, however, one reaction was carried out on 
oxazole itself and the 2-subsituted product 317 was generated exclusively, albeit in a 
low yield of 25%. 
 
 
Figure 13: Miura [{PdCl(η3-C3H5)}2] catalysed C-2 alkylation of oxazoles 
(a) 5-phenyl-1,3-oxazole or oxazole, X-R, [{PdCl(η3-C3H5)}2] (3.75 mol%), P(nBu)3 (30 mol%), LiO-
tBu (3 equiv), diglyme, 120 °C, 4 h. 
 
Nickel catalysis has also proved to be successful in alkylation of oxazoles, as 
demonstrated by Hu and co-workers (table 15).138 In these examples, alkyl iodides 
were just as successful as the bromides, with the octyl product 319a being generated 
in 86% yield (table 15, entry 1). The ether functionality was tolerated (table 15, entry 
2) and, surprisingly, the more sterically hindered (bromomethyl)cyclohexane also 
afforded the desired product 319c in high yield (table 15, entry 3). It is, however, 
noteworthy that reactions between benzoxazole and secondary alkyl halides such as 
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(a) X-R, [(MeNN2)NiCl] (5 mol%), CuI (5 mol%), LiO-tBu (1.4 equiv), dioxane, 140 °C, 16 h. 
 
Table 15: Hu Nickel catalysed C-2 alkylation of 5-substitued oxazoles. 
Entry R     Halide Yield % 









4.3.1.2   Oxazole C-H Activation Results 
  
Investigations were carried out into coupling ethyl 4-oxazole carboxylate (244) and 
readily available compounds to act as model substrates for the C(5)-C(9) tosylate 306 
or bromide. The optimised conditions developed by Hoarau134 were chosen for this 
investigation. Ethyl 4-oxazole carboxylate 244 was stirred at 110 ºC with the 
coupling partner, palladium acetate, cyclohexyl Johnphos (313) and caesium 
carbonate in dioxane overnight, the reaction mixture was filtered through celite and 

























244 312 320  
(a) X-R, Pd(OAc)2 (5 mol%), cyclohexyl Johnphos 313 (10 mol%), Cs2CO3 (2 equiv), 1,4-dioxane, 
110 ºC, 18 h. 
Table 16: Attempted Pd catalysed alkylation of ethyl 4-oxazole carboxylate with model 
substrates 
Entry X-R X Result 
1 
 
 Trace 312 and 320 a 
2 
 
 Isolated 320 
3 
 
 No reaction a 
4 
 
 No reaction a 
5 
 
Cl Isolated 320 
6  Br Isolated 320 
7  I No reaction a 
8  OTs 290 Isolated 320 and unidentified by-product 
9 
 
 Trace 312 by NMR and mass spectrometry 
10 
 
 Trace product 307 
11 
 
 95% yield of 312a isolated 
a from analysis of crude proton NMR spectrum 
 
 In all reactions, the major component of the crude reaction mixture was the oxazole 
starting material 244. No product 312 could be isolated from reactions with alkyl 
bromides featuring a β-alcohol or methyl ether (table 16, entries 1-4). In some cases, 
a trace of product 312 could be identified in the NMR spectrum, however after 
attempted isolation only homo-coupled oxazole 320 could be isolated. Comparisons 
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between the chloro-, bromo-, iodo- and tosyl- substrates (table 16, entries 5-8) 
proved inconclusive and only homo-coupled oxazole 320 could be isolated. In the 
case of the tosylate (table 16, entry 8), a by-product was isolated where the tosyl 
group was present. However, it appeared that the ethyl ester had been displaced; but 
this product was not fully characterised and identified. It would appear that the 
oxazole 244 is more reactive than the halides, thereby generating the homo-coupled 
oxazole 320 and reducing the availability of the oxazole to couple to the halide. 
 
1-Iodo-2-methoxyhexane (which was deemed a better model substrate) 322 was 
readily synthesised via a methanolysis and iodination of 1-hexene 321 (scheme 102). 
Following the reaction with 1-iodo-2-methoxyhexane (table 16, entry 9), traces of the 
desired product 312 could be seen in the proton NMR spectrum, and in addition, a 
peak at m/z 262 representing [M+Na]+ was visible in an LC-MS of the crude 
mixture; but unfortunately, the product could not be isolated. 
 
Scheme 102: Synthesis of 1-iodo-2-methoxyhexane 
(a) I2, Ag2O, MeOH, 0 ºC, 6 h, 90%. 
 
Since the reaction of iodoalkane 322 in entry 9 showed potential, further 
investigations towards optimisation for this substrate were pursued. The literature 
reaction with 1-bromo-2-methylpropene (table 16, entry 11)134 was shown to be 
reproducible in our hands, affording the alkenylated product 312a in 95% yield. This 
result indicated that perhaps, a slight variation of conditions was required to enable 
the reaction of iodoalkane 322 to proceed in greater yield. Screening common 
palladium catalysts including Pd(dba)2, Pd(PPh3)4 and Pd(PPh3)2Cl2 and alteration of 
the solvent to THF failed to improve the yield and the two starting materials (244 and 
1-iodo-2-methoxyhexane 322) were the main components of the crude mixture. Once 
the tosylate 306 had been synthesised, a palladium coupling was attempted with ethyl 
4-oxazole carboxylate 244 (table 16, entry 10). Unfortunately, only traces of product 
could be seen in the NMR spectrum and column chromatography only resulted in the 
starting material oxazole 244 being recovered. 
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Hu had shown that the hindered substrate (bromomethyl)cyclohexane can be 
successfully coupled with a 5-substituted oxazole138 under nickel/copper catalysis, 
and we wanted to see if these conditions could be applied to ethyl 4-oxazole 
carboxylate 244. Applying Hu’s reaction conditions138 and substituting the oxazole 
substrate for ethyl 4-oxazole carboxylate 244 generated inconclusive results (scheme 
103). The major component of the crude NMR spectrum was the oxazole starting 
material 244, but a singlet was apparent in the proton NMR spectrum of the crude 
mixture at 8.22 ppm. While this is representative of the C-5 proton of a 2,4-
substituted oxazole, the desired product 323 could not be isolated. Given that the 
high yields reported by Hu could not be repeated on ethyl 4-oxazole carboxylate 
(244), no further investigations with other substrates were carried out regarding this 
nickel/copper catalyst and our focus was now towards the lithiation approach. 
 
 
Scheme 103: Attempted Ni catalysed alkylation of ethyl 4-oxazole carboxylate with 
(bromomethyl)cyclohexane  
(a) (bromomethyl)cyclohexane, [(MeNN2)NiCl] (5 mol%), CuI (5 mol%), LiO-tBu (1.4 equiv), 
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4.3.2 Oxazole Lithiation 
 
C-2 lithiation of oxazole is a developed methodology,139 and with the tosylate 306 in 
hand, it was proposed that the C(1)-C(9) fragment 324 could be constructed via a 




Scheme 104: Proposed oxazole lithiation strategy 
 
4.3.2.1 Oxazole Lithiation Background 
 
The C-2 proton of oxazole (325) has been shown to be the most acidic,140 however 
investigations by Hodges et al. into the lithiation of oxazole (325) lead to some 
unexpected results. Lithiation of oxazole (325) with nBuLi at −75 ºC (scheme 105), 
followed by exposure to benzaldehyde resulted in only 2% yield of the expected 
product 328 and 20% yield of the C-4 substituted product 331 (plus 20% benzyl 
alcohol isolated).141 This observation can be explained by the aldehyde reacting with 
the ring open enolate 327 form of the oxazole, faster than it reacts with the lithium 
species 326. A series of temperature controlled experiments demonstrated that the C-
2 substituted product 328 was not formed at temperatures below 0 ºC. Following the 
lithiation of oxazole 325 with nBuLi a range of electrophiles were investigated, and 
it was found that aldehydes predominantly afforded the C-5 substituted products. 
However, reactions with iodobutane and benzylbromide were unsuccessful, even 
after prolonged reaction times at higher temperature 
 






































Scheme 105: 2-Lithiooxazole ring opening mechanism 
 
Jacobi et al. carried out studies into the alkylation of the disubstituted oxazole 332, 
and in all cases, only the formation of the ring opened products 333 was observed 
(table 17).142 These results contrast those published by Hodges, where no reaction 
was observed with alkyl halides. It is postulated that these differences in the 
observed results could be due to the different substituents of the oxazoles 325 and 
332 resulting in different enolate stabilities. In the case of the results observed by 
Jabobi, the enolate could be stabilised by lithium co-ordination between the oxygens 
of the ethyl ether and the oxazole, therefore the ring opening of 332 is a fast process 
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(a) i. nBuLi, −78 ºC; ii. R-X. 
 
Table 17: Jacobi observation of ring opened products after attempted C-2 alkylation 
Entry R-X Yield % (isolated/GC) 
1 MeI 81/93 
2 nBuI 76/99 
3 Benzyl bromide 77/86 
 
 
Vedejs and Monahan sought to solve the problem of the ring opening of oxazole in 
order to devise a regioselective, reliable method for the synthesis of 2-substituted 
oxazoles.143 They proposed that a Lewis acid could be used to complex to the 
nitrogen lone pair (335) and therefore prevent the ring opening; this complexation 
was also predicted to activate the C-2 proton for metallation.143 Pleasingly, this 
hypothesis was true and only C-2 substituted products (336) were observed and no 
ring opened products were formed after electrophiles were reacted with 334 
following lithiation (table 18). Reactions with iodomethane and an alkyltriflate 
successfully generated the 2-substitued products 336 in good yields of 74% and 65% 
respectively (table 18, entries 1 and 2). The reaction between the alkyltriflate and 
unsubstituted oxazole (325) also exclusively formed the 2-substituted product (76% 
yield). 
 
i. BH3•THF, −78 ºC; ii. nBuLi; iii. E
+, −20 ºC. 
Table 18: Vedejs alkylation examples of C-2 oxazole lithiation mediated by BH3•THF 
coordination  
Entry E+ Yield %  
1 MeI 74 
2 PhCH2CH2OTf 65 
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An example of lithiation of a C-4 protected alcohol oxazole is featured in Shioiri and 
co-workers’ studies towards the synthesis of bengazoles.144 Lithiation of 246 and 337 
with nBuLi, followed by addition of 5-formyloxazole resulted in the secondary 
alcohols 339a and 339b in moderate yields (scheme 106). The protecting group 
appears to have an effect on yield; the TBS product 339a was isolated in 35% yield 
and the TBDPS product 339b was isolated in 50% yield. The reaction took 3 days 
and resulted in moderate yields; moreover, attempts to improve the yield by altering 
the base, solvent and by the addition of a Lewis acid all failed.144  
 
 
Scheme 106: C-2 lithiation of 2-substituted oxazole 
(a) nBuLi, Et2O, −75 ºC to 0 ºC, 3 days, 339a 35%, 339b 50%. 
 
4.3.2.2 Oxazole Lithiation Results 
 
Previous attempts at synthesising the alcohol 245 (Section 3.2.2.2) had failed due to 
the volatility of the compound and the consequential difficulty in handling. However, 
we were able to purchase 500 mg of alcohol 245 to try out a few small scale 
reactions to attempt to complete the chiral synthesis of the C(1)-C(9) fragment of 
disorazole C1. The alcohol was protected with a MOM group (340), based upon 
results obtained towards the synthesis of the racemic fragment (Section 2.6.6), and a 
TBDMS group (246) based upon the results observed by Shioiri et al. (scheme 107). 
Synthesis of the TBDPS protected alcohol 337 using TBDPSCl and imidazole in 
DMF was also attempted; however it could not be obtained in sufficient purity 
(possibly due to contamination with TBDPS alcohol) to advance to the next step. It 
was hoped that protection of the alcohol would ease the handling of the oxazole and 
it was thought that the protecting group could have an effect on the regioselectivity 
of the reaction. 
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Scheme 107: Alcohol protection 
(a) i. NaH, THF, 0 ºC, 10 min; ii. MOMCl, 3 h, rt, 73%; (b) 2,6-lutidine, TBDMSOTf, DCM, 0 ºC, 1 
h, 85%. 
 
Based on the literature, our desired reaction appeared feasible and conditions using 
borane and nBuLi were adopted in order to direct C-2 lithiation. Shioiri et al reported 
exclusive formation of the C-2 substituted product without the use of borane;144 
however, the electrophile in their case was an aldehyde, and the tosylate 306 or 
iodide 341 to be used in our synthesis were predicted to be less reactive. Therefore, 
the addition of borane was more likely to be beneficial than detrimental. The reaction 
with MOM protected oxazol-4-ylmethanol (340) and iodomethane showed promising 
results as product 212c was isolated, albeit in a low yield (table 19, entry 1). 
However, the reaction with the tosylate 306 failed and only the two starting materials 
(306 and 340) were visible in the crude NMR spectrum (table 19, entry 2). 
Conversion of the tosylate 306 to the more reactive iodide 341 appeared to have no 
effect and no product could be seen in the NMR spectrum of this reaction (table 19, 
entry 3). The lithiation of oxazoles is a temperature dependent reaction, but 
unfortunately, even after leaving the tosylate and iodide reactions for 3 days at room 
temperature, none of the product 215 could be detected. The reaction with the TBS 
protected alcohol 246 and iodomethane (table 19, entry 4) was more successful than 
with the MOM protected oxazole. The desired product 212a was the main 
component of the crude reaction mixture, demonstrating a 4:1 ratio of product 212a 
to starting material 246 by proton NMR analysis. Furthermore, this reaction was 
cleaner than the reaction with iodomethane and MOM protected alcohol 340. To 
further test the lithiation with the TBS protected alcohol, a reaction with 1-iodo-2-
methoxyhexane (322) was performed and traces of the desired product could be 
observed in the proton NMR spectrum. In addition, a peak observed at m/z 326 in the 
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negative ESI mass spectrum is representative of [M−H]−. A large scale, reliable 
synthesis of the TBS (or TBDPS) protected alcohol 246 is required in order for 
optimisation and further investigation into this lithiation reaction. 
 
 
(a) i. BH3•THF, rt; ii. nBuLi, −78 ºC; iii. X-R, −78 ºC to rt. 
 
Table 19: Investigations into lithiation of TBS and MOM protected alcohol oxazole 
Entry P Substrate Result 
1 MOM MeI 10% yield 212c (P = MOM, R = Me) 
2 MOM 
 




4 TBS MeI 4:1 (212a:246) unseparable mixture 70% overall yield 
5 TBS 
 
Trace product in NMR and identified in mass spectrum 
 
4.3.3 Summary 
Investigations were carried out into the palladium catalysed C-H activation of ethyl 
4-oxazole carboxylate, followed by alkylation with a number of model substrates. 
Traces of product could be identified by NMR spectroscopy and mass spectrometry, 
however further studies and optimisation will be required in order for the C(1)-C(9) 
fragment to be synthesised using this route.  
 
Based on the literature evidence and our preliminary results with the TBS protected 
oxazole, the lithiation strategy coupled with the tosylate or iodide appears to be the 
most practical route towards the synthesis of the C(1)-C(9) fragment of disorazole 
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C1. Unfortunately, at this time only small amounts of the oxazole and tosylate were 
available and optimisation and extensive studies into this reaction were not possible. 
Further investigations towards a reliable synthesis of the alcohol 245 are required, as 
well as optimisation of the Takai olefination (or alternative routes from the alcohol 
295 to enyne 306). The application of novel tosylate 306 towards heterocyclic 
analogues will be discussed in the next section. 
 
4.4 Heterocyclic Analogues 
As highlighted in the discussion of disorazole SAR in section 1.3, to our knowledge, 
no investigations have been carried out regarding heterocyclic analogues of 
disorazole C1. Centred around our desire to construct the ester linkage at C(1) of 
disorazole C1 via an Evans-Tishchenko (ET) reaction, the Hulme group recently 
reported the first examples of the use of heteroaryl aldehydes in the ET reaction.145 
The Evans-Tishchenko reaction was modelled using the β-hydroxyketone 349 and 
the results showed it to be a promising reaction for generating the required ester in 
disorazole C1, particularly with electron-poor heteroaryl aldehydes.  
 
Application of the optimised ET conditions of SmI2 (2.0 equiv), benzaldehyde (2.0 
equiv), heteroaryl aldehyde (4.0 equiv), 342 (1.0 equiv), resulted in excellent yields 
and high diastereoselectivity of the products 346 using furancarboxaldehydes and 
thiophenecarboxaldehydes (table 20, entries 1-4).145,146 Substituted furans and 
thiophenes were also tolerated (table 20, entries 5-8), particularly electron 
withdrawing substituents such as a nitro group (table 20, entry 6). Bicyclic systems 
such as benzo[b]thiophene-3-carboxaldehyde and N-Boc-indole-3-carboxaldehyde 







Results and Discussion 3 
 128 
 
i. SmI2 (2.0 equiv), PhCHO (2.0 equiv), THF, rt, 30 min; ii. HetCHO (4.0 equiv), 342 (1.0 equiv), 
THF, −15 ºC, 1 h. 
Table 20: Scope of heteroaryl aldehyde ET reaction 
Entry Aldehyde Yield % dr 
1 3-furancarboxaldehyde 98 >95:5 
2 2-furancarboxaldehyde 99 91:09 
3  3-thiophenecarboxaldehyde 99 >95:5 
4 2-thiophenecarboxaldehyde 99 91:09 
5 5-phenylfuran-2-carboxaldehyde 92 >95:5 
6 5-nitrofuran-2-carboxaldehyde 93 >95:5 
7 5-bromofuran-2-carboxaldehyde 90 94:6 
8 5-bromothiophene-2-carboxaldehyde 99 >95:5 
9 benzo[b]thiophene-3-carboxaldehyde 95 92:8 
10 N-Boc-indole-3-carboxaldehyde 90 90:10 
 
N-Boc-indole-3-carboxaldehyde (349) performed well in the ET reaction (table 20, 
entry 10), however no reaction was observed with the unprotected indole 347.146 It is 
possible that complexation with samarium results in delocalisation around the indole, 
which would lead to the stable enolate species 348, rendering hemi-acetal formation 
with the alcohol of the β-hydroxyketone unfavourable (scheme 108). However, 
Lewis-acid activation of the aldehyde is favoured in the Boc-protected species 350 
and the ET reaction proceeds with excellent yield. 
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Scheme 108: Possible enolate formation of Sm intermediate with indole 
 
Interestingly, it appears that a nitrogen at the 2-position relative to the aldehyde has a 
detrimental effect in the ET reaction. Examples of heteroaryl aldehydes which have 
failed in the ET reaction (figure 14) include 2-methyl-oxazole-4-carbaldehyde 352, 
2-pyridine-carboxaldehyde 353, 2-pyrrole carboxaldehyde 354 and N-methyl-2-
pyrrole carboxaldehyde 355. This observation could be due to the nitrogen being in a 
favourable position to co-ordinate to the samarium (356) and thereby rendering the 
samarium intermediate inactive. A brief investigation was carried out in the Hulme 
group with 2-pyridine-carboxaldehyde (353) to attempt to overcome the issue of 
nitrogen co-ordination. Attempts at methods such as ‘capping’ the samarium with 
cyclen, tetraglyme or BINAP, thus disabling the nitrogen co-ordination, gave only 
poor yields of product in the ET reaction.146 Co-ordination of the lone pair of the 
nitrogen into a quarternised salt also failed to improve the yield of the reaction; 
however, low solubility of the salt could have been a factor in this low yield.146 
Further investigations into the ET reaction with heteroaryl aldehydes are required 
and in particular with the oxazole. 
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Figure 14: Heterocycles which failed in preliminary ET reaction studies 
 
In view of the previous results obtained with heteroaryl aldehydes in the ET reaction, 
novel heterocyclic analogues were designed that could readily be synthesised by 
coupling to the tosylate 306 (figure 15). A rapid route towards such analogues could 
be via an N-alkylation, therefore the pyrrole 357, pyrazole 358 and indole 360 
analogues were designed. These analogues do not have a nitrogen in the 2-position 
relative to the aldehyde and the nitrogen is alkylated, which will prevent resonance 
structures, such as the postulated enolate intermediate 348. The triazole analogue 359 
does possess a nitrogen in the 2-position relative to the aldehyde, however this 
heterocycle has not yet been subjected to the ET reaction. The triazole can be readily 
synthesised from the tosylate 306 and synthesis of this analogue would allow SAR 
development through comparison of the heterocycles containing 1, 2 and 3 nitrogen 
atoms. Taking into consideration the published analogues of disorazole C1, 
preservation of the five membered heterocyclic shape was desired to prevent an 
alteration of the overall 3D structure of disorazole C1. However, N-Boc-indole-3-
carboxaldehyde (349) had performed well in the preliminary ET studies and we had 
an accessible route to this analogue through N-alkylation. 
 
 
Figure 15: Designed heterocyclic analogues 
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The pyrazole analogue 358 was synthesised via an N-alkylation of commercially 
available ethyl 1H-pyrazole-4-carboxylate (361) with potassium carbonate and 
tosylate 306 (scheme 109). The reaction was stirred at room temperature for 48 
hours, yet the reaction did not go to completion and upon work-up and purification 
by column chromatography the pyrazole analogue 358 was obtained in 58% yield.  
 
 
Scheme 109: Pyrazole analogue synthesis 
(a) K2CO3, DMF, rt, 48 h, 58%. 
 
The pyrrole 364 was synthesised in 43% yield following literature procedures,147 via 
the van Leusen method,148 from TosMIC (362) and ethylacrylate (363). This 
moderate yield is comparable to the literature procedure and a by-product was 
observed, possibly formed by a Michael addition of the pyrrole to ethyl acrylate. 
Under the alkylation conditions used for the synthesis of the pyrazole analogue, with 
potassium carbonate no reaction was observed between the pyrrole 364 and tosylate 
306 after 72 h. The use of the stronger base sodium hydride did not improve the 
reaction. A trace of product 357 could be seen by proton NMR spectroscopy after 
using potassium hydroxide as the base, but unfortunately the product 357 could not 
be isolated.  






362 363 364 357
 
Scheme 110: Pyrrole analogue synthesis 
(a) NaH, Et2O/DMSO (2:1), rt, 3 h, 43%; (b) 306, KOH, DMSO, rt, 18 h. 
 
Poor conversion was also observed for the alkylation of the indole 365 (scheme 111). 
The alkylation was attempted with sodium hydride at room temperature for up to 72 
hours and at an elevated temperature of 80 ºC, however the conversion could not be 
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increased and only traces of the desired product 360 were observed by proton NMR 
spectroscopy. Model studies with tosylates are currently ongoing within the Hulme 
group to optimise the N-alkylations of these heterocycles. 
 
Scheme 111: Attempted indole analogue synthesis 
(a) 306, NaH, DMF, rt, 72 h. 
 
The tosylate 306 was readily converted to the azide via a displacement with sodium 
azide in quantitative yield (scheme 112). A copper catalysed azide-alkyne 
cycloaddition reaction149 between the azide and methyl propiolate resulted in the 
triazole analogue 359 in 58% yield. The “click” reaction is usually very high yielding 
and this observed moderate yield can be attributed to the high volatility of the azide, 
which meant the exact amount of azide used in the reaction was unknown. 
 
 
Scheme 112: Triazole analogue synthesis 
(a) NaN3, DMSO, reflux, 2 h, quant; (b) methyl propiolate (1.1 equiv), CuSO4 (10 mol %), sodium 
ascorbate (20 mol %), H2O:tBuOH (1:2), TBTA (10 mol %), rt, 18 h, 58%. 
 
4.5 Summary 
A novel route towards the synthesis of the C(1)-C(9) fragment and heterocyclic 
analogues of disorazole C1 has been developed. The tosyl enyne side chain is a novel 
route towards the synthesis of the C(1)-C(9) fragment of disorazole C1, this side 
chain also enables a highly convergent synthesis of the fragment and heterocyclic 
analogues. Optimisation of the route from the alcohol 295 to the vinyl iodide 305 is 
required. 
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The successful synthesis of the stable tosyl enyne side chain 306 opened up the 
possibility of palladium C-H activation of the oxazole. Alkylation of oxazoles under 
palladium catalysis is a new and emerging area of research and further exploration of 
catalysts, ligands and solvents is required to find the optimum conditions for the 
coupling of the oxazole and tosylate (or iodide) fragments. Lithiation of oxazole was 
attempted and appears to be the most promising route towards the synthesis of the 
C(1)-C(9) fragment of disorazole C1, however a reliable synthesis of the TBS (or 
TBDPS) protected oxazole alcohol is first required in order for further investigations 
to be carried out. 
 
Two fragment analogues have successfully been synthesised, namely the pyrazole 
and triazole. Once these are incorporated into the total synthesis of disorazole C1 
SAR can be developed to gain insight into the role of the oxazole in the binding of 





5 Future work 
5.1 Completion of C(1)-C(9) Fragment 
The immediate future work for this project will revolve around optimisation of the 
synthesis of the vinyl iodide 305 from the alcohol 295 (scheme 113). This will be 
achieved either through optimisation of the Takai olefination; or alternative routes 
such as conversion to the alkyne with the Ohira-Bestmann reagent, followed by 
hydrostannylation/metal-iodine exchange to the (E)-vinyl iodide, based on 
Hoffmann’s synthesis of disorazole C1.30 
 
 
Scheme 113: Synthesis of vinyl iodide 
 
Another possible option which would further shorten the synthesis of the enyne 306 
would be a Wittig reaction between the aldehyde 366 and phosphorus ylide 250 
(scheme 114). There is literature precedent for Wittig reactions performed in the 
presence of tosylates150 and the literature discussed in section 3.2.5 suggests that the 
(E)-isomer would be the major product following a Wittig reaction with 250. 
 
 
Scheme 114: Proposed Wittig reaction 
 
Based on encouraging preliminary results, once a reliable route to the tosylate 306 
has been established, further investigations into the palladium catalysed C-H 
activation and lithiation of the oxazole can be performed. C-H activation of oxazoles 
followed by alkylation is dependent on a number of factors, therefore screening to 
establish the optimum combination of ligand, catalyst, solvent and substrate (X = 
OTs, OTf, I, Br or Cl) will be required. Based on our limited oxazole lithiation 
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investigations, lithiation of the TBDMS protected oxazole showed the most promise, 
however a robust synthesis of the required oxazole 246 (or the TBDPS protected 
oxazole) needs to be established. 
 
 
Scheme 115: Completion of C(1)-C(9) fragment 
 
5.2 Heterocyclic Analogues 
 
In order to develop a detailed SAR of disorazole C1 a range of heterocyclic 
analogues of the C(1)-C(9) fragment are required. It is anticipated that the 
heterocyclic analogues shown in figure 16 could be synthesised after further 
development of the C-H activation and lithiation methodology. Possible heterocyclic 
analogues include furan 367, thiophene 368, thiazole 369, isoxazole 370 and a 2,5-
substituded oxazole 371. Without greatly altering the 3D-shape of disorazole C1 
these analogues could provide insight into the role of the heteroatoms in the binding 
of disorazole C1 to tubulin. To complete the initial studies detailed in this thesis, 
model studies are currently ongoing in the Hulme group to optimise the N-alkylation 
of pyrrole and indole with tosylates and a simple change of base to Cs2CO3 appears 




















367 368 369 370 371
 
Figure 16: Possible heterocyclic analogues 
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5.3 Evans-Tishchenko Coupling 
 
Further heterocyclic Evans-Tishchenko reaction model studies are underway, and 
particular attention is required regarding the reaction of the oxazole with the β-
hydroxyketone. It is anticipated that, based on previous results, the pyrrole, pyrazole, 
indole, thiophene and furan analogues would be successful substrates for the Evans-
Tishchenko reaction.145,146 If however, a method for the Evans-Tishchenko reaction 
with the oxazole cannot be established, an alternative route towards the desired 
fragment 374 would be to construct the ester linkage via a standard esterification 
between the alcohol 372 and carboxylic acid 373 (scheme 116). The required alcohol 
could be synthesised from the β-hydroxyketone 130 via an ET reaction with a 
sacrificial aldehyde such as benzaldehyde to generate the ester. The free alcohol 
formed would need to be protected and hydrolysis of the benzyl ester would yield the 
required alcohol 372. 
 
 




5.4 Alkyne Metathesis 
  
Alkyne metathesis, and particularly ring-closing alkyne metathesis (RCAM), is a 
relatively new field of research and has recently been applied to the total synthesis of 
natural products including epothilone A and C152 and amphidinolide.153 RCAM is a 
reliable method for the construction of cyclic alkynes, and in turn, stereoselective 
alkenes via partial hydrogenation. There are however, limited examples of the 
synthesis of cyclic diynes via a dimeric alkyne cross metathesis followed by RCAM. 
 
In studies directed towards the synthesis of epothilones A and C the Fürstner group 
have investigated the use of new RCAM catalysts and have reported an example of 
the formation of a cyclic diyne.152 After treating the diyne 375 with the catalyst 
[Mo{(tBu)(3,5-dimethylphenyl)N}3] 378 the cyclic monomer 376 was isolated in 
45% yield and in addition the cyclic diyne 377 was isolated in 40% yield. This 
unexpected result was attributed to the high ring-strain experienced in the 11-
membered monomer 376. 
 Scheme 117: Observed cyclic diyne 
(a) 378 activated with DCM, toluene, 80 ºC, 20 h, 376 45%, 377 40%. 
 
In efforts to expand on Fürtsner’s results, with the aim of synthesising cyclic diynes, 
Gleiter et al. performed alkyne metathesis reactions on a range of diynes (379) of 
varying chain lengths using the Mortreux154 system (due to its ease of preparation).155 
The results indicated in table 21 show that the optimum ring size for the formation of 
the cyclic diynes 381 is 16-26. Only the cyclic alkyne 380 was isolated when n = 12 
(table 21, entry 1) and RCAM of the alkyne 379 was favourable. The yield of the 














(a) Mo(CO)6/trifluoromethyl phenol, toluene, 110 ºC. 
 
Following on from the development of a new tungsten-based alkyne metathesis 
catalyst 385,156 the Tamm group investigated the effect of the substitution pattern 
around a phenyl ring on RCAM.157 The results in table 22 show that the meta-
substituted ring favoured monomer RCAM to 383, however the para-substituted ring 
favoured the formation of the 28-membered cyclic diyne 384. Interestingly, the more 
constrained ortho-substituted ring generated a mixture of 383 and 384, favouring the 
diyne ring 384. It was proposed that an equilibrium exits between 383 and 384 via a 
reversible ring-opening and ring-closing metathesis (RORCM). Following DTF 
calculations, the standard Gibbs free energy (∆Gº) of the equilibrium between 383 
and 384 for the meta-substituted alkyne was found to be +4.00 kcal mol-1 and the 
para-substituted alkyne −9.66 kcal mol-1, this shows that for the para-substituted 
system the cyclic diyne 384 is the thermodynamically favoured product. The ∆Gº for 
the ortho-substituted alkyne was calculated to be −2.78 kcal mol-1, therefore 
suggesting that the cyclic diyne 384 is the thermodynamically favoured product, as 
indicated by the experimental ratio. These results signify that the orientation of 
substitution has an effect on the outcome of the RCAM reaction. The most important 
factor determining the outcome of the alkyne metathesis is whether the cyclic 

















Table 22: Effect of substitution on RCAM outcome 
 
 
5.4.1 Application to Disorazole C1 Synthesis 
  
The proposed alkyne metathesis end-game of disorazole C1 is shown in scheme 118. 
A cross metathesis of 374 to 386, followed by ring closing alkyne metathesis is 
anticipated based on the results of Hoffmann’s studies (Section 1.4.2) which showed 
that placement of the alkyne at the C(9)-C(10) bond favoured the 30-membered 
dimer 10, rather than the 15-membered monomer.29 Taking into account published 
reports of cyclic diyne synthesis, it is possible that the desired ACM followed by 
RCAM will occur. Head-to-tail dimerisation of alkenes via alkene cross-metathesis 
has been reported by Smith during the total synthesis of (−)-cylindrocyclophanes A 
and F.158 No tail-to-tail product was obsererved in this example, it was thought that 
the desired product was the most thermodynamically stable and the reversible nature 
of alkene cross-metathesis drove the reaction to the favoured product. However, the 
outcome of our proposed alkyne metathesis cannot be predicted as it is unknown how 
the oxazole substitution pattern, functional groups and branching of the disorazole 
fragment will affect the bias towards one ring size over the other. The published 
cyclic diyne examples all featured symmetrical linear alkynes and it is unknown 
whether the unsymmetrical disorazole monomers will undergo cross-metathesis in 
Isomer 383 384 
o-382 24 76 
m-382 100 0 
p-382 0 100 
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the desired orientation. Therefore, computational studies are underway in the Hulme 
group to investigate the thermodynamic energies of alkyne metathesis of potential 
heterocyclic analogues. It could also be possible to use a templated alkyne metathesis 
strategy using a metal such as gold or platinum to co-ordinate to the oxazole 
nitrogen, therefore holding the monomers in the correct orientation for cross 
metathesis followed by RCAM. 
 
 
Scheme 118: Proposed alkyne metathesis strategy 
 
5.5 Sonogashira option 
 
If however, the cross-metathesis strategy is proving to be problematic, the C(1)-C(9) 
and C(10)-C(19) fragments could readily be transformed into Sonogashira reaction 
substrates 387 and 388 to facilitate the coupling (scheme 119) as demonstrated by 
Hoffmann and Wipf’s syntheses of the disorazole C1 macrocycle. This process would 
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result in a more step-wise synthesis; however it could be more reliable than the 
unpredictable alkyne cross-metathesis which would precede the RCAM. 
 
 
Scheme 119: Sonogashira back-up strategy 
 
To conclude, novel routes towards the C(1)-C(9) fragment of disorazole C1 have 
been developed and  progress towards optimisation and scale up of the fragment are 
underway. A route towards the C(10)-C(19) fragment has been developed in the 
Hulme group, and further investigations into the Evans-Tishchenko reaction are on-
going. As detailed in this chapter, there is an end-game strategy in place based on 
ET/RCAM and a back-up approach has been considered if it will be required. With a 
convergent route towards the C(1)-C(9) fragment developed this will allow rapid 
access to heterocyclic analogues of disorazole C1. Biological evaluation of these 
novel analogues will take place in Edinburgh in due course. 
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6 Chapter 6: Experimental 
6.1 General Experimental 
 
1H NMR spectra were recorded at ambient temperature (unless otherwise stated) on 
Bruker ARX250 (250 MHz), DPX360 (360 MHz), AVA400 (400 MHz), Open400 
(400 MHz) and AVA500 (500 MHz) Fourier Transform instruments. The data is 
presented as follows: chemical shift (in ppm on the δ scale relative to δTMS = 0), 
integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet, br s = broad singlet), coupling constants (in Hertz, Hz) and interpretation. 
13C NMR spectra were recorded at ambient temperature (unless otherwise stated) on 
Bruker ARX250 (62.9 MHz), DPX360 (90.6 MHz) AVA400 (101 MHz), Open400 
(101 MHz) and AVA500 (126 MHz) Fourier Transform instruments and were 
referenced to the solvent carbon peak. The data is presented as follows: chemical 
shift (in ppm on the δ scale) and assignment; and were confirmed by DEPT90 and 
DEPT135. 
 
Infra-red spectra were recorded on a Perkin Elmer Paragon 100 FT-IR using 5mm 
sodium chloride plates or a Shimadzu IRAffinity-1 machine as thin films unless 
otherwise stated. The wavelengths of maximum absorbance (υmax) are quoted in cm-1. 
 
Melting points were determined on a Gallenkamp Electrothermal melting point 
apparatus and are uncorrected. 
 
Fast Atom Bombardment (FAB) mass spectra were obtained using a Kratos MS50TC 
mass spectrometer, Electrospray ionisation (ESI) mass spectra were recorded on a 
Finnigan LCQ instrument, Electron Ionisation (EI) mass spectra were recorded on a 
Finnigan 4500 or a MAT 900 XP mass spectrometer. The parent ion or relevant 
fragment is quoted, followed by significant fragments and their percentages.   
 
Optical rotations were measured on an AA-1000 polarimeter with a path length of 
1.0 dm at the sodium D line (589 nm) and are reported as follows: [ ]D, concentration 
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(c in g/ 100 cm3), and solvent. All optical rotations were measured at room 
temperature. 
 
TLC was performed on Merck 60F245 (0.25 mm) aluminium plates and visualised by 
ultraviolet light, potassium permanganate stain, ammonium molybdate stain or 
anisaldehyde stain. Flash  column  chromatography  was  carried  out  using  silica  
gel  (Fisher  Scientific  60Å particle  size  35-70  micron) 
 
All non-aqueous reactions were performed under an inert atmosphere of nitrogen and 
under anhydrous conditions using oven- or flame-dried glassware cooled in a 
desiccator prior to use and anhydrous solvents were used (unless otherwise stated). 
Solvent were  dried  and  purified  by  passage  through  activated  alumina  columns  
using a solvent purification system from  www.glasscontoursolventsystems.com.  
 
Organic layers were dried using magnesium sulfate unless otherwise stated. All 
reagents were used as supplied except where otherwise stated in the experimental 
text. Saturated aqueous solutions of inorganic salts are represented as (volume; sat. 
aq). Serine methyl ester hydrochloride was recrystallised from anhydrous ethanol. 
Oxalyl chloride and crotonaldehyde were distilled over CaCl2. Triethylamine and 















6.2 Experimental for Chapter 2 
Methyl 2-chloromethyl-1,3-oxazole-4-carboxylate 139a 
 
Sodium methoxide (4.0 µL, 25 % w/w solution in methanol, 0.064 mmol) was added 
to a solution of methanol (2 mL) in DCM (15 mL) at 0 °C under nitrogen. After 5 
min, dichloroacetonitrile (0.52 mL, 6.40 mmol) was added, and the solution was 
stirred at 0 °C for 1 h. Serine methyl ester hydrochloride (1.00 g, 6.40 mmol, 
recrystallised from ethanol) was added at 0 °C, and the resulting slurry was allowed 
to warm to rt and stirred for 18 h. The reaction mixture was diluted with DCM (10 
mL) and water (20 mL) and the aqueous phase was extracted with DCM (2 × 15 
mL). The organic extracts were combined, dried, filtered and concentrated in vacuo 
to give the intermediate methyl 2-(dichloromethyl)-4,5-dihydro-1,3-oxazole-4-
carboxylate 143 as a brown gum (1.1 g, 84 %), which was used without further 
purification. 
1H NMR δ (360 MHz, CDCl3) 6.28 (1H, s, CHCl2), 4.90 (1H, dd, J = 10.8, 8.2 Hz 
CHAHBO), 4.68 (1H, dd, J = 8.8, 8.2 Hz, CHN), 4.59 (1H, dd, 10.8, 8.8 Hz, 
CHAHBO), 3.82 (3H, s, CH3). 
To a solution of the crude oxazoline 143 (1.12 g, 5.28 mmol) in DCM (10 mL) was 
added DIPEA (1.38 mL, 7.92 mmol), the resulting mixture was stirred at 50 °C for 6 
h, then at rt for ~18 h. The reaction mixture was diluted with DCM (30 mL) and 
water (20 mL), the aqueous phase was extracted with DCM (2 × 15 mL). The organic 
extracts were combined, dried, filtered and concentrated in vacuo and the crude 
residue was recrystallised from diethyl ether and hexane to give the oxazole 139a as 
pale pink needles (776 mg, 69 %). 
Rf (Hexane:EtOAc, 1:1) = 0.41; Mp = 73-74 °C, lit74 73-74 °C; IR (neat, cm-1) 1715 
(C=O), 1580 (C=C); 1H NMR δ (360 MHz, CDCl3) 8.24 (1H, s, ArH), 4.62 (2H, s, 
CH2), 3.91 (3H, s, CH3); 13C NMR δ (62.9 MHz, CDCl3) 160.87 (C), 159.72 (C), 
144.91 (CH), 133.55 (C), 52.14 (CH3), 35.12 (CH2); m/z (ESI+, MeOH) 373 
([2M+Na]+, 75 %), 198 ([M+Na]+, 100), 176 ([M+H]+, 41). 





Cyanoacetic acid (8.00 g, 94.0 mmol) and N-bromosuccinimide (33.9 g, 188 mmol) 
were stirred in cold water (100 mL). Within 5 min, the solution clouded and a 
slightly exothermic reaction commenced with evolution of carbon dioxide. After 
another 5 min the mixture went clear and was allowed to settle into two layers. The 
bottom dibromoacetonitrile phase was removed and the top aqueous phase was 
extracted with ether (3 × 5 mL). The organic extracts were combined, washed with 
water (100 mL), dried and filtered. The ether was removed in vacuo and the residual 
dibromoacetonitrile dried under high vacuum giving the nitrile 149 as a pale brown 
oil (10.75 g, 96 %). 
Rf (Hexane:EtOAc, 9:1) = 0.26; IR (neat, cm-1) 1703 (C≡N); 1H NMR δ (250 MHz, 
CDCl3) 5.82 (1H, s); 13C NMR δ (62.9 MHz, CDCl3) 113.87 (C), 5.31 (C); m/z (CI, 
i-butane) 219 ([81Br81BrM+H2O]+, 45 %), 217 ([81Br79Br+H2O]+, 100), 215 
([79Br79Br+H2O]+, 46). 


















 Methyl 2-bromomethyl-1,3-oxazole-4-carboxylate 139b 
 
Sodium methoxide (4.0 µL, 25 % w/w solution in methanol, 0.064 mmol) was added 
to a solution of methanol (2 mL) in DCM (15 mL) at 0 °C under nitrogen. After 5 
min, dibromoacetonitrile (0.33 mL, 6.4 mmol) was added, and the solution was 
stirred at 0 °C for 1 h. Serine methyl ester hydrochloride (1.00 g, 6.40 mmol) was 
added at 0 °C, and the resulting slurry was allowed to warm to rt and stirred for ~18 
h. The reaction mixture was diluted with DCM (10 mL) and water (20 mL) and the 
aqueous phase was extracted with DCM (2 × 15 mL). The organic extracts were 
combined, dried, filtered and concentrated in vacuo to give methyl 2-
(dibromomethyl)-4,5-dihydro-1,3-oxazole-4-carboxylate as a pink oil (1.23 g, 64 %), 
which was used without further purification. 
1H NMR δ (360 MHz, CDCl3) 6.13 (1H, s, CHBr2), 4.84 (1H, dd, J = 10.7, 8.1 Hz, 
CHAHBO), 4.68 (1H, t, J = 8.6 Hz, CHN), 4.62 (1H, dd, J = 10.7, 8.8 Hz, CHAHBO), 
3.82 (3H, s, CH3). 
The crude oxazoline (1.23 g, 4.09 mmol) was dissolved in DCM (25 mL) and the 
resulting solution cooled to 0 °C. DBU (0.709 mL, 4.75 mmol) was then introduced 
in one portion. After one minute, the reaction was diluted with diethyl ether (75 mL) 
and washed with NH4Cl (40 mL, sat aq), water (40 mL), brine (40 mL), dried, 
filtered and concentrated in vacuo to provide the oxazole 139b as a brown solid (711 
mg, 79 %). 
Rf (Hexane:EtOAc, 3:1) = 0.36; Mp = 54 °C, lit23 49-51 °C; IR (neat, cm-1) 1738 
(C=O), 1579 (C=C); 1H NMR δ (360 MHz, CDCl3) 8.26 (1H, s, ArH), 4.47 (2H, s, 
CH2), 3.93 (3H, s, CH3);  13C NMR δ (62.9 MHz, CDCl3) 160.85 (C), 159.90 (C), 
144.80 (CH), 133.71 (C), 52.14 (CH3), 19.22 (CH2); m/z (EI) 221 ([81BrM]+, 7 %), 
219 ([79BrM]+, 7 %), 190 (6), 188 (6), 140 (100). 






Methyl 2-iodomethyl-1,3-oxazole-4-carboxylate 139c 
 
Methyl 2-chloromethyl-1,3-oxazole-4-carboxylate 139a (0.20 g, 1.10 mmol) and NaI 
(0.82 g, 5.50 mmol) were dissolved in THF (5 mL) and stirred for 20 min at rt.  The 
solution was diluted with EtOAc (20 mL) and washed with water (2 × 10 mL), 
NaHSO3 (15 mL, sat aq) and brine (20 mL), dried, filtered and concentrated in vacuo 
to give oxazole 139c as a brown oil. The crude product was crystallised from diethyl 
ether and hexane (1:4) to give a colourless solid (0.24 g, 79 %).  
Rf (Hexane:EtOAc, 1:1) = 0.47; Mp = 68-69 °C, lit74 67 °C; IR (neat, cm-1) 1749 
(C=N), 1738 (C=O), 1579 (C=C); 1H NMR δ (360 MHz, CDCl3) 8.22 (1H, s, ArH), 
4.39 (2H, s, CH2), 3.92 (3H, s, CH3);  13C NMR δ (62.9 MHz, CDCl3) 161.43 (C), 
161.17 (C), 144.46 (CH), 134.17 (C), 52.33 (CH3), -12.55 (CH2); m/z (CI, i-butane) 
268 ([M+H]+, 100 %), 142 (7). 




















Methyl 2-methyl-1,3-oxazole-4-carboxylate 128 
 
Method A52 
Sodium methoxide (32 µL, 25 % w/w solution in methanol, 0.14 mmol) was added to 
a solution of methanol (1 mL) in DCM (9 mL) at 0-5 °C. After 5 min, 
chloroacetonitrile (1.00 mL, 15.8 mmol) was added, and the solution was stirred at 0-
5 °C for 1.5 h. Serine methyl ester hydrochloride (1.99 g, 12.8 mmol) was added at 
0-5 °C, and the resulting slurry was allowed to warm to room temperature and stirred 
for ~18 h. Water (10 mL) was added, the mixture stirred for 10 min, and then the 
aqueous and organic layers were separated. The organic layer was washed with water 
(20 mL), dried, filtered and then concentrated in vacuo to leave a residual volume of 
~5 mL. Fresh DCM (10 mL) was added, and the solution was warmed to 30 °C. 
DBU (1.89 mL, 12.6 mmol) was added dropwise over 30 min while maintaining the 
reaction temperature at 30 °C, during addition of DBU the solution turned from 
colourless to dark red/brown. Upon completion of the addition the reaction mixture 
was cooled to rt, and HCl (8 mL, 1 M aq) was added and the layers separated. Then 
the organic layer was washed with water (10 mL). The organic layer was 
concentrated in vacuo to leave a residual volume of ~6 mL. Hexane (8 mL) was 
added, and the solution was concentrated in vacuo to leave a residual volume of ~6 
mL. More hexane (2 mL) was added, the solution was cooled to 0-5 °C and for 1.5 h 
and a colourless precipitate formed. The slurry was filtered, and the filtercake was 
washed with cold hexane and then dried to give methyl ester 128 as a colourless solid 
(1.18 g, 65 %).  
 
Method B53 
To a stirred suspension of ethyl acetimidate hydrochloride (1.00 g, 8.09 mmol) and 
serine methyl ester hydrochloride (1.26 g, 8.09 mmol) in DCM (16 mL) was added 
dropwise over 20 min a solution of triethylamine (2.44 mL, 17.5 mmol) in DCM (6 
mL). The resulting solution was stirred at rt for ~18 h, after which the solids were 
removed by filtration and washed with ether. The filtrate was concentrated in vacuo, 
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and the resulting solid residue was taken into water (20 mL) and washed with ether 
(4 × 20 mL). The combined organic extracts were dried, filtered and concentrated in 
vacuo to give crude 4,5-dihydro-2-methyloxazole-4-carboxylic acid methyl ester 
153.  
Hexamethylenetetramine (2.83 g, 20.2 mmol) and DBU (3.02 mL, 20.0 mmol) were 
added to a stirred suspension of CuBr2 (4.51 g, 20.2 mmol) at 0 °C. After 20 min, the 
crude oxazoline 153 was added in THF (10 mL), and the reaction mixture was stirred 
at rt for 3 h. The solvent was removed in vacuo, and the residue was partitioned 
between EtOAc (30 mL) and a 1:1 mixture of NH4Cl (10 mL, sat aq) and NH4OH 
(10 mL, sat aq). The aqueous layer was extracted with EtOAc (30 mL), and the 
combined organic layers were washed with a 1:1 mixture of NH4Cl (10 mL, sat aq) 
and NH4OH (10 mL, sat aq), citric acid (20 mL, 10 % aq), NaHCO3 (20 mL, sat aq), 
and brine (20 mL), then dried, filtered and evaporated in vacuo to give the crude 
oxazole 128 as a brown oil (0.6 g, 52 %).  
Rf (Hexane:EtOAc, 1:1) = 0.34; Mp = 50 °C, lit52 48 °C; IR (neat, cm-1)  1736 
(C=O), 1592 (C=C); 1H NMR δ (250 MHz, CDCl3) 8.12 (1H, s, ArH), 3.89 (3H, s, 
OCH3), 2.50 (3H, s, CH3); 13C NMR δ (62.9 MHz, CDCl3) 162.21 (C), 161.48 (C), 
143.60 (CH), 132.98 (C), 51.86 (CH3), 13.60 (CH3); m/z (EI) 141 ([M]+, 84 %), 110 
(100), 100 (95). 














(2-Methyl-1,3-oxazol-4-yl)methanol 141  
 
Methyl ester 128 (2.82 g, 20.0 mmol) was suspended in diethyl ether (30 mL) and 
cooled to −5 °C. Lithium aluminium hydride solution (18.0 mL, 1.0 M in THF, 18.0 
mmol) was added while maintaining the temperature at −5 °C. After 1 h water (1 
mL) was added, followed by NaOH (1 mL, 15 % w/v aq) and further water (1.5 mL). 
Sodium sulfate (15 g) was added, and the resulting suspension was allowed to warm 
to rt. The slurry was filtered and the filtercake was washed with DCM (3 × 30 mL). 
The filtrate and washes were combined and then concentrated in vacuo to afford 
alcohol 141 as a brown solid (1.59 g, 70 %). 
Rf (MeOH:DCM, 1:9) = 0.47; Mp = 42-43 °C, lit52 40-41 °C; IR (neat, cm-1) 3387 
(OH), 1645 (C=N), 1580 (C=C); 1H NMR δ (250 MHz, CDCl3) 7.47 (1H, s, ArH), 
4.54 (2H, s, CH2OH), 2.44 (3H, s, CH3); 13C NMR δ (62.9 MHz, CDCl3) 162.03 (C), 
140.18 (C), 134.78 (CH), 55.58 (CH2), 13.58 (CH3); m/z (EI) 113 ([M]+, 100%), 96 
(15). 














Ethyl (2Z)-3-iodoprop-2-enoate 158 
 
A stirred suspension of sodium iodide (10.0 g, 66.8 mmol, dried for ~18 h at 140 ºC) 
and acetic acid (20 mL) was heated to 70 ºC until all of the solid material was 
dissolved. To this yellow solution was added ethyl propiolate (4.50 mL, 44.4 mmol) 
and the mixture was stirred for 3 h at 70 ºC. The dark brown solution was cooled to rt 
and diethyl ether (50 mL) and water (50 mL) were added. The organic layer was 
separated and the aqueous phase was extracted with diethyl ether (3 × 50 mL) until 
the aqueous layer is colourless. The combined organic layers were adjusted to pH 7 
with KOH (3 M, aq), and the organic layer was washed with Na2S2O3 (50 mL, 10 % 
aq) and brine (50 mL). The clear colourless solution was dried, filtered and 
concentrated in vacuo to afford (Z)-alkene 158 as a brown oil (9.12 g, 91 %). 
Rf (Hexane:EtOAc, 1:1) = 0.65; IR (neat, cm-1) 1725 (C=O), 1600 (C=C); 1H NMR 
δ (250 MHz, CDCl3) 7.44 (1H, d, J = 9.0 Hz, CH), 6.89 (1H, d, J = 9.0 Hz, CH), 
4.24 (2H, q, J = 7.0 Hz, CH2CH3), 1.32 (3H, t, J = 7.0 Hz, CH2CH3);  13C NMR δ 
(62.9 MHz, CDCl3) 164.48 (C), 129.81 (CH), 94.62 (CH), 60.71 (CH2), 14.11 (CH3); 
(ESI+, MeOH) 264 ([M+K]+, 100 %), 239 (36), 208 (76). 
















Ethyl (2E)-3-iodoprop-2-enoate 159 
 
A solution of (Z)-alkene 158 (9.12 g, 40.3 mmol) in toluene (20 mL) was treated 
with hydroiodic acid (0.55 mL, 57 % aq). The resulting mixture was heated at 80 ºC 
for 6 h, after which, the solution was cooled to rt and diluted with diethyl ether (60 
mL). The organic layer was washed with NaHCO3 (30 mL, sat aq), Na2S2O3 (30 mL, 
10 % aq) and brine (30 mL). The organic phase was dried, filtered and concentrated 
in vacuo to afford (E)-alkene 159 as a brown liquid (8.43 g, 92 %). 
Rf (Hexane:EtOAc, 9:1) = 0.28; IR (neat, cm-1) 1732 (C=O), 1680 (C=C); 1H NMR 
δ (360 MHz, CDCl3) 7.86 (1H, d, J = 14.8 Hz, CH), 6.86 (1H, d, J = 14.8 Hz, CH), 
4.19 (2H, q, J = 7.2 Hz, CH2CH3), 1.28 (3H, t, J = 7.2 Hz, CH2CH3);  13C NMR δ 
(62.9 MHz, CDCl3) 164.18 (C), 136.54 (CH), 99.26 (CH), 60.97 (CH2), 14.15 (CH3); 
m/z (ESI+, MeOH) 264 ([M+K]+, 100 %), 242 (28), 209 (27), 198 (19).  



















Ethyl (2E)-hex-2-en-4-ynoate 161  
 
A solution of 1-propynylmagnesium bromide (354 mL, 0.50 M in THF, 177 mmol) 
was added dropwise to a stirred slurry of dry ZnCl2 (24.1 g, 177 mmol) in THF (70 
mL) at 0 °C. After 15 min a solution of (E)-vinyl iodide 158 (20.0 g, 88.5 mmol) in 
THF (10 mL) and Pd(PPh3)2Cl2 (3.11 g, 4.43 mmol) were added and the resulting 
mixture was stirred for ~18 h at rt. The reaction mixture was then poured into NH4Cl 
(400 mL, sat aq) and extracted with ether (4 × 200 mL). The combined organic 
extracts were washed with brine (20 mL), dried, filtered and concentrated in vacuo. 
The residue was passed through a short silica column eluting with hexane to give the 
alkyne 161 as a yellow oil (10.9 g, 90 %).  
Rf (Hexane:EtOAc, 9:1) = 0.24; IR (neat, cm-1) 2222 (C≡C), 1714 (C=O), 1621 
(C=C); 1H NMR δ (360 MHz, CDCl3) 6.72 (1H, dq, J = 15.8, 2.5 Hz, CH=CHC), 
6.12 (1H, dq, J = 15.8, 0.7 Hz, CO2EtCH=CH), 4.19 (2H, q, J = 7.2 Hz, CH2CH3),  
2.01 (3H, dd, J = 2.5, 0.7 Hz, CCH3), 1.28 (3H, t, J = 7.2, Hz, CH2CH3); 13C NMR δ 
(62.9 MHz, CDCl3) 165.00 (C), 129.28 (CH), 125.91 (CH), 96.09 (C), 77.00 (C), 
60.48 (CH2), 14.10 (CH3), 4.61 (CH3); m/z (CI, i-butane) 154 ([M+CH4]+, 80 %), 
139 ([M+H]+, 100), 111 (79). 
















To a solution of ester 161 (1.50 g, 10.8 mmol) in DCM (8 mL) at −78 ºC was added 
DIBAL (32.5 mL, 1 M in hexanes, 32.5 mmol) dropwise. The reaction mixture was 
stirred at −78 ºC for 1 h and then warmed to 0 °C and diluted with ether (20 mL). 
Water (1.25 mL) was added slowly, followed by NaOH (2 mL, 10 % aq) and further 
water (3 mL), The mixture was then allowed to warm to rt and stirred for 15 min. 
MgSO4 (~5 g) was added and the mixture stirred for 30 min, after which the 
suspension was filtered and the filtrate concentrated in vacuo. The crude oil was 
purified by flash chromatography (hexane:EtOAc, 9:1) to give the alcohol 162 as a 
light yellow oil (0.790 g, 73 %). 
Rf (Hexane:EtOAc, 3:1) = 0.19; IR (neat, cm-1) 3379 (OH), 2223 (C≡C), 1633 
(C=C); 1H NMR δ (500 MHz, CDCl3) 6.15 (1H, dtq, J = 15.8, 5.4, 0.6 Hz, 
CH2CH=CH), 5.69 (1H, dq, J = 15.8, 2.2 Hz, CH=CHC), 4.17 (2H, d, J = 5.4 Hz, 
CH2),  1.94 (3H, dd, J = 2.2, 0.6 Hz, CCH3); 13C NMR δ (126 MHz, CDCl3) 140.24 
(CH), 111.26 (CH), 86.80 (C), 77.50 (C), 63.09 (CH2), 4.26 (CH3); m/z (CI, i-butane) 
97 ([M+H]+, 63 %), 79 (94), 71 (100).  



















To a solution of ester 161 (100 mg, 0.72 mmol) in DCM (1 mL) at −78 ºC was added 
DIBAL (0.80 mL, 1 M in hexanes, 0.80 mmol) dropwise. The reaction mixture was 
stirred at −78 ºC for 1 h, then quenched with MeOH (0.5 mL) followed by sodium 
potassium tartrate (2 mL, sat aq). The reaction mixture was warmed to rt, diluted 
with ether (10 mL), and stirred for 30 min while protected from light, then diluted 
with further ether (5 mL) and water (5 mL). The organic phase was separated and the 
aqueous phase was extracted with ether (3 × 15 mL) and the combined organic 
extracts were washed with brine (1 × 15 mL), dried, filtered and concentrated in 
vacuo to give the highly volatile aldehyde 140 as a pale yellow oil, which was used 
immediately in subsequent steps without further purification. 
Method B 
To a solution of the alcohol 162 (230 mg, 2.30 mmol) in DMSO (5 mL) at rt was 
added 2-iodoxybenzoic acid (3.28 g, 45 wt. %, 5.27 mmol), the solution was stirred 
at rt for 30 min.  The reaction mixture was diluted with ether (20 mL) and water (30 
mL), the organic phase was separated and the aqueous phase was extracted with 
ether (2 × 20 mL), the organic phases were combined, washed with brine (15 mL), 
dried, filtered and concentrated in vacuo to give the highly volatile aldehyde 140 as a 
pale yellow oil, which was used immediately in subsequent steps without further 
purification. 
 
Method C60  
A thoroughly stirred suspension of manganese dioxide (1.03 g, 11.9 mmol) in diethyl 
ether (10 mL) was treated with ultrasonic vibration for 30 min, then alcohol 162 (57 
mg, 0.59 mmol) dissolved in diethyl ether (1 mL) was added. The suspension was 
stirred for ~18 h at rt and then filtered through celite and the solvent was carefully 




oil, which was used immediately in subsequent steps without further purification. 
Rf (Hexane:EtOAc, 13:1) = 0.51; 1H NMR δ (360 MHz, CDCl3) 9.54 (1H, d, J = 7.9 
Hz, CHO), 6.56 (1H, dq, J = 15.5, 2.3 Hz, CH=CHC), 6.40 (1H, dd, J = 15.5, 7.9 Hz, 
CHOCH=CH),  2.09 (3H, d, J = 2.3 Hz, CCH3); m/z (CI, i-butane) 189 ([2M+H]+, 8 
%), 187 (27), 171 (100), 149 (8), 95.0 ([M+H]+, 6 %). 
Spectroscopic data are in good agreement with the literature.58  
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ster 182 as a yellow oil (317 mg, 90 %). 
9:1) = 0.48; IR (neat, cm-1) 2220 (C≡C), 1660 (C=O), 1598 
250 MHz, CDCl3) 6.63 (1H, dq, J = 15.6, 2.4 Hz, CH=CHC), 
6, 0.7 Hz, COSEtCH=CH), 2.94 (2H, q, J = 7.4 Hz, CH2CH3),  
 0.7 Hz, CCH3), 1.27 (3H, t, J = 7.4 Hz, CH2CH3); 13C NMR δ 
189.63 (C), 136.06 (CH), 122.12 (CH), 97.20 (C), 77.77 (C), 
CH3), 5.25 (CH3); m/z (EI) 154 ([M]+, 16  %), 126 (20), 93 







To a solution of the alcohol 141 (1.00 g, 8.84 mmol) in DCM (80 mL) at 0 °C was 
added tert-butyldimethylsilyl trifluoromethanesulfonate (2.13 mL, 9.28 mmol) 
followed by 2,6-lutidine (1.24 mL, 10.6 mmol). After stirring for 1 h at 0 °C the 
reaction was quenched by the addition of sodium bicarbonate (20 mL, sat aq) and 
extracted with DCM (3 × 40 mL). The organic extracts were combined, dried, 
filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (hexane:EtOAc, 9:1) to give the silyl ether 212a as pale yellow oil 
(1.67 g, 89 %). 
Rf (Hexane:EtOAc, 10:1) = 0.19; IR (neat, cm-1) 1581 (C=C), 1253 (SiCH3); 1H 
NMR δ (360 MHz, CDCl3) 7.41 (1H, s, ArH), 4.60 (2H, s, OCH2), 2.43 (3H, s, 
ArCH3),  0.91 (9H, s, C(CH3)3), 0.10 (6H, s,  2 × SiCH3) ; 13C NMR δ (126 MHz, 
CDCl3) 161.31 (C), 141.06 (C), 134.56 (CH), 58.45 (CH2), 25.78 (CH3), 18.25 (C), 
13.74 (CH3), −5.49 (CH3); m/z (ESI+, MeOH) 476 ([2M+Na]+, 100 %),  250 
([M+Na]+, 75), 228 ([M+H]+, 86). 



















































odium hydride (97 mg, 60% in mineral oil, 2.43 mmol) was added to a solution of 
lcohol 141 (250 mg, 2.21 mmol) in THF (4 mL) at 0 °C, and the mixture was stirred 
t 0 °C for 10 min and at rt for an additional 1 h. The mixture was cooled to 0 °C and 
-(trimethylsilyl)ethoxymethyl chloride (0.469 mL, 2.65 mmol) was added dropwise. 
he reaction mixture was stirred at 0 °C for 10 min and at rt for an additional 3 h. 
he mixture was poured into water (15 mL) and extracted with ethyl acetate (2 × 30 
L). The combined organic extracts were washed with brine (20 mL), dried, filtered 
nd concentrated in vacuo. The crude material was purified by flash chromatography 
hexane:EtOAc, 1:1) to give the ether 212b as a pale yellow oil (370 mg, 68 %). 
f (Hexane:EtOAc, 1:1) = 0.50; IR (neat, cm-1) 1581 (C=C), 1271 (SiCH3); 1H 
MR δ (400 MHz, CDCl3) δ 7.52 (1H, s, ArH), 4.78 (2H, s, OCH2O), 4.51 (2H, s, 
CH2Ar), 3.77 – 3.61 (2H, m, OCH2), 2.47 (3H, s, ArCH3), 1.04 – 0.95 (2H, m, 
H2Si), 0.05 (9H, s, SiCH3);13C NMR δ (101 MHz, CDCl3) 162.03 (C), 137.51 (C), 
35.86 (CH), 94.31 (CH2), 65.36 (CH2), 61.07 (CH2), 18.13 (CH2), 13.92 (3 × CH3), 
1.39 (CH3); m/z (CI, i-butane) 244 ([M+H]+, 100 %); HRMS (CI, i-butane) 



































odium hydride (0.53 g, 60 % in mineral oil, 13.4 mmol) was added to a solution of 
lcohol 141 (1.37 g, 12.2 mmol) in THF (25 mL) at 0 °C, and the mixture was stirred 
t 0 °C for 10 min and at rt for an additional 1 h. The mixture was cooled to 0 °C and 
hloromethyl methyl ether (1.10 mL, 14.6 mmol) was added dropwise. The reaction 
ixture was stirred at 0 °C for 10 min and at rt for an additional 3 h. The mixture 
as poured into water (50 mL) and extracted with EtOAc (2 × 100 mL). The 
ombined organic extracts were washed with brine (50 mL), dried, filtered and 
oncentrated in vacuo. The crude material was purified by flash chromatography 
hexane:EtOAc, 3:2) to give the ether 212c as an orange oil (1.41 g, 73 %). 
f (Hexane:EtOAc, 1:1) = 0.21; IR (neat, cm-1) 1581 (C=C); 1H NMR δ (500 MHz, 
DCl3) 7.52 (1H, s, ArH), 4.72 (2H, s, OCH2O), 4.48 (2H, s, OCH2), 3.41 (3H, s, 
CH3), 2.46 (3H, s, ArCH3); 13C NMR δ (126 MHz, CDCl3) 162.14 (C), 137.22 (C), 
36.03 (CH), 95.79 (CH2), 60.83 (CH2), 55.46 (CH3), 13.99 (CH3); m/z (EI) 157 




General Procedure A 
Methyl oxazole (1.77 mmol) was dissolved in dry THF (10 mL) and was cooled with 
stirring to −78 °C. To this solution nBuLi (8.85 mmol, 0.83 M in hexanes) was added 
dropwise and the solution allowed to stir for 1 h, after which diethylamine (10.6 
mmol) was added. After a further 45 min the aldehyde (2.55 mmol) was added and 
the solution was stirred for 45 min at −78 °C. The reaction mixture was quenched 
with NH4Cl (10 mL, sat aq) and allowed to warm to rt, the reaction mixture was then 
extracted with DCM (3 × 20 mL). The organic extracts were combined, dried, 
filtered and concentrated in vacuo to give the alcohol. The crude mixture was 




General procedure A was followed with methyl oxazole 141 (200 mg, 1.77 mmol). 
Flash chromatography (1:19 MeOH:DCM) resulted in an inseparable mixture of 
methyl oxazole starting material (141) and product 194. 
 Rf (DCM:MeOH, 9:1) = 0.23; IR (neat, cm-1) 3349 (OH), 1671 (C=N), 1581 (C=C); 
1H NMR (250 MHz, CDCl3) δ 7.51 (1H, s, ArH), 5.70 (1H, dqd, CH=CHCH3, J = 
15.4, 6.5, 1.1 Hz), 5.55 (1H, ddq, J = 15.4, 6.5, 1.4 Hz, CHOHCH=CH), 4.58 − 4.55 
(3H, m, CH2OH and CHOH), 2.95 – 2.92 (2H, m, ArCH2CH), 1.69 (3H, dd, J = 6.5, 
1.4 Hz, CHCH3); 13C NMR δ (90.6 MHz, CDCl3) 163.03 (C), 139.98 (C), 134.98 
(CH), 132.04 (CH), 127.71 (CH), 69.85 (CH), 56.42 (CH2), 35.99 (CH2), 17.65 
(CH3); m/z (EI) 183 ([M]+, 5%), 165 (36), 113 (88), 95 (100); HRMS (EI) [M]+ 








General ed with SEM protected oxazole 212b (100 mg, 
0.41 mmol). Flash chromatography (1:49 MeOH:DCM) resulted in an inseparable 
mixture of methyl oxazole starting material (212b) and product 213b. 
Rf (hexane: EtOAc, 1:1) = 0.36; 1H NMR (500 MHz, CDCl3) δ 7.54 (1H, s, ArH), 
5.75 (1H, dq, CH=CHCH3, J = 15.4, 6.5 Hz), 5.56 (1H, ddq, J = 15.4, 6.5, 1.4 Hz, 
CHCH=CH), 4.75 (2H, s, OCH2O), 4.57 - 4.56 (1H, m, CHOH), 4.49 (2H, s, 
ArCH2O), 3.67 – 3.63 (2H, m, OCH2),  3.27 (1H, s, OH), 2.94 – 2.88 (2H, m, 
ArCH2CH), 1.69 (3H dd, J = 6.5, 1.4 Hz CHCH3), 0.97 – 0.94 (2H, m, CH2Si), 0.02 
(9H, s, Si(CH3)3); m/z (ESI+, MeOH) 649 ([2M+Na]+, 87 %), 336 ([M+Na]+, 100), 
314 ([M+H]+, 31). 
  
4-[(Methoxymethoxy)methyl]-2-[(3E)-pent-3-en-2-ol-1-yl]-1,3-oxazole 213c 















[M+H]+ fprocedure A was follow
 
161 
procedure A was followed with MOM protected oxazole 212c (130 mg, 
ol). The product was purified by flash chromatography (1:8 MeOH:DCM) 
e alcohol 213c as an brown gum (94 mg, 50 %).  
:DCM, 1:9) = 0.57; IR (neat, cm-1) 3408 (OH), 1672 (C=N), 1570 (C=C); 
 δ (500 MHz, CDCl3) 7.52 (1H, s, ArH), 5.72 (1H, dqd, CH=CHCH3, J = 
 1.0 Hz), 5.53 (1H, ddq, J = 15.3, 6.5, 1.5 Hz, CHOHCH=CH), 4.67 (2H, s, 
 4.54 - 4.49 (1H, m, CHOH), 4.46 (2H, s, ArCH2O), 3.33 (3H, s, OCH3), 
8 (2H, m, ArCH2CH)  1.66 (3H, dd, J = 6.5, 1.5 Hz, CHCH3); 13C NMR δ 
z, CDCl3) 163.03 (C), 137.29 (C), 136.07 (CH), 132.04 (CH), 127.71 (CH), 
2), 69.89 (CH), 60.81 (CH2), 55.41 (CH3), 35.92 (CH2), 17.66 (CH3); m/z 
tane) 228 ([M+H]+, 47 %), 210 (89), 57 (100); HRMS (CI, i-butane) 































eneral procedure A was followed with MOM protected oxazole 212c (480 mg, 
.06 mmol). The product was purified by flash chromatography (1:20 MeOH:DCM) 
wice to give the alcohol 214 as a brown gum  (192 mg, 25 % (40 % yield based on 
ecovered starting material from 2nd column)).  
f (DCM:MeOH, 11:1) = 0.47; IR (neat, cm-1) 3383 (OH), 2200 (C≡C), 1610 
C=N), 1570 (C=C), 1149;  1H NMR (400 MHz, CDCl3) δ 7.55 (1H, s, ArH), 6.08 
1H, dd, J = 15.8, 5.7 Hz, CHOHCH=CH), 5.78 (1H, dhex, J = 15.8, 2.3 Hz, 
H=CHC), 4.71 (2H, s, OCH2O), 4.66-4.64 (1H, m, CHOH), 4.49 (2H, s, ArCH2O), 
.45 (1H, br s, OH), 3.41 (3H, s, OCH3), 2.99 (1H, dd, J = 16.0, 4.0 Hz, 
rCHXCHYCH), 2.90 (1H, dd, J = 16.0, 8.3 Hz, ArCHXCHYCH), 1.95 (3H, d, J = 
.3 Hz, CCH3); 13C NMR δ (126 MHz, CDCl3) 162.56 (C), 141.56 (CH), 137.30 
C), 136.26 (CH), 111.62 (CH), 95.78 (CH2), 87.50 (C), 77.27 (C), 69.15 (CH), 
0.71 (CH2), 55.50 (CH3), 35.35 (CH2), 4.37 (CH3); m/z (EI) 251 ([M]+, 22 %), 157 







To a solution of alcohol 214 (100 mg, 0.40 mmol) in THF (3 mL) at 0 °C was added 
NaH (39 mg, 0.99 mmol, 60 % dispersion in mineral oil), and the suspension was 
stirred for 30 min. Iodomethane (0.05 mL, 0.8 mmol) was then added and the 
mixture stirred at 0 °C for 40 min and then at rt for ~18 h. The excess NaH was 
quenched by dropwise addition of NaHCO3 (5 mL, sat aq) and diethyl ether was 
added (10 mL). The two layers were separated and the organic layer was washed 
with Na2S2O3 (10 mL, 0.1 M), water (10 mL) and brine (10 mL), then dried, filtered 
and concentrated in vacuo. The product was purified by flash chromatography (1:1 
EtOAc:hexane) to give the methyl ether 215 as a brown oil (30 mg, 29 %). 
Rf (EtOAc:hexane, 1:3) = 0.28; IR (neat, cm-1) 2220 (C≡C), 1680 (C=N), 1571 
(C=C);  1H NMR (500 MHz, CDCl3) δ 7.56 (1H, s, ArH), 5.95 (1H, dd, J = 15.9, 7.7 
Hz, CHCH=CH), 5.70 (1H, dd, J = 15.9, 2.0 Hz, CH=CHC), 4.74 (2H, s, OCH2O ), 
4.53 (2H, s, ArCH2O), 4.12 (1H, q, J = 7.6 Hz, CHOMe), 3.43 (3H, s, OCH3), 3.29 
(3H, s, OCH3 ), 3.07 (1H, dd, J = 15.0, 7.6 Hz, ArCHXCHYCH), 2.96 (1H, dd, J = 
15.0, 5.8 Hz, ArCHXCHYCH), 1.97 (3H, d, J = 2.0 Hz, CCH3). 13C NMR δ (126 
MHz, CDCl3) 161.95 (C), 140.07 (CH), 137.57 (C), 136.18 (CH), 113.72 (CH), 
95.85 (CH2), 87.52 (C), 79.36 (CH), 77.19 (C), 61.05 (CH2), 56.71 (CH3), 55.45 
(CH3), 34.76 (CH2), 4.27 (CH3); m/z (EI) 265 ([M]+, 4 %), 234 (3), 109 (100), 






To a solution of MOM protected alcohol 215 in methanol was added HCl (5 drops, 
conc. aq) and the solution was stirred for ~18 h at rt. The solvent was removed in 
vacuo and the residue was taken into EtOAc, washed with NaHCO3 (10 mL, sat aq). 
The aqueous phase was extracted with EtOAc (2 × 10 mL). The organic layers were 
combined, dried, filtered and concentrated in vacuo, to give the alcohol 389 as a 
brown oil 42 mg (74 %). 
Rf (MeOH:DCM, 1:9) = 0.50; IR (neat, cm-1) 3392 (OH), 2223 (C≡C), 1680 (C=C), 
1570 (C=C);  1H NMR (500 MHz, CDCl3) δ 7.50 (1H, s, ArH), 5.90 (1H, dd, J = 
15.9, 7.7 Hz, CHCH=CH), 5.67 (1H, dq, J = 15.9, 2.2 Hz, CH=CHC), 4.55 (2H, s, 
CH2OH ), 4.06 (1H, q, J = 7.4 Hz, CHOMe), 3.25 (3H, s, OCH3), 3.02 (1H, dd, J = 
15.1, 7.4 Hz, ArCHXCHYCH), 2.91 (1H, dd, J = 15.1, 5.7 Hz, ArCHXCHYCH), 1.93 
(3H, d, J = 2.2 Hz, CCH3). 13C NMR δ (126 MHz, CDCl3) 162.01 (C), 140.26 (C), 
139.91 (CH), 135.10 (CH), 113.85 (CH), 87.62 (C), 79.26 (CH), 77.14 (C), 56.68 
(CH2), 56.60 (CH3), 34.68 (CH2), 4.26 (CH3); m/z (EI) 221 ([M]+, 26 %), 167 (27), 















NaHCO3 (201 mg, 2.4 mmol) was suspended in DCM (5 mL) and Dess-Martin 
periodinane (100 mg, 0.024 mmol) was added and the suspension stirred for 5 min at 
rt. The mixture was cooled to 0 °C and alcohol 389 (35 mg, 0.16 mmol) was added in 
DCM (1 mL) and the suspension was stirred at 0 °C for 2 h, after which a 1:1 
mixture of NaHCO3 (5 mL, sat aq) and Na2S2O3 (5 mL, 0.1 M aq) was added and the 
mixture stirred for 10 min. The biphasic mixture was separated and the aqueous layer 
extracted with DCM (2 × 10 mL), the organic layers were combined, dried, filtered 
and concentrated in vacuo. The product was purified by flash chromatography (1:1 
EtOAc:hexane) to give the aldehyde (±)-131 as a brown oil (15 mg, 43 %). 
Rf (EtOAc:hexane, 1:1) = 0.38; IR (neat, cm-1) 2220 (C≡C), 1699 (C=O), 1583 
(C=C);  1H NMR (500 MHz, CDCl3) δ 9.91 (1H, s, CHO) 8.19 (1H, s, ArH), 5.92 
(1H, dd, J = 15.9, 7.7 Hz, CHCH=CH), 5.70 (1H, dqd, J = 15.9, 2.1, 0.9 Hz, 
CH=CHC), 4.15-4.11 (1H, m, CHOMe), 3.27 (3H, s, OCH3), 3.10 (1H, dd, J = 15.2, 
7.7 Hz, ArCHXCHYCH), 3.01 (1H, dd, J = 15.2, 5.5 Hz, ArCHXCHYCH), 1.95 (3H, 
d, J = 2.1 Hz, CCH3). 13C NMR δ (126 MHz, CDCl3) 184.02 (CH), 163.10 (C), 
144.43 (CH), 140.94 (C), 139.44 (CH), 113.31 (CH), 87.96 (C), 79.10 (CH), 77.23 
(C) 56.74 (CH3), 34.59 (CH2), 4.28 (CH3); m/z (EI) 219 ([M]+, 23 %), 204 (11), 188 











6.3 Experimental for Chapter 3 
2-[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]acetaldehyde 221 
 
To  a  stirred  solution  of  oxalyl  chloride (4.34 mL,  51.3 mmol)  in  dry  DCM (80 
mL),  DMSO (8.83 mL, 82.1 mmol) was added at −78 °C and stirred at −78 °C for 
30 min. A solution of alcohol 220 (5.00 g, 34.2 mmol) in DCM (10 mL) was added 
at −78 °C and stirred for 3 h at −78 °C. The reaction mixture was warmed to 0 °C, 
treated with Et3N (23.0 mL, 165 mmol) and stirred for 15 min. The reaction mixture 
was diluted with DCM (300 mL) and washed with water (200 mL). The organic layer 
was dried, filtered and concentrated in vacuo to afford aldehyde 221 as a pale yellow 
syrup (quant), which was used directly in the next step. 
1H NMR (400 MHz, CDCl3) δ 9.80 (1H, t, J = 1.6 Hz, CHO), 4.53 (1H, quintet, J = 
6.4 Hz, CH2CHCH2), 4.19 (1H, dd, J = 8.3, 6.0 Hz, CHCHXCHY), 3.59 (1H, dd, J = 
8.3, 6.7 Hz, CHCHXCHY), 2.84 (1H, ddd, J = 17.1, 6.6, 1.6 Hz, CHOCHACHB), 2.64 
(1H, ddd, J = 17.1, 6.5, 1.6 Hz, CHOCHACHB), 1.41 (3H, d, J = 0.4 Hz, CH3), 1.36 
(3H, d, J = 0.4 Hz, CH3). 
















2-[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]acetic acid 26b 
 
To a stirred solution of aldehyde 221 (assumed 34.2 mmol) in tert-butanol/water 
(7:3, 1000 mL), sodium chlorite (4.64 g, 51.3 mmol), and H2O2 (25 mL, 6% aq) were 
added and the mixture was stirred at rt for ~18 h. The reaction mixture was 
concentrated, the residue dissolved in EtOAc (100 mL), washed with water (20 mL) 
and brine (20 mL), dried, filtered and concentrated in vacuo. The crude product was 
passed through a silica plug eluting with EtOAc to afford the unstable acid 26b as a 
colourless syrup (4.15 g, 76 % over 2 steps). 
1H NMR (400 MHz, CDCl3) δ 4.47 (1H, quintet, J = 6.5 Hz, CH2CHCH2), 4.16 (1H, 
dd, J = 8.4, 6.0 Hz, CHCHXCHYO), 3.66 (1H, dd, J = 8.4, 6.2 Hz, CHCHXCHYO), 
2.74 (1H, dd, J = 16.2, 6.7 Hz, CO2HCHACHB), 2.57 (1H, dd, J = 16.2, 6.7 Hz, 
CO2HCHACHB), 1.42 (3H, d, J = 0.5 Hz, CH3), 1.36 (3H, d, J = 0.5 Hz, CH3). 






















To a solution of acid 26b (1.20 g, 6.89 mmol) in THF (10 mL) at 0 °C was added 
1,1'- carbonyldiimidazole (1.34 g, 6.96 mmol), and the mixture was stirred for 30 
min. The cooling bath was removed, serine methyl ester hydrochloride (1.08 g, 6.96 
mmol) was added in one portion, and the reaction mixture was stirred for ~18 h at rt. 
The solvent was removed in vacuo, and the crude residue was partitioned between 
EtOAc/brine (4:1, 25 mL). The resulting biphasic mixture was separated, and the 
aqueous phase was extracted with EtOAc (4 × 10 mL). The organic extracts were 
combined, dried, filtered and concentrated in vacuo. The crude residue was purified 
by flash chromatography (1:9, hexane: EtOAc) to provide amide 27b as a pale 
orange syrup (0.850 g, 47%). 
Rf (Hexane:EtOAc, 1:9) = 0.20; [α]D = +11.6 (c 0.86, CHCl3), lit25 ent +31.0 (c 0.5, 
CHCl3) ; IR (neat, cm-1) 3354 (OH/NH),  1747 (C=O), 1660 (C=O); 1H NMR δ (400 
MHz, CDCl3) 7.01 (0.45 H, d, J = 6.5 Hz, NH), 6.88 (0.55H, d, J = 6.5 Hz, NH), 
4.69 – 4.64 (1H, m, CH2CHCH2), 4.46 (1H, m, CHCHXCHYO), 4.14 (1H, m, 
CHCHXCHYO), 3.96 (2H, dd, J = 3.4, 2.0 Hz, CH2OH), 3.80 (3H, s, CO2CH3), 3.66 
(1H, dt, J = 6.5, 2.0, Hz, COCHNH), 2.59 – 2.54 (2H, m, COCH2), 1.47 (1.35H, s, 
CH3), 1.45 (1.65H, d, J = 8.6 Hz, CH3), 1.37 (3H, s, CH3); 13C NMR δ (101 MHz, 
CDCl3) 170.82*, 170.74 (C), 170.33*, 170.24 (C), 109.56*, 109.52 (C), 72.54*, 
72.15 (CH), 69.01*, 68.62 (CH2), 63.36, 63.08* (CH2), 54.97, 54.81* (CH), 52.80 
(CH3), 40.57*, 40.20 (CH2), 26.90*, 26.61 (CH3), 25.48*, 25.06 (CH3) (*denotes 
minor rotamer); m/z (ESI−, MeOH) 260 ([M-H]−, 100  %), 230 (56). 











To a solution of amide 27b (0.800 g, 3.06 mmol) in DCM (8 mL) at −78 °C was 
added diethylaminosulfur trifluoride (DAST) (0.420 mL, 3.22 mmol), and the 
reaction was stirred for 45 min. Solid K2CO3 (0.845 g, 6.12 mmol) was then added, 
and the reaction was stirred for 1 h and then warmed to rt. The orange slurry was 
slowly added to saturated aqueous NaHCO3 (10 mL), and the resultant biphasic 
mixture was separated. The aqueous phase was extracted with DCM (2 × 10 mL), 
and the combined organics were dried, filtered and concentrated in vacuo. The crude 
oxazoline 390 was taken on without further purification.  
1H NMR δ (400 MHz, CDCl3) 4.74 (1H, m, CH2CHCH2), 4.51 – 4.38 (3H, m, 
NOCHCH2and CH2ring), 4.14 (1H, m, CHCHXCHYO), 3.79 (3H, s, CO2CH3), 3.70 
(1H, m,  CHCHXCHYO), 2.73 (1H, m, CHCHACHBCH), 2.52 (1H, m, 





Crude oxazoline 390 (assumed 3.06 mmol) was dissolved in DCM (15 mL), and then 
cooled to 0 °C. To this solution was added DBU (0.91 mL, 6.12 mmol) followed by 
BrCCl3 (0.33 mL, 3.40 mmol), and the reaction mixture was stirred for ~18 h without 
further cooling. NH4Cl (20 mL, sat aq) was then added, and the biphasic mixture was 
separated.  The  aqueous  phase  was extracted with DCM (3 × 10 mL) and the 
combined organic extracts were dried, filtered and concentrated in vacuo, and the 
crude residue was purified via column chromatography (1:1, hexane:EtOAc) to 
provide the oxazole 28b (0.50 g, 68%, over two steps) as a colourless oil. 
Experimental 
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Rf (Hexane:EtOAc, 1:1) = 0.24; [α]D = +4.8 (c 1.43, CHCl3), lit25 ent −0.7 (c 1.0, 
CHCl3); IR (neat, cm-1) 1743 (C=O), 1587 (C=C); 1H NMR δ (500 MHz, CDCl3) 
8.18 (1H, s, ArH), 4.56 (1H, quintet, J = 6.0 Hz, CH2CHCH2), 4.14 (1H, dd, J = 8.5, 
6.0 Hz CHCHXCHYO), 3.90 (3H, s, CO2CH3), 3.77 (1H, dd, J = 8.5, 6.0 Hz, 
CHCHXCHYO), 3.15 (1H, dd, J = 15.2, 6.5 Hz, ArCHACHB), 3.02 (1H, dd, J = 15.2, 
6.5 Hz, ArCHACHB), 1.40 (3H, s, CH3), 1.34 (3H, s, CH3); 13C NMR δ (126 MHz, 
CDCl3) 162.20 (C), 161.59 (C), 144.15 (CH), 133.39 (C), 109.75 (C),  73.04 (CH), 
68.77 (CH2), 52.18 (CH3), 32.94 (CH2), 26.89 (CH3), 25.47 (CH3); m/z (ESI+, 
MeOH) 264 ([M+Na]+, 100  %), 242 ([M+H]+, 7), 184 (33). 
Spectroscopic data are in good agreement with the literature.25 
 
Methyl 2-[(2R)-2,3-dihydroxyprop-1-yl]-1,3-oxazole-4-carboxylate 391 
 
To a solution of acetonide 28b (0.65 g, 2.69 mmol) in methanol (10 mL) was added 
DOWEX 50WX8-200 until the solution was acidic (monitored by pH indicator 
paper) and the reaction mixture was stirred at rt for ~18 h. The solids were removed 
by filtration through celite and the solvent removed in vacuo to give diol 391 as an 
orange oil (0.54 g, quant). 
Rf (DCM:MeOH, 9:1) = 0.24; [α]D = +19.5 (c 0.41, CHCl3), lit25 ent −21.3 (c 0.4, 
CHCl3);  IR (neat, cm-1) 3354 (OH), 1737 (C=O), 1587 (C=C); 1H NMR δ (400 
MHz, CDCl3) 8.18 (1H, s, ArH), 4.37 – 4.18 (1H, m, CH2CHCH2), 3.91 (3H, s, 
CO2CH3), 3.77 (1H, dd, J = 11.3, 3.7 Hz, CHCHXHYO), 3.62 (1H, dd, J = 11.3, 5.8 
Hz CHCHXHYO), 3.09 (1H, dd, J = 16.0, 8.1 Hz, ArCHAHBCH), 3.02 (1H, dd, J = 
16.0, 4.6 Hz, ArCHAHBCH), 2.04 (1H, br s, OH); 13C NMR δ (126 MHz, CDCl3) 
163.39 (C), 161.50 (C), 144.02 (CH), 133.14 (C), 69.13 (CH), 65.64 (CH2), 52.21 
(CH3), 32.01 (CH2); m/z (ESI+, MeOH/DCM) 425 [2M+Na]+, 100  %), 224 
([M+Na]+, 32), 202 ([M+H]+, 9). 








To a solution of diol 391 (0.500 g, 2.49 mmol) in DCM (40 mL) at −78 °C was 
added 2,6-lutidine (0.320 mL, 2.73 mmol) followed by TIPSOTf (0.800 mL, 2.98 
mmol). The solution was stirred at −78 °C for 1 h and allowed to warm to rt over 1 h. 
Brine (50 mL) was added and the reaction mixture was extracted with DCM (2 × 50 
mL), the combined organic layers were dried, filtered and concentrated in vacuo. The 
crude residue was purified by flash chromatography (1:1, hexane: EtOAc) to give the 
silyl ether 223 as pale yellow oil (0.690 g, 78 %). 
Rf (Hexane:EtOAc, 1:1) = 0.40; [α]D = +15.7 (c 1.66, CHCl3), lit25 ent -13.9 (c 0.9, 
CHCl3);  IR (neat, cm-1) 3450 (OH), 1741 (C=O), 1587 (C=C); 1H NMR δ (400 
MHz, CDCl3) 8.21 (1H, s, ArH), 4.27– 4.20 (1H, m, CH2CHCH2), 3.94 (3H, s, 
CO2CH3), 3.81 (1H, dd, J = 9.9, 4.6 Hz, CHXHYOTIPS), 3.74 (1H, dd, J = 9.9, 5.6 
Hz, CHXHYOTIPS), 3.08 (1H, dd, J = 13.2, 3.2 Hz, ArCHAHBCH ), 3.04 (1H, dd, J = 
13.2, 5.0 Hz, ArCHAHBCH), 2.90 (1H, d, J = 5.3 Hz, OH), 1.28 - 0.95 (21H, m, 
Si(CH(CH3)2)3); 13C NMR δ (101 MHz, CDCl3) 163.41 (C), 161.65 (C), 143.98 
(CH), 133.29 (C), 69.64 (CH), 66.36 (CH2), 52.14 (CH3), 32.27 (CH2), 17.93 (6CH3), 
11.89 (3CH); m/z (ESI+, MeOH/DCM) 737 ([2M+Na]+, 62  %), 380 ([M+Na]+, 
100), 358 (([M+H]+, 32). 













Alcohol 223 (0.350 g, 1.03 mmol), iodomethane (1.16 mL, 18.6 mmol) and silver(I) 
oxide (0.429 g, 1.85 mmol) in MeCN (20 mL) were heated at 60 °C for ~18 h. The 
brown suspension was allowed to cool to rt, ether (50 mL) was added and the solids 
were removed by filtration through celite. The solvent was removed in vacuo and the 
crude residue was purified by flash chromatography (3:1, hexane: EtOAc) to give the 
methyl ether 392 as a yellow oil (0.240 g, 63 %). 
Rf (Hexane:EtOAc, 3:1) = 0.30; [α]D = +24.0 (c 0.25, CHCl3), lit25 ent −7.8 (c 0.5, 
CHCl3);  IR (neat, cm-1) 1749 (C=O), 1585 (C=C); 1H NMR δ (500 MHz, CDCl3) 
8.19 (1H, s, ArH), 3.94 (3H, s, CO2CH3), 3.89 – 3.78 (2H, m, CHXCHYOTIPS and 
CH2CHCH2), 3.76 - 3.73 (1H, m, CHXCHYOTIPS), 3.17 (3H, s, OCH3), 3.17 (1H, 
dd, J = 15.3, 4.8 Hz, ArCHACHB), 3.03 (1H, dd, J = 15.3, 7.7 Hz, ArCHACHB), 1.18-
0.99 (21H, m, Si(CH(CH3)2)3); 13C NMR δ (126 MHz, CDCl3) 163.76 (C), 161.80 
(C), 143.85 (CH), 133.32 (C), 79.72 (CH), 64.42 (CH2), 58.06 (CH3), 52.11 (CH3), 
30.89 (CH2), 17.95 (6CH3), 11.90 (3CH); m/z (ESI+, MeOH/DCM) 394 ([M+Na]+, 
100  %), 372 ([M+H]+, 75). 





Methyl 2-[(2R)-2,3-dihydroxyprop-1-yl]-1,3-oxazole-4-carboxylate 29b 
 
To a solution of silyl ether 392 (95 mg, 0.25 mmol) in THF (5 mL) at 0 °C was 
added TBAF (0.38 mL, 0.38 mmol, 1 M in THF) dropwise and the solution was 
stirred for ~18 h at rt. The solvent was removed in vacuo and the crude residue was 
purified by flash chromatography (1:1, hexane: EtOAc) to give the alcohol 29b as an 
orange oil (40 mg, 73 %). 
Rf (Hexane:EtOAc, 1:3) = 0.24; [α]D = −14.3 (c 0.45, CHCl3), lit29 -13.89 (c 3.47, 
CHCl3);  IR (neat, cm-1) 3471 (OH), 1737 (C=O), 1585 (C=C); 1H NMR δ (500 
MHz, CDCl3) 8.20 (1H, s, ArH), 3.94 (3H, s, CO2CH3), 3.82 – 3.78 (2H, m, 
CHXCHYOH and CH2CHCH2), 3.63 - 3.58 (1H, m, CHXCHYOH), 3.43 (3H, s, 
OCH3), 3.15 (1H, dd, J = 15.3, 6.1 Hz, ArCHACHB), 3.07 (1H, dd, J = 15.3, 6.4 Hz, 
ArCHACHB), 2.06 (1H, t, J = 6.1 Hz, OH); 13C NMR δ (126 MHz, CDCl3) 162.90 
(C), 161.61 (C), 144.01 (CH), 133.39 (C), 78.99 (CH), 63.20 (CH2), 57.58 (CH3), 
52.18 (CH3), 30.20 (CH2); m/z (ESI+, MeOH/DCM) 453 ([2M+Na]+, 100  %), 238 
(([M+Na]+, 36), 216 (([M+H]+, 20). 











































thyl bromopyruvate (2.00 mL, 15.9 mmol) and urea (1.44 g, 23.9 mmol) in ethanol 
5 mL) were heated under reflux for 2 h. The cooled reaction mixture was 
oncentrated in vacuo to give an oil, to this was added water (5 mL) and the mixture 
djusted to pH 10 by the addition of NaOH (10 % aq). The mixture was extracted 
ith ether (4 × 30 mL) and the extract treated with HCl in ether (20 mL, 1 M) and 
he precipitate filtered to give the hydrochloride salt of amino oxazole 240 as 
olourless solid (2.23 g, 73 %). 
f (DCM:MeOH, 9:1) = 0.00 Mp = 135-138 °C, lit163 133-135 °C ; IR (neat, cm-1) 
381 (NH2), 1715 (C=O); 1H NMR δ (500 MHz, DMSO-d6) 8.27 (1H, s,  ArH), 5.18 
2H, br s, NH2), 4.23 (2H, q,  J = 7.1 Hz, CH2), 1.25 (3H, t, J = 7.1 Hz, CH3); 13C 
MR δ (126 MHz, DMSO-d6) 160.82 (C), 160.04 (C), 138.08 (CH), 128.31 (C), 
1.31 (CH2), 14.54 (CH3); m/z (EI) 156 ([M]+, 100 %), 128 (89), 110 (12). 
pectroscopic data are in good agreement with the literature.163  
Experimental 
 175 
Ethyl 2-chloro-1,3-oxazole-4-carboxylate 230a 
 
2-Aminooxazole 240 (200 mg, 1.28 mmol) was added in portions to a solution of 
tert-butyl nitrite (0.220 mL, 1.50 mmol) and copper (II) chloride (258 mg, 1.50 
mmol) in acetonitrile (6 mL) at 60 °C. The mixture was then heated at 80 °C for 2 h. 
The mixture was cooled and partitioned between DCM (30 mL), water (15 mL), and 
HCl (2 mL, conc). The aqueous layer was further extracted with DCM (2 × 20 mL) 
and the combined organics were washed with brine, dried, filtered and concentrated 
in vacuo. The residue was purified by flash chromatography (3:1 hexane:ether) to 
give chlorooxazole 230a (60 mg, 27 %). 
 Rf (EtOAc:hexane, 1:3) = 0.42; IR (neat, cm-1) 1766 (C=N), 1726 (C=O), 1523 
(C=C); Mp = 75 °C, lit164 97-99 °C ; 1H NMR δ (500 MHz, CDCl3) 8.20 (1H, s, 
ArH), 4.40 (2H, q,  J = 7.1 Hz, CH2), 1.39 (3H, t, J = 7.1 Hz, CH3); 13C NMR δ (126 
MHz, CDCl3) 160.04 (C), 148.29 (C), 145.42 (CH), 135.09 (C), 61.74 (CH2), 14.27 
(CH3); m/z (EI) 175 ([M]+, 100 %), 157 (42), 147 (33), 130 (58), 119 (49), 111 (100). 














Ethyl 1,3-oxazole-4-carboxylate 244 
 
To a solution of formic acid (2.00 mL, 53.0 mmol) in THF (30 mL) at rt was added 
1,1-dicarbonyldiimidazole (8.58 g, 53.0 mmol) portionwise. The resulting solution 
was stirred for 30 min after which, ethyl isocyanoacetate (5.79 mL, 53.0 mmol) was 
added, followed by triethylamine (14.8 mL, 106mmol). The resulting solution was 
stirred for 1 h at rt and then heated at reflux for 20 h. The mixture was cooled to rt 
and concentrated in vacuo, the residue was dissolved in ether (50 mL) and washed 
with water (80 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL), the 
combined organic layers were washed with brine (50 mL), dried, filtered and 
concentrated in vacuo. The residue was purified by flash chromatography (1:1 
hexane:EtOAc) to give oxazole 244 as a brown liquid which solidified on standing 
(6.0 g, 80 %). 
Rf (EtOAc:hexane, 1:1) = 0.46; IR (neat, cm-1) 1732 (C=O), 1577 (C=C); Mp = 39-
41 °C, lit165 47-49 ºC; 1H NMR δ (400 MHz, CDCl3) 8.29 (1H, d, J = 1.0 Hz, ArH), 
7.95 (1H, d, J = 1.0 Hz, ArH), 4.42 (2H, q,  J = 7.1 Hz, CH2), 1.42 (3H, t, J = 7.1 Hz, 
CH3); 13C NMR δ (101 MHz, CDCl3) 160.99 (C), 151.38 (CH), 144.03 (CH), 133.40 
(C), 61.35 (CH2), 14.27 (CH3); m/z (EI) 141 ([M]+, 73 %), 113 (68), 96 (100). 












Pent-3-yn-1-yl 4-methylbenzene-1-sulfonate 264 
 
A solution of toluene-p-sulfonyl chloride (25.3 g, 132 mmol) in warm pyridine (12.0 
mL, 154 mmol) was cooled rapidly in ice to obtain small crystals and pent-3-ynol 
(10.0 g, 118 mmol) was added slowly to keep the temperature below 25 °C. The 
reaction mixture was stirred at rt for ~18 h, then cooled to 0 °C and water (20 mL) 
was added. The mixture was poured into more water (200 mL) and extracted with 
ether (200 mL). The organic layer was washed with HCl (4 × 200 mL, 1 M aq) and 
NaHCO3 (100 mL, sat aq), dried, filtered and concentrated in vacuo to give the 
tosylate 264 as a colourless liquid (26.0 g, 92 %). 
Rf (EtOAc:hexane, 1:1) = 0.56; IR (neat, cm-1) 1597 (C=C), 1359 (S=O), 1174 
(S=O); 1H NMR δ (500 MHz, CDCl3 ) 7.83 (2H, d, J = 8.1 Hz, ArH), 7.27 (2H, d, J 
= 8.1 Hz, ArH), 4.08 (2H, t, J = 7.2 Hz, TsOCH2), 2.52 - 2.49 (2H, m, CH2C), 2.48 
(3H, s, CH3Ar), 1.74 (3H, t, J = 2.5 Hz, CCH3); 13C NMR (126 MHz, CDCl3) δ 
144.86 (C), 133.01 (C), 129.85 (2 × CH), 127.99 (2 × CH), 78.22 (C), 73.12 (C), 
68.26 (CH2), 21.66 (CH3), 19.71 (CH2), 3.40 (CH3); m/z (CI, i-butane) 239.0 
([M+H]+, 100 %), 149 (73), 132 (74).  














Tosylate 264 (26.0 g, 109 mmol) in ethanol (15 mL) was added dropwise to a 
solution of potassium hydroxide (7.35 g, 131 mmol) in water (15 mL) and ethanol 
(10 mL) containing a trace of detergent at 120 °C. Enyne 248 was evolved as a gas 
which was collected by passage through a fractionating column and condenser. The 
colourless highly volatile liquid collected (1.20 g) was used immediately in the next 
step. 
BP  60 °C, lit114 57-59 °C; 1H NMR δ (400 MHz, CDCl3) 5.78 (1H, ddq, J = 17.7, 
11.0, 2.3 Hz, CH2=CH), 5.57 (1H, dd, J = 17.7, 2.3 Hz, CHXHY=CH), 5.40 (1H, dd, 
J = 11.0, 2.3 Hz, CHXHY=CH), 1.97 (3H, d, J = 2.3, CCH3). 
Spectroscopic data are in good agreement with the literature.114  
Attempted synthesis of 2-[(1E)-pent-1-en-3-yn-1-yl]oxirane 231  Grubbs method 
 
To  a  solution  of  enyne 248  (0.08  g,  1.21  mmol)  in  DCM  (12 mL)  were  added  
butadiene monoxide  (0.2  mL,  2.44  mmol)  followed  by  Grubbs II  (18  mg, 20 
µmol). The reaction mixture was heated at reflux for 5 h, after which more catalyst 
was added (18 mg, 20 µmol) and the reaction heated for ~18 h. The solvent was 
removed in vacuo and the crude residue purified by column chromatography (9:1 
hexane:EtOAc). The only product isolated was 2-[(E)-2-(oxiran-2-yl)ethenyl]oxirane 
254 (20 mg). 
2-[(E)-2-(oxiran-2-yl)ethenyl]oxirane 254  
 
Rf (EtOAc:hexane, 1:3) = 0.49; 1H NMR δ (400 MHz, CDCl3) δ 5.72 – 5.60 (2H, m, 
2 × CH), 3.35 (2H, ddd, J = 6.7, 4.3, 2.6 Hz, 2 × CHO), 2.96 (2H, dt, J = 5.3, 3.8 Hz,  
2 × CHXHY), 2.71 – 2.60 (2H, m, 2 × CHXHY). 
Spectroscopic data are in good agreement with the literature.116 
Experimental 
 179 





1-Bromo-2-butyne (1.00 mL, 11.4 mmol)and triphenyl phosphine (2.99 g, 11.42 
mmol) were stirred at rt for 16 h. The resultant solid was filtered, washed with 
hexane (20 mL) and dried under vacuum to give phosphonium salt 250 as a yellow 
solid (3.24 g, 72 %). 
Rf (MeOH:DCM, 1:9) = 0.48; IR (neat, cm-1) 1585 (C=C), 997 (C=C); Mp = 195-
197 °C; 1H NMR δ (500 MHz, CDCl3) 7.82 - 7.74 (9H, m, ArH), 7.66 – 7.62 (6H, 
m, ArH), 4.87 (2H, dq, J = 14.8, 2.5 Hz, CH2),  1.60 (3H, dt, J = 6.3, 2.5 Hz, CH3); 
13C NMR (126 MHz, CDCl3) δ 135.34 (d, 4JPC = 3.0 Hz, 3 × CH), 133.90 (d, 3JPC = 
9.9 Hz, 6 × CH), 130.35 (d, 2JPC = 12.8 Hz, 6 × CH), 117.62 (d, 1JPC = 87.4 Hz, 3 × 
C), 84.85 (d, 3JPC = 9.5 Hz, C), 66.21 (d, 2JPC = 13.6 Hz, C), 18.21 (d, 1JPC = 55.9 Hz, 
CH2), 3.72 (d, 4JPC = 3.3 Hz, CH3); m/z (ESI+, MeOH) 315 ([M]+, 100 %).  
Spectroscopic data are in good agreement with the literature.119 
 
 
Polymer supported But-2-ynyltriphenylphosphonium bromide 271 
 
1-Bromo-2-butyne (1.16 mL, 13.2 mmol) was added dropwise to a suspension of 
polymer bound triphenyl phosphine (4.00 g, 12 mmol, 3mmol/g) in DMF (15 mL). 
The mixture was heated at 70 °C for 48 h, after cooling the suspension was filtered 
and washed several times with DCM, then ether over the course of several hours. 




Attempted synthesis of 2-[(1E)-pent-1-en-3-yn-1-yl]oxirane 231  Wittig method 
 
NaHCO3 (1.83 g, 15 mmol) was suspended in DCM (30 mL) and Dess-Martin 
periodinane (0.925 g, 2.18 mmol) was added at rt. The mixture was stirred for 5 min, 
then cooled to 0 °C and glycidol (0.096 mL, 1.45 mmol) was added and the mixture 
was stirred for 2 h. 
To a suspension of polymer supported phosphine 271 (0.812 g, 1.74 mmol) in THF 
(10 mL) was added nBuLi (0.91 mL, 1.75 mmol, 1.6 M in hexane) and the reaction 
was stirred at rt for 1 h. This suspension was added into the Dess-Martin reaction 
above and the reaction stirred for ~18 h at rt. The reaction mixture was filtered and 
washed with DCM (30 mL) and the filtrate was then washed with NaHCO3 (30 mL, 
sat aq) and brine (50 mL). The organic layer was dried, filtered and concentrated in 
vacuo and the crude residue purified by flash chromatography (9:1 hexane:EtOAc) to 
give the product 277 as a yellow oil (50 mg). 
Possible product 277 
 
Rf (EtOAc:hexane, 1:3) = 0.65; IR (neat, cm-1) 1693 (C=O); 1H NMR (400 MHz, 
CDCl3) δ 6.74 (1H, d, J = 7.6 Hz), 3.92 (1H, ddd, J = 7.6, 4.2, 2.5 Hz), 3.19 (1H, dd, 
J = 5.4, 4.2 Hz), 2.89 (1H, dd, J = 5.4, 2.5 Hz), 2.83 (2H, qd, J = 7.2, 2.5 Hz), 1.17 
(3H, t, J = 7.2 Hz); 13C NMR (126 MHz, CDCl3) δ 193.93 (C), 140.42,(CH) 128.89 
(C), 51.24 (CH), 48.23 (CH2), 31.95 (CH2), 8.40 (CH3); m/z (CI, i-butane) 176 








Diethyl (but-2-yn-1-yl)phosphonate 281 
 
1-bromo-2-butyne (0.50 mL, 5.71 mmol) and triethyl phosphate (1.07 mL, 6.28 mL) 
were heated at reflux for 3 h. The reaction mixture was allowed to cool to rt and 
water (20 mL) and EtOAc (30 mL) were added. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 × 30 mL), the combined organic layers 
were washed with brine (30 mL), dried, filtered and concentrated in vacuo. The 
residue was passed through a short plug of silica eluting with 1:1 EtOAc:hexane to 
give the phosphonate 281 as a brown liquid (1.08 g, quant). 
Rf (EtOAc) = 0.30; IR (neat, cm-1) 1257 (P=O), 1242 (P=O), 1020 (P-OEt); 1H 
NMR δ (500 MHz, CDCl3) 4.25 - 4.11 (4H, m, 2 × CH2CH3), 2.69 (2H, dq, J = 21.8, 
2.7 Hz, CH2), 1.80 (3H, dt, J = 6.2, 2.7 Hz, CH3), 1.35 (6H, t, J = 7.1 Hz, 2 × 
CH2CH3); 13C NMR (126 MHz, CDCl3) δ 78.56 (d, 3JPC = 10.1 Hz, C), 68.44 (d, 
2JPC = 14.6 Hz, C), 62.78 (d, 2JPC = 6.6 Hz, 2 × CH2), 17.92 (d, 1JPC = 146.6 Hz, 
CH2), 16.37 (d, 3JPC = 5.9 Hz, 2 × CH3), 3.61 (d, 4JPC = 3.4 Hz, CH3); m/z (CI, i-
butane) 191 ([M+H]+, 100 %).  












6.4 Experimental for Chapter 4 
[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl 4-methylbenzene-1-sulfonate 290 
 
To a solution of (R)-2,2-dimethyl-1,3-dioxolane-4-methanol (15.0 g, 113 mmol) in 
pyridine (50 ml) at 0 °C p-toluenesulfonyl chloride (21.9 g, 114 mmol) was added 
and stirred at rt for ~18 h. Diethyl ether was added (200 mL) and the precipitate was 
removed by filtration and washed with a small amount of ether. The organic phase 
was washed with HCl (100 mL, 1 M aq), water (100 mL), NaHCO3 (100 mL, sat aq) 
and more water (100 mL). The organic layer was dried, filtered and concentrated in 
vacuo giving the tosylate 290 as a colourless oil (32.4 g, quant)  
Rf (Hexane:EtOAc, 1:1) = 0.69; [α]D = +7.7 (c 0.65, EtOH), lit168 +4.3 (c 1.0, EtOH); 
IR (neat, cm-1) 1598 (C=C), 1363 (S=O), 1179 (S=O); 1H NMR (400 MHz, CDCl3) 
δ 7.78 (2H, d, J = 8.2 Hz,  ArH), 7.34 (2H, d, J = 8.2 Hz, ArH), 4.36 – 4.19 (1H, m, 
CH2CHOCH2), 4.01 (1H, dd, J = 8.8, 6.3 Hz, CHXHYO), 4.00 (1H, dd, J = 10.1, 5.2 
Hz, TsOCHACHB), 3.96 (1H, dd, J = 10.1, 5.2 Hz, TsOCHACHB), 3.74 (1H, dd, J = 
8.8, 5.2 Hz, CHXHYO), 2.43 (3H, s,  CH3Ar ), 1.31 (3H, s, CH3C), 1.29 (3H, s, 
CH3C); 13C NMR (101 MHz, CDCl3) δ 145.10 (C), 132.65 (C), 129.94 (2 × CH), 
128.00 (2 × CH), 110.05 (C), 72.92 (CH), 69.52 (CH2), 66.17 (CH2), 26.63 (CH3), 
25.15 (CH3), 21.65 (CH3); m/z (ESI+) 595 ([2M+Na]+, 14 %), 309 ([M+Na]+, 100), 
287 ([M+H]+, 10). 








 (2S)-3-{[(4-Methylbenzene)sulfonyl]oxy}propane-1,2-diol 291 
 
To a solution of acetonide 290 (32.4 g, 113 mmol) in methanol (250 mL) was added 
DOWEX 50WX8-200 until the solution was acidic (monitored by pH indicator 
paper) and stirred at rt for ~18 h. The solids were removed by filtration through celite 
and the solvent removed in vacuo to give a pale orange oil. Ether was added to the 
oil and it was allowed to stand at −18 °C for ~18 h. A colourless solid formed which 
was collected by filtration to give the diol 291 (34.3 g, 87 %). 
Rf (EtOAc, 1:1) = 0.44; Mp = 56-58 °C Et2O, lit169 59-60°C Et2O; [α]D = +10.2 (c 
1.18, EtOH), lit169 +9.7 (c 1.00, EtOH); IR (neat, cm-1) 3473 (OH), 1357 (S=O), 
1174 (S=O); 1H NMR (500 MHz, CDCl3) δ 7.83 (2H, d, J = 8.2 Hz, ArH), 7.39 (2H, 
d, J = 8.2 Hz, ArH), 4.13 (1H, dd, J = 10.0, 4.4 Hz, TsOCHACHB), 4.10 (1H, dd, J = 
10.0, 5.5 Hz, TsOCHACHB), 4.02-3.95 (1H, m, CH2CHOCH2O), 3.74 (1H, ddd, J = 
10.0, 5.6, 4.3 Hz, CHXHYOH), 3.67-3.63 (1H, m, CHXHYOH), 2.60 (1H, d, J = 5.3 
Hz, CHOH) 2.49 (3H, s, CH3Ar ), 2.03 (1H, t, J = 6.0 Hz, CH2OH); 13C NMR (126 
MHz, CDCl3) δ 145.29 (C), 132.44 (C), 130.04 (2 × CH), 128.01 (2 × CH), 70.63 
(CH2), 69.63 (CH), 66.70 (CH2), 21.70 (CH3); m/z (ESI+) 269 ([M+Na]+, 100 %). 

















2-ol 393                                                                                                                                                                       
 
To a solution of diol 291 (5.00 g, 20.3 mmol) in DCM (300 mL) at −78 °C was 
added 2,6-lutidine (2.59 mL, 22.3 mmol) followed by TIPSOTf (6.55 mL, 24.4 
mmol). The solution was stirred at −78 °C for 1 h and then allowed to warm to rt 
over 1 h. Brine (200 mL) was added, the layers were separated and the aqueous layer 
was extracted with DCM (2 × 200 mL). The combined organic layers were dried, 
filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (1:1 hexane: EtOAc) to give the silyl ether 393 as colourless liquid 
(8.17 g, quant). 
Rf (Hexane:EtOAc, 1:1) = 0.75; [α]D = +16.4 (c 0.67, EtOH); IR (neat, cm-1) 3541 
(OH), 1598 (C=C), 1361 (S=O), 1176 (S=O); 1H NMR (500 MHz, CDCl3) δ 7.83 
(2H, d, J = 8.2 Hz, ArH), 7.37 (2H, d, J = 8.2 Hz, ArH), 4.13 (1H, dd, J = 10.1, 5.5 
Hz TsOCHXHY), 4.07 (1H, dd, J = 10.1, 5.6 Hz, TsOCHXHY), 3.94 - 3.86 (1H, m,  
CHOH), 3.74 (2H, d, J = 5.0 Hz, CH2OTIPS) 2.48 (3H, s, CH3Ar ), 1.10 - 1.01 (21H, 
m, Si(CH(CH3)2)3); 13C NMR (101 MHz, CDCl3) δ 144.99 (C), 132.69 (C), 129.90 
(2 × CH), 128.04 (2 × CH), 70.12 (CH2), 69.44 (CH), 63.26 (CH2), 21.66 (CH3), 
17.88 (6 × CH3), 11.80 (3 × CH); m/z (ESI+) 827 ([2M+Na]+, 15 %), 425 ([M+Na]+, 















Alcohol 393 (7.00 g, 17.4 mmol), iodomethane (19.4 mL, 313 mmol) and silver (I) 
oxide (7.25 g, 31.3 mmol) in acetonitrile (100 mL) were heated at 60 °C for ~18 h. 
The brown suspension was allowed to cool to rt, ether (200 mL) was added and the 
suspension filtered through celite. The solvent was removed in vacuo and the crude 
residue was purified by flash chromatography (19:1 hexane: EtOAc) to give the 
methoxy ether 294 as a colourless oil (3.98 g, 55 %). 
Rf (Hexane:EtOAc, 9:1) = 0.64; [α]D = +15.1 (c 1.52, DCM); IR (neat, cm-1) 1598 
(C=C), 1363 (S=O), 1178 (S=O); 1H NMR (400 MHz, CDCl3) δ 7.82 (2H, d, J = 8.2 
Hz, ArH), 7.35 (2H, d, J = 8.2 Hz, ArH), 4.26 (1H, dd, J = 10.4, 3.6 Hz TsOCHXHY), 
4.07 (1H, dd, J = 10.4, 5.9 Hz, TsOCHXHY), 3.75 (1H, dd, J = 10.3, 5.0 Hz, 
CHAHBOTIPS) 3.63 (1H, dd, J = 10.3, 6.6 Hz, CHAHBOTIPS), 3.47 - 3.43 (1H, m, 
CHOH), 3.38 (3H, s, OCH3), 2.46 (3H, s, CH3Ar), 1.18-0.77 (21H, m, 
Si(CH(CH3)2)3; 13C NMR (101 MHz, CDCl3) δ 144.73 (C), 132.94 (C), 129.78 (2 × 
CH), 128.01 (2 × CH), 79.49 (CH), 69.38 (CH2), 61.66 (CH2), 58.17 (CH3), 21.62 
(CH3), 17.88 (6 × CH3), 11.80 (3 × CH); m/z (ESI+) 439 ([M+Na]+, 100 %), 417 
















To a solution of diol 291 (10.0 g, 40.6 mmol) in DMF (100 mL) was added p-
methoxy benzaldehyde dimethyl acetal (13.8 mL, 81.3 mmol) and p-toluene sulfonic 
acid monohydrate (0.770 g, 4.06 mmol), the solution was stirred at rt for ~18 h. The 
reaction mixture was diluted with DCM (200 mL) and washed with NaHCO3 (200 
mL, sat aq) and water (2 × 250 mL). The organic layer was dried, filtered and 
concentrated in vacuo. Ether was added to the crude residue, it was cooled to 0 °C 
and a colourless solid precipitated. The solid was removed by filtration to give the 
acetal 296 (11.8 g, 80 %). 
Rf (Hexane:EtOAc, 3:1) = 0.16; Mp = 121-123 °C, EtOAc; [α]D = −3.3 (c 1.51, 
DCM); IR (neat, cm-1) 1614 (C=C),1598 (C=C), 1516 (C=C), 1363 (S=O), 1180 
(S=O); 1H NMR (400 MHz, CDCl3) δ 7.82 (2H, d, J = 8.2 Hz, ArH), 7.36 (2H, d, J 
= 8.2 Hz, ArH), 7.34 (2H, d, J = 8.7 Hz, ArH), 6.89 (2H, d, J = 8.7 Hz, ArH), 5.74 
(1H, s, CHPMP), 4.47 – 4.39 (1H, m, CH2CHCH2), 4.14 (1H, dd, J = 10.2, 5.0 Hz, 
TsOCHXHY), 4.08 (1H, dd, J = 10.2, 6.3 Hz, TsOCHXHY), 4.08 (1H, dd, J = 8.6, 6.8 
Hz, CHCHAHBO), 4.04 (1H, dd, J = 8.6, 4.2 Hz, CHCHAHBO), 3.84 (3H, s, OCH3), 
2.48 (3H, s, CH3Ar); 13C NMR (101 MHz, CDCl3) δ 160.64 (C), 145.12 (C), 132.60 
(C), 129.96 (2 × CH), 128.58 (C), 128.04 (2 × CH), 113.78 (2 × CH), 104.71 (2 × 
CH), 73.09 (CH), 69.43 (CH2), 67.49 (CH2), 55.33 (CH3), 21.69 (CH3); m/z (EI+) 











To a solution of acetal 296 (5.00 g, 13.7 mmol) in DCM (100 mL) at −78 °C was 
added DIBAL (31.1 mL, 1 M in hexanes, 30.2 mmol) and the solution was stirred at 
−78 °C for 45 min. The ice bath was removed and the excess DIBAL was quenched 
slowly with MeOH until the effervescence ceased, Rochelle’s salt (20 mL, sat aq) 
and DCM (20 mL) were added and the reaction mixture allowed to warm to rt. Water 
(100 mL) was added and the aqueous layer was extracted with DCM (3 × 70 mL). 
The organic layers were combined, dried, filtered and concentrated in vacuo to give 
alcohol 299 as a colourless liquid (5.02 g, quant). 
Rf (Hexane:EtOAc, 1:1) = 0.35; [α]D = +5.9 (c 1.33, CHCl3); IR (neat, cm-1) 3549 
(OH), 1612 (C=C), 1512 (C=C), 1361 (S=O), 1176 (S=O); 1H NMR (500 MHz, 
CDCl3) δ 7.81 (2H, d, J = 8.2 Hz, ArH), 7.37 (2H, d, J = 8.2 Hz, ArH), 7.22 (2H, d, 
J = 8.7 Hz, ArH), 6.90 (2H, d, J = 8.7 Hz, ArH), 4.46 (2H, s, OCH2PMP), 4.12 (1H, 
dd, J = 10.1, 4.9 Hz, TsOCHXHY), 4.07 (1H, dd, J = 10.1, 5.7 Hz, TsOCHXHY), 4.04 
- 3.98 (1H, m, CHOH), 3.84 (3H, s, ArOCH3), 3.53 (1H, dd, J = 9.7, 4.6 Hz, 
CHAHBOPMB), 3.49 (1H, dd, J = 9.7, 5.4 Hz, CHAHBOPMB), 2.47 (3H, s, CH3Ar), 
2.43 (1H, d, J = 5.6 Hz, OH); 13C NMR (126 MHz, CDCl3) δ 159.44 (C), 145.04 
(C), 132.65 (C), 129.93 (2 × CH), 129.56 (C), 129.45 (2 × CH), 128.02 (2 × CH), 
113.91 (2 × CH), 73.22 (CH2), 70.56 (CH2), 69.70 (CH2), 68.38 (CH), 55.31 (CH3), 
21.68 (CH3); m/z (EI+) 366 ([M]+, 44 %), 216 (26), 173 (41), 155 (67), 137 (100); 












To  a  stirred  solution  of  oxalyl  chloride (0.080 mL, 1.02 mmol)  in  dry  DCM (10 
mL),  DMSO (0.120 mL, 1.63 mmol) was added at −78 °C and the reaction mixture 
was stirred −78 °C for 30 min. A solution of alcohol 299 (0.250g, 0.680 mmol) in 
DCM (5 mL) was added at −78 °C and stirred for 3 h at −78 °C. The reaction 
mixture was treated with Et3N (0.450 mL, 3.26 mmol) and stirred for 15 min. The 
reaction mixture was diluted with DCM (30 mL) and washed with water (20 mL). 
The layers were separated and the organic layer was dried, filtered and concentrated 
in vacuo. The crude residue was passed through a plug of silica eluting with DCM to 
afford ketone 300 as an orange syrup (0.21 g, 91 %). 
Rf (Hexane:EtOAc, 1:1) = 0.42; IR (neat, cm-1) 1749 (C=O), 1612 (C=C), 1597 
(C=C), 1514 (C=C), 1359 (S=O), 1174 (S=O); 1H NMR (500 MHz, CDCl3) δ 7.83 
(2H, d, J = 8.2 Hz, ArH), 7.38 (2H, d, J = 8.2 Hz, ArH), 7.26 (2H, d, J = 8.7 Hz, 
ArH), 6.92 (2H, d, J = 8.7 Hz, ArH), 4.79 (2H, s, TsOCH2) 4.52 (2H, s, OCH2PMP), 
4.17 (2H, s, CH2OPMB), 3.85 (3H, s, ArOCH3), 2.48 (3H, s, CH3Ar); 13C NMR (126 
MHz, CDCl3) δ 200.19 (C), 159.72 (C), 145.44 (C), 132.41 (C), 129.99 (2 × CH), 
129.77 (2 × CH), 128.53 (C), 128.10 (2 × CH), 114.05 (2 × CH), 73.40 (CH2), 73.08 
(CH2), 70.86 (CH2), 55.33 (CH3), 21.71 (CH3); m/z (EI+) 364 ([M]+, 5%), 155 (11), 










Alcohol 299 (4.71 g, 12.8 mmol), iodomethane (14.4 mL, 321 mmol) and silver (I) 
oxide (5.36 g, 23.1 mmol) in acetonitrile (100 mL) were heated at 60 °C for ~18 h. 
The brown suspension was allowed to cool to rt, ether (100 mL) was added and the 
suspension filtered through celite. The solvent was removed in vacuo and the crude 
residue was purified by flash chromatography (4:1 hexane: EtOAc) to give the 
methoxy ether 303 as a colourless oil (4.18 g, 85 %). 
Rf (Hexane:EtOAc, 3:1) = 0.24; [α]D = +8.6 (c 1.39, CHCl3 ); IR (neat, cm-1) 1612 
(C=C), 1514 (C=C), 1359 (S=O), 1176 (S=O); 1H NMR (400 MHz, CDCl3) δ 7.81 
(2H, d, J = 8.2 Hz, ArH), 7.35 (2H, d, J = 8.2 Hz, ArH), 7.22 (2H, d, J = 8.7 Hz, 
ArH), 6.89 (2H, d, J = 8.7 Hz, ArH), 4.43 (2H, s, OCH2PMP), 4.20 (1H, dd, J = 
10.5, 4.1 Hz, TsOCHXHY), 4.10 (1H, dd, J = 10.5, 5.6 Hz, TsOCHXHY), 3.83 (3H, s, 
ArOCH3), 3.61 - 3.54 (1H, m, CHOMe), 3.49 (2H, d, J = 5.0 Hz, CH2OPMB), 3.49 
(3H, s, OCH3), 2.47 (3H, s, CH3Ar); 13C NMR (101 MHz, CDCl3) δ 159.31 (C), 
144.84 (C), 132.89 (C), 129.84 (2 × CH), 129.46 (C), 129.33 (2 × CH), 128.00 (2 × 
CH), 113.82 (2 × CH), 77.75 (CH), 73.16 (CH2), 69.13 (CH2), 67.93 (CH2), 58.08 
(CH3), 55.30 (CH3), 21.66 (CH3); m/z (EI+) 380 ([M]+, 21 %), 155 (29), 137 (71), 










To a solution of PMB ether 303 (3.80 g, 10.0 mmol) in DCM:water (80 mL:8 mL) 
was added DDQ (2.72 g, 12.0 mmol) and the green/brown suspension was stirred at 
rt for 30 min. The reaction mixture was diluted with DCM (100 mL) and washed 
with NaHCO3 (2 × 100 mL, sat aq) and brine (100 mL). The organic layer was dried, 
filtered and concentrated in vacuo and the crude residue was purified by flash 
chromatography (3:1 hexane: EtOAc) to give the alcohol 295 as a colourless oil 
(2.06 g, 79 %). 
Rf (Hexane:EtOAc, 1:1) = 0.19; [α]D = −21.4 (c 3.31, CHCl3 ); IR (neat, cm-1) 3516 
(OH), 1597 (C=C), 1354 (S=O), 1174 (S=O); 1H NMR (400 MHz, CDCl3) δ 7.81 
(2H, d, J = 8.2 Hz, ArH), 7.37 (2H, d, J = 8.2 Hz, ArH), 4.15 (1H, dd, J = 9.0, 3.5 
Hz, CHXHYOTs), 4.12 (1H, dd, J = 9.0, 3.5 Hz, CHXHYOTs), 3.70 (1H, dd, J = 11.8, 
4.2 Hz, CHAHBOH), 3.58 (1H, dd, J = 11.8, 5.1 Hz, CHAHBOH), 3.52 - 3.47 (1H, m, 
CHOMe), 3.40 (3H, s, OCH3), 2.46 (3H, s, CH3Ar), 2.14 (1H, br s, OH); 13C NMR 
(101 MHz, CDCl3) δ 145.09 (C), 132.65 (C), 129.94 (2 × CH), 127.96 (2 × CH), 
78.93 (CH), 68.31 (CH2), 60.99 (CH2), 58.10 (CH3), 21.66 (CH3); m/z (EI+) 261 













(2S,3E)-4-Iodo-2-methoxybut-3-en-1-yl 4-methylbenzene-1-sulfonate 305 
 
NaHCO3 (970 mg, 11.6 mmol) was suspended in DCM (3 mL) and Dess-Martin 
periodinane (489 mg, 1.15 mmol) was added and the suspension stirred for 5 min at 
rt. The mixture was cooled to 0 °C and the alcohol 295 (200 mg, 0.77 mmol) was 
added in DCM (3 mL) and the suspension was stirred at 0 °C for 2 h, after which a 
1:1 mixture of NaHCO3 (5 mL, sat aq) and Na2S2O3 (5 mL, 0.1 M aq) was added and 
the mixture stirred for 10 min. The biphasic mixture was separated and the aqueous 
layer extracted with DCM (2 × 20 mL), the organic layers were combined, washed 
with water (30 mL), dried, filtered and evaporated in vacuo. The crude mixture was 
used directly in the next step. 
To a suspension of dry CrCl2 (946 mg, 7.70 mmol) in THF (1 mL) was added the 
aldehyde (assumed 0.77 mmol) and iodoform (827 mg, 2.10 mmol) in 1,4-dioxane (6 
mL), the suspension was stirred at rt for ~18 h. The reaction mixture was diluted with 
ether (15 mL) and washed with water (2 × 20 mL). The organic layer was dried, 
filtered and concentrated in vacuo and the crude residue was purified by flash 
chromatography (3:1 hexane: EtOAc) to give the vinyl iodide 305 (E:Z = 5:1) as a 
yellow oil (134 mg, 45 % over 2 steps). 
Rf (Hexane:EtOAc, 3:1) = 0.44; [α]D = +50.0 (c 0.62, CHCl3 ); IR (neat, cm-1) 1598 
(C=C), 1361 (S=O), 1176 (S=O); m/z (CI+) 383 ([M+H]+, 5%), 351 (39), 255 (16), 
211 (22), 197 (100); HRMS (CI+) [M+H]+ found 382.9805, C12H16O4IS requires 
382.9808. 
E-isomer 1H NMR (400 MHz, CDCl3) δ 7.81 (2H, d, J = 8.2 Hz, ArH), 7.38 (2H, d, 
J = 8.2 Hz, ArH), 6.51 (1H, dd, J = 14.6, 0.9 Hz, CH=CHI), 6.33 (1H, dd, J = 14.6, 
7.1 Hz, CH=CHI), 4.00 (2H, d, J = 5.3 Hz, TsOCH2), 3.86 - 3.81 (1H, m, CHOMe), 
3.30 (3H, s, OCH3), 2.48 (3H, s, CH3Ar); 13C NMR (101 MHz, CDCl3) δ 145.02 (C), 
141.11 (CH), 132.78 (C), 129.92 (2 × CH), 128.02 (2 × CH), 81.72 (CH), 81.02 
(CH), 70.05 (CH2), 57.24 (CH3), 21.70 (CH3). 
Z-isomer diagnostic peaks 1H NMR (400 MHz, CDCl3) δ 6.63 (1H, dd, J = 7.9, 1.1 
Hz, CH=CHI), 6.12 (1H, t, J = 7.9 Hz, CH=CHI), 3.31 (3H, s, OCH3), 2.47 (3H, s, 
Experimental 
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CH3Ar); 13C NMR (101 MHz, CDCl3) δ 144.88 (C), 136.92 (CH), 132.96 (C), 
129.84 (2 × CH), 128.08 (2 × CH), 87.40 (CH), 80.85 (CH), 69.86 (CH2), 57.05 
(CH3), 21.68 (CH3). 
 
(2S,3E)-2-Methoxyhept-3-en-5-yn-1-yl 4-methylbenzene-1-sulfonate 306 
 
A solution of 1-propynylmagnesium bromide (1.82 mL, 0.50 M in THF, 0.910 
mmol) was added dropwise to a stirred slurry of dry ZnCl2 (0.124 g, 0.910 mmol) in 
THF (5 mL) at 0 °C. After 15 min a solution of iodide 305 (0.175 g, 0.450 mmol) in 
THF (2 mL) and Pd(PPh3)2Cl2 (16 mg, 0.022 mmol) were added and the resulting 
mixture was stirred at rt for ~18 h. The reaction mixture was then poured into NH4Cl 
(10 mL, sat aq) and extracted with ether (4 × 20 mL). The combined organic layers 
were washed with brine (10 mL), dried, filtered and concentrated in vacuo. The 
residue was passed through a short silica column eluting with hexane to give the 
enyne 306 (E:Z = 5:1) as a brown oil (0.114 g, 86 %).  
Rf (Hexane:EtOAc, 3:1) = 0.42; [α]D = +65.3 (c 0.26, CHCl3 ); IR (neat, cm-1) 2220 
(C≡C), 1598 (C=C), 1359 (S=O), 1176 (S=O); m/z (ESI+) 317 ([M+Na]+, 100 %); 
HRMS (ESI+) [M+Na]+ found 317.0816, C15H18O4NaS requires 317.0818. 
E-isomer 1H NMR (500 MHz, CDCl3) δ 7.81 (2H, d, J = 8.2 Hz, ArH), 7.36 (2H, d, 
J = 8.2 Hz, ArH), 5.78 - 5.70 (2H, m, CH=CH), 4.04 - 3.95 (2H, m, TsOCH2), 3.88-
3.85 (1H, m, CHOMe),   3.27 (3H, s, OCH3), 2.47 (3H, s, CH3Ar), 1.97 (3H, d, J = 
1.6 Hz, CCH3); 13C NMR (126 MHz, CDCl3) δ 144.86 (C), 136.02 (CH), 132.93 
(C), 129.83 (2 × CH), 128.02 (2 × CH), 115.41 (CH), 88.31 (C), 79.12 (CH), 76.96 
(C), 71.03 (CH2), 57.00 (CH3), 21.67 (CH3), 4.27 (CH3). 
Experimental 
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Z-isomer diagnostic peaks 1H NMR (500 MHz, CDCl3) δ 5.71 – 5.69 (1H, m, 
CH=CHI), 5.62 – 5.80 (1H, m, CH=CHI), 4.47 (1H, td, J = 7.8, 3.3 Hz, CHOMe), 
4.12 (1H, dd, J = 10.4, 3.3 Hz, TsOCHACHB), 3.29 (3H, s, OCH3), 2.00 (3H, d, J = 
2.3 Hz,  CCH3); 13C NMR (101 MHz, CDCl3) δ 144.70 (C), 136.20 (CH), 133.15 





 To a stirred mixture of hex-1-ene (1.24 mL, 10.0 mmol), silver oxide (2.66 g, 11.5 
mmol), and methanol (50 mL) cooled to 0 °C, iodine (3.01 g, 11.9 mmol) was added 
portionwise.  The resulting mixture was stirred for 6 h at rt and then filtered. The 
methanolic solution was diluted with water (50 mL) and extracted with diethyl ether 
(2 × 30 mL).  The combined organic layers were  washed  with sodium thiosulfate 
(50 mL, sat aq) and brine (50 mL), dried, filtered and concentrated in vacuo to give 
iodide 322 as a colourless liquid (2.17 g, 90 %). 
Rf (hexane:EtOAc, 3:1) = 0.62; IR (neat, cm-1) 1458, 1093; 1H NMR δ (500 MHz, 
CDCl3) 3.36 (3H, s, OCH3), 3.28 (1H, dd, J = 10.6, 5.0 Hz, ICHXHY), 3.24 (1H, dd, J 
= 10.6, 5.0 Hz, I CHXHY), 3.05-2.97 (1H, m, CHOCH3), 1.56 (2H, q, J = 7.0 Hz, 
CHCH2), 1.40 – 1.25 (4H, m, CH2CH2), 0.93 – 0.88 (3H, m, CH2CH3); 13C NMR 
(126 MHz, CDCl3) δ 79.78 (CH), 57.01 (CH3), 34.02 (CH2), 27.34 (CH2), 22.64 
(CH2), 14.02 (CH3), 9.89 (CH2); m/z (EI) 242 ([M]+, 12 %), 185 (52), 101 (100); 









Attempted Oxazole C-H Activation 312 
 
General Procedure: To a solution of ethyl oxazole-4-carboxylate 244 (100 mg, 0.71 
mmol) in dioxane (2 mL) was added the alkyl halide (1.42 mmol), palladium acetate  
(8.0 mg, 0.034 mmol), caesium carbonate (0.460 g, 1.42 mmol) and (2-
biphenyl)dicyclohexylphosphine (21.0 mg, 0.071 mmol) and the reaction was stirred 
at 110 °C for ~18 h. The reaction mixture was allowed to cool to rt, filtered through 
Celite and concentrated in vacuo.  The residue was purified by flash chromatography 
(3:1 hexane:EtOAc to 1:3 hexane:EtOAc).  
 
Ethyl 2-[4-(ethoxycarbonyl)-1,3-oxazol-2-yl]-1,3-oxazole-4-carboxylate 320 
 
Rf (EtOAc:hexane, 1:1) = 0.34; IR (neat, cm-1) 1720 (C=O); Mp = 191-193 °C; 1H 
NMR δ (400 MHz, CDCl3) 8.39 (2H, s, 2 × ArH), 4.44 (4H, q, J = 7.1 Hz, 2 × 
CH2CH3), 1.14 (6H, t, J = 7.1 Hz, 2 × CH2CH3); 13C NMR (101 MHz, CDCl3) δ 
160.16 (2 × C), 145.35 (2 × CH), 135.48 (2 × C), 110.00 (2 × C), 61.80 (2 × CH2), 
14.28 (2 × CH3); m/z (EI) 280 ([M]+, 66 %), 253 (56), 141 (100); HRMS (EI) [M]+ 






To  a solution of tosylate 306 (50 mg, 0.170 mmol) in DMSO (2 mL) was added 
sodium azide (110 mg, 1.70 mmol) and the solution was heated at reflux for 2 h. The 
solution was cooled to rt and diluted with CHCl3 (20 mL) and washed with water (3 
×15 mL). The aqueous phase was extracted with CHCl3 (20 mL) and the combined 
organic phases were dried, filtered and concentrated in vacuo. The crude residue was 
purified by flash chromatography (3:1 hexane: EtOAc) to give the azide 394 (E:Z = 
10:1) as a colourless volatile liquid (29 mg, quant). 
Rf (Hexane:EtOAc, 3:1) = 0.58; [α]D = +74.2 (c 0.31, CHCl3); IR (neat, cm-1) 2220 
(C≡C), 2100 (N=N), 1632 (C=C); 1H NMR (500 MHz, CDCl3) δ  5.89 (1H, ddq, J = 
15.9, 7.3, 0.5 Hz, CHCH=CH), 5.77 (1H, dq J = 15.0, 2.2 Hz, CHCH=CHC), 3.89 - 
3.74 (1H, m, CHOMe), 3.37 (3H, s, OCH3), 3.33 (1H, dd, J = 12.9, 7.5 Hz, 
N3CHXHY), 3.20 (1H, dd, J = 12.9, 3.8 Hz, N3CHXHY), 1.98 (3H, d, J = 2.2 Hz, 
CCH3); 13C NMR (126 MHz, CDCl3) δ 137.90 (CH), 114.63 (CH), 88.05 (C), 81.06 
(CH), 77.23 (C), 56.85 (CH3), 54.50 (CH2), 4.27 (CH3). 
Z-isomer diagnostic peaks 1H NMR (500 MHz, CDCl3) 2.02 (3H, d, J = 2.2 Hz, 
CCH3); 13C NMR (126 MHz, CDCl3) δ 138.16 (CH), 114.76 (CH), 92.98 (C), 78.14 










To a solution of azide 394 (8.0 mg, 50 µmmol) in tert-butanol (2 mL) and water (1 
mL), copper sulfate pentahydrate (2.0 mg, 5 µmmol) and sodium ascorbate (2.0 mg, 
10 µmmol) were added and the mixture was stirred at rt for 10 min. After this time 
methyl propiolate (12 µL, 60 µmmol) and TBTA (3.0 mg, 5 µmmol) were added and 
the reaction was stirred at rt for ~18 h. The solution was diluted with EtOAc (10 mL) 
and washed with water (10 mL), the organic layer was dried, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (1:1 
hexane: EtOAc) to give the triazole 359 (E:Z = 11:1) as a colourless solid (7.2 mg, 
58 %). 
Rf (Hexane:EtOAc, 1:1) = 0.31; Mp = 97-99 °C; [α]D = +39.1 (c 0.25, CHCl3); IR 
(neat, cm-1) 2223 (C≡C), 1728 (C=O), 1634 (C=C), 1543 (C=C); 1H NMR (500 
MHz, CDCl3) δ 8.22 (1H, s, ArH), 5.81 - 5.76 (2H, m, CH=CH), 4.60 (1H, dd, J = 
14.1, 3.3 Hz, ArCHXHY), 4.34 (1H, dd, J = 14.1, 8.2 Hz, ArCHXHY), 4.04 - 4.00 (1H, 
m, CHOMe), 3.99 (3H, s, CO2CH3), 3.26 (3H, s, OCH3), 1.98 (3H, d, J = 1.6 Hz, 
CCH3); 13C NMR (126 MHz, CDCl3) δ 161.27 (C), 139.85 (C), 135.96 (CH), 129.00 
(CH), 116.08 (CH), 89.00 (C), 79.85 (CH), 76.70 (C), 56.89 (CH3), 54.32 (CH2) 
52.21 (CH3), 4.29 (CH3); m/z (ESI+) 272 ([M+Na]+, 53 %), 250 ([M+H]+, 5); 
HRMS (ESI+) [M+Na]+ found 272.0998, C12H15N3O3Na requires 272.1006. 








Ethyl 1H-pyrrole-3-carboxylate 364 
 
Ethylacrylate (1.00 g, 9.99 mmol) and TosMIC (1.93 g, 9.89 mmol) in diethyl 
ether/DMSO (42 mL, 2:1) were slowly added via an addition funnel to a suspension 
of NaH (0.816 g, 60% dispersion in mineral oil, 19.58 mmol) in diethyl ether (30 
mL). The reaction was stirred at rt for 3 h. Water (50 mL) was added carefully and 
the layers were separated. The aqueous phase was extracted with diethyl ether (3 × 
20 mL) and the combined organic layers were dried, filtered and concentrated in 
vacuo. The crude residue was purified by flash chromatography (3:1 hexane: EtOAc) 
to give the pyrrole 364 as a yellow liquid (0.60 g, 43 %). 
Rf (Hexane:EtOAc, 1:1) = 0.50; IR (neat, cm-1) 3327 (NH), 1697 (C=O), 1554 
(C=C), 1504 (C=C); 1H NMR (400 MHz, CDCl3) δ 8.58 (1H, br s, NH), 7.46 (1H, 
dt, J = 3.2, 1.8 Hz, ArH), 6.78 (1H, br q, J = 3.2 Hz, ArH), 6.69 (1H, td, J = 2.8, 1.5 
Hz, ArH), 4.31 (2H, q, J = 7.1 Hz, CH2CH3), 1.37 (3H, t, J = 7.1 Hz, CH2CH3); 13C 
NMR (101 MHz, CDCl3) δ 165.10 (C), 123.41 (CH), 118.72 (CH), 116.76 (C), 
109.81 (CH), 59.76 (CH2), 14.49 (CH3); m/z (EI) 139 ([M]+, 91 %), 94 (100). 







Ethyl 1-[(2S,3E)-2-methoxyhept-3-en-5-yn-1-yl]-1H-pyrazole-4-carboxylate 358 
 
To a solution of tosylate 306 (30 mg, 0.1 mmol) in DMF (2 mL) was added ethyl 1H-
pyrazole-4-carboxylate (16 mg, 0.11 mmol) and K2CO3 (21 mg, 0.15 mmol) and the 
mixture was stirred for 48 h at rt. The reaction mixture was diluted with EtOAc (10 
mL) and washed with water (3 × 20 mL) and brine (20 mL). The organic layer was 
dried, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (3:1 hexane: EtOAc) to give the pyrazole 358 (E:Z = 5:1) as a 
yellow oil (15 mg, 58 %). 
Rf (Hexane:EtOAc, 3:1) = 0.22; [α]D = +28.2 (c 0.43, CHCl3); IR (neat, cm-1) 2223 
(C≡C), 1712 (C=O), 1554 (C=C); 1H NMR (500 MHz, CDCl3) δ 7.96 (1H, s, ArH), 
7.93 (1H, s, ArH), 5.85 (1H, ddq, J = 16.0, 7.3, 0.5 Hz, CHCH=CH), 5.75 (1H, dq J 
= 16.0, 2.2 Hz, CHCH=CHC), 4.31 (2H, q, J = 7.1 Hz, CH2CH3), 4.21 (1H, dd, J = 
13.9, 3.9 Hz, ArCHXHY), 4.11 (1H, dd, J = 13.9, 8.0 Hz, ArCHXHY), 4.04 (1H, td, J 
= 7.3, 3.8 Hz CHOMe), 3.24 (3H, s, OCH3), 1.97 (3H, d, J = 2.2 Hz, CCH3), 1.37 
(3H, t, J = 7.1 Hz, CH2CH3); 13C NMR (126 MHz, CDCl3) δ 163.08 (C), 141.18 
(CH), 137.21 (CH), 133.99 (CH), 115.10 (C), 115.07 (CH), 88.26 (C), 80.13 (CH), 
76.98 (C), 60.16 (CH2), 57.02 (CH3), 56.56 (CH2), 14.40 (CH3), 4.28 (CH3); m/z (EI) 
262 ([M]+, 11 %), 217 (7), 204 (13), 109 (100); HRMS (EI) [M]+ found 262.1310, 
C14H18O3N2 requires 262.1312. 
Z-isomer diagnostic peaks 1H NMR (500 MHz, CDCl3) 7.99 (1H, s, ArH), 5.66 – 
5.60 (1H, m, CHCH=CHC), 3.30 (3H, s, CH3), 2.01 (3H, d, J = 2.4 Hz, CCH3); 13C 
NMR (126 MHz, CDCl3) δ 163.18 (C), 140.90 (CH), 137.31 (CH), 133.92 (CH), 
115.43 (CH), 115.15 (C), 93.24 (C), 77.21 (CH), 60.12 (CH2), 56.82 (CH3), 55.94 









Tosylate 306 (25 mg, 0.085 mmol) and NaI (50 mg, 0.340 mmol) in acetone were 
heated at 60 °C for ~18 h. The reaction mixture was cooled and the solvent removed 
in vacuo. The residue was dissolved in ether (10 mL) and washed with water (10 
mL) and brine (10 mL), the organic layer was dried, filtered and concentrated in 
vacuo to give iodide 341 (E:Z = 10:1) as a yellow oil (13 mg, 62 %).  
Rf (Hexane:EtOAc, 9:1) = 0.67; [α]D = −3.5 (c 0.23, CHCl3); IR (neat, cm-1) 2223 
(C≡C); 1H NMR (500 MHz, CDCl3) δ 5.88 (1H dd, J = 15.9, 7.5 Hz, CHCH=CH), 
5.75 (1H, dq J = 16.0, 2.2 Hz, CHCH=CHC), 3.70 (1H, m, CHOMe), 3.36 (3H, s, 
OCH3), 3.22 (1H, dd, J = 9.0, 3.8 Hz, ICHXCHY), 3.19 (1H, dd, J = 9.0, 5.1 Hz, 
ICHXCHY),   1.99 (3H, d, J = 2.2 Hz, CCH3); 13C NMR (126 MHz, CDCl3) δ 139.34 
(CH), 114.52 (CH), 88.12 (C), 80.99 (CH), 77.23 (C), 56.99 (CH3), 8.19 (CH2), 4.27 
(CH3). m/z; (CI, i-butane) 251 ([M]+, 3 %), 196 (100), 165 (24). HRMS (CI, i-
butane) [M+H]+ found 250.9928, C8H12OI requires 250.9927. 
 



















Sodium hydride (0.088 g, 60 % in mineral oil, 2.20 mmol) was added to a solution of 
alcohol 245 (0.200 g, 2.02 mmol) in THF (5 mL) at 0 °C, and the mixture was stirred 
at 0 °C for 10 min and at rt for an additional 1 h. The mixture was cooled to 0 °C and 
chloromethyl methyl ether (0.182 mL, 2.40 mmol) was added dropwise. The reaction 
mixture was stirred at 0 °C for 10 min and at rt for an additional 3 h. The mixture 
was poured into water (10 mL) and extracted with EtOAc (2 × 20 mL). The 
combined organic extracts were washed with brine (20 mL), dried, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography 
(3:1, hexane:EtOAc) to give the ether 340 as an orange oil (1.41 g, 73 %). 
Rf (Hexane:EtOAc, 1:1) = 0.29; IR (neat, cm-1) 1514 (C=C); 1H NMR δ (500 MHz, 
CDCl3) 7.90 (1H, s, ArH), 7.68 (1H, q, J = 0.7 Hz, ArH), 4.74 (2H, s, OCH2O), 4.58 
(2H, d, J = 0.7 Hz, CH2Ar), 3.43 (3H, s, OCH3); 13C NMR δ (126 MHz, CDCl3) 
151.38 (CH), 137.35 (C), 136.45 (CH), 95.86 (CH2), 60.87 (CH2), 55.44 (CH3); m/z 
(EI) 143 ([M]+, 2 %), 113 (20), 83 (100); HRMS (EI) [M]+ found 143.0576, 






















To a solution of alcohol 245 (50.0 mg, 0.05 mmol) in DCM (2 mL) at 0 °C was 
added tert-butyldimethylsilyl trifluoromethanesulfonate (0.122 mL, 0.53 mmol) 
followed by 2,6-lutidine (0.070 mL, 0.60 mmol). After stirring for 1 h at 0 °C the 
reaction was quenched by the addition of sodium bicarbonate (5 mL, sat. aq.) and 
extracted with DCM (3 × 10 mL). The organic extracts were combined, dried, 
filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (hexane:EtOAc, 9:1) to give the silyl ether 246 as pale yellow oil 
(91.0 mg, 86 %). 
Rf (Hexane:EtOAc, 10:1) = 0.24; IR (neat, cm-1) 1516 (C=C), 1256 (SiCH3); 1H 
NMR δ (400 MHz, CDCl3) 7.86, (1H, s, ArH), 7.60 (1H, s, ArH), 4.72 (2H, s, 
OCH2), 0.96 (9H, s, C(CH3)3), 0.14 (6H, s,  2 × SiCH3) ; 13C NMR δ (101 MHz, 
CDCl3) 151.05 (CH), 141.01 (C), 135.35 (CH), 58.57 (CH2), 25.88 (3CH3), 18.38 
(C), −5.34 (2CH3); m/z (ESI+, MeOH) 237 ([M+Na]+, 100 %), 214 ([M+H]+, 7); 
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CM Cross metathesis 
COSY Homonuclear correlation spectroscopy 





DFT Discrete Fourier transform 
DIBAL Diisobutylaluminium hydride 
DIPEA N,N-Diisopropylethylamine 




DMP Dess–Martin periodinane 
DMSO Dimethyl sulfoxide 
DPTC O,O'-Di(2-pyridyl) thiocarbonate 
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
ee Enantiomeric excess 





FAB  Fast aton bombardment 




HPLC High-performance liquid chromatography 
HRMS High resolution mass spectrometry 
HSQC Heteronuclear Single Quantum Coherence 
HWE Horner-waddsworth-Emmons 
IBCF Isobutyl chloroformate 
IBX 2-iodoxybenzoic acid 
IC50 Half maximal inhibitory concentration 
Imid Imidazole 
IR Infra Red 
KHMDS Potassium bis(trimethylsilyl)amide 
LCMS Liqiud chromatography mass spectrometry 
LDA Lithium diisopropylamide 
LG Leaving group 
LHMDS Lithium bis(trimethylsilyl)amide 
Lys Lysine 
MDR Multiple drug resistance 
Me Methyl 
Mes Mesityl (2,4,6-trimethylphenyl) 
MMFF Merck molecular forc field 
MIC Minimum inhibitory concentration 
MNBA 2-Methyl-6-nitrobenzoic anhydride 
MOM Methoxymethyl 
MS Molecular sieves 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 






NMR Nuclear magnetic resonance 
NRPS Non-robosomal polyketide synthase 
OD Optical density 
PDC Pyridinium dichromate 
Pgp P-glycoprotein 1 
Ph Phenyl 
PLE Pig liver esterase 
PMB Paramethoxybenzyl 
PMP Paramethoxyphenyl 
PPTs Pyridinium p-toluenesulfonate 
Pr Propyl 
Py Pyridine 
RCAM Ring-closing alkyne metathesis 
RCM Ring-closing matathesis 
Red-Al Sodium bis(2-methoxyethoxy)aluminium hydride 
RORCM Ring-opening/ring-closing metathesis 
Rt Room temperature 
SEM 2-(Trimethylsilyl)ethoxymethyl 
Ser Serine 
TBAF Tetra-n-butylammonium fluoride 





TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIPS Triisopropylsilyl 





TOCSY Total Correlation Spectroscopy 
Ts Tosyl 
Tyr Tyrosine 
Val Valine 
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